Loma Linda University

TheScholarsRepository@LLU: Digital Archive of Research,
Scholarship & Creative Works
Loma Linda University Electronic Theses, Dissertations & Projects
6-1993

Caffeine and Nicotine : A Review of Their Combined Use,
Interactive Effects and the Impact of Caffeine Abstinence on
Tobacco Cessation and Withdrawal
John A. Swanson

Follow this and additional works at: https://scholarsrepository.llu.edu/etd
Part of the Public Health Education and Promotion Commons

Recommended Citation
Swanson, John A., "Caffeine and Nicotine : A Review of Their Combined Use, Interactive Effects and the
Impact of Caffeine Abstinence on Tobacco Cessation and Withdrawal" (1993). Loma Linda University
Electronic Theses, Dissertations & Projects. 920.
https://scholarsrepository.llu.edu/etd/920

This Dissertation is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. It has been accepted for inclusion in Loma Linda University Electronic
Theses, Dissertations & Projects by an authorized administrator of TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. For more information, please contact scholarsrepository@llu.edu.

mWERSITY LIBRARY
loma LINDA. California

LOMA LINDA UNIVERSITY
School of Public Health

CAFFEINE AND NICOTINE: A REVIEW OF THEIR COMBINED USE,
INTERACTIVE EFFECTS AND THE IMPACT OF CAFFEINE
ABSTINENCE ON TOBACCO CESSATION AND WITHDRAWAL
by
John A. Swanson

A Dissertation in Partial Fulfillment of the
Requirements for the
Degree of Doctor of Public Health
In Health Promotion and Education

June 1993

c
c

m

03

C\
G\

00

©

<

£o

Each person whose signature appears below certifies that this dissertation in his opinion, is
adequate in scope and quality as a dissertation for the degree Doctor of Public Health.

4

Jerry W. Lee,
Chabnfafi
Professor of HeaKh Promotion and Education, SPH

pee W. Hopp, PhD
^ ^
’rofes«or of Health Promotion and Education, SPH

Lee S. Berk, DrPH
Assistant Research Professor Pathology and Lab Medicine, SM
Assistant Professor of Preventive Medicine, SM
Assistant Professor of Health Promotion and Education, SPH

\

ABSTRACT OF DISSERTATION

There is good epidemiologic support to suggest a strong significant relationship
between coffee consumption and smoking. In six epidemiological studies reviewed and
analyzed, 86.4% of smokers consumed coffee versus 77.2% of nonsmokers. Seventeen
experimental studies suggest that the phannacologic effect of caffeine in coffee may be
partially but not totally responsible for the relationship. The behavioral relationship appears to
be supported by conditioning, a reciprocal interaction (caffeine intake increases anxiety/arousal
- nicotine decreases it), and combined effects of third variables (e.g., stress, alcohol).
In abstinent smokers, caffeine plasma levels increase, remain elevated for as long as
six months and may be sufficient to produce a caffeine toxicity syndrome. A review of 86
studies of nicotine withdrawal, caffeine withdrawal and caffeine toxicity suggests that the
symptoms are similar enough to be confused. Symptoms reported as nicotine withdrawal may
include symptoms of caffeine toxicity.
In this study we tested whether caffeine abstinence influenced smoking cessation and
whether smoking abstinence would induce high caffeine plasma levels and subsequent caffeine
toxicity symptoms. One-hundred sixty-two caffeine using smokers were enlisted from 41
American Lung Association cessation clinics. Volunteers were randomly assigned by clinic to
caffeine use or caffeine abstinence conditions and measured for 3 weeks post-smoking
cessation, at six months and at one year. Caffeine abstainers were asked to use only
decaffeinated products for at least one week. Results showed a significant linear increase in
caffeine sputum levels across four time points for those who quit smoking and continued using
caffeine. At 21 days post-cessation, sputum caffeine levels increased above 200% of baseline
levels even though reported intake remained stable. Caffeine abstinence significantly increased
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headache, fatigue, muscle aches/twitches, tobacco craving, and decreased stimulation
immediately following tobacco cessation. There were no differences between the groups on
other withdrawal symptoms and no evidence of caffeine toxicity. These initial effects in the
caffeine abstinence group might be counter productive in facilitating the process of smoking
cessation, however, no significant difference in success existed in either group at 16 days, 6
months or 12 months. Short-term caffeine abstinence (reduction) appears to be neither helpful
or harmful in smoking cessation.
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CHAPTER 1 INTRODUCTION
Definition of the problem

Smoking cessation programs such as The Five-Day Plan, Breathe-Free Plan, and other
plans emphasize the importance of eliminating caffeine consumption when one is trying to quit
smoking cigarettes. The Five-Day Plan has been following this practice for over 30 years with
no evaluation of its effectiveness. Plans such as those offered by the Lung Association and the
American Cancer Society do not have a similar emphasis. While there is ample research
documenting the relationship between caffeine consumption and cigarette smoking, we have
found no research that provides direct evidence that elimination of caffeine is helpful in
smoking cessation.
One rationale that smoking cessation program leaders give for asking individuals to
quit caffeine use is that "it will help them get over the craving much quicker if they drop off
the caffeine" (McFarland & Folkenberg, 1978). I have found no studies, however, that have
measured the impact of simultaneous caffeine and tobacco cessation on withdrawal symptoms.
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Purpose of the Study

The purpose of the study was twofold:
1. To determine whether reduction or elimination of caffeine aids in smoking
cessation.
2. To determine how caffeine consumption contributes to the tobacco
withdrawal syndrome.

Rationale and Literature Review

Relationship between Caffeine Consumption and Tobacco
Many studies have shown that there is an association between caffeine consumption and
use of tobacco (Greden, Procter, and Victor, 1981; Emurian, Nellis, Brady, and Ray, 1982;
Nellis, Emurian, Brady, and Ray, 1982; Lang, Bureau, Degoulet, Salah, and Benattar, 1983;
Shirlow, 1983; Grunberg, Morse, 1984; Cannody, et-al., 1985; Hemminki, Rahkonen, Rimpela,
and Rimpela, 1988). Istvan and Matarazzo (1984), in a review studying the link between
tobacco, alcohol, and caffeine use, concluded that there was a moderately strong link between
cigarette smoking and caffeine consumption. Marshall, Epstein, and Green (1980a) and Ossip
and Epstein (1981) found that when the number of cups of coffee consumed was
experimentally increased, cigarette smoking increased. Marshall, et al. (1980b) found that this
could not be accounted for by changes in urine acidity suggested that this could be due to
stimulus control properties of coffee drinking. Coffee drinking, because its use often
accompanies cigarette smoking, comes to be a stimulus that produces cigarette smoking. Thus
one rationale for expecting that caffeine consumption makes smoking cessation more difficult
2

is that the use of caffeine stimulates the need for cigarettes.
More recently, Benowitz, Hall, and Modin (1989) have found that when individuals quit
smoking cigarettes their bodies do not metabolize caffeine as rapidly, resulting in increased
serum concentrations of caffeine. This provides another possible rationale for telling those
quitting smoking to avoid caffeine. The increased levels of serum caffeine could cause
symptoms of caffeinism such as nervousness, irritability, or insomnia. The individual might
then attribute these symptoms to the smoking withdrawal and go back to smoking to reduce
them. While there appears to be adequate rationale for expecting that giving up caffeine might
facilitate successful smoking cessation, there appears to be no study that has directly
manipulated caffeine consumption to detennine whether this occurs.

Smoking Withdrawal Symptoms
The cited research above suggests that there may be a link between caffeine use and
nicotine withdrawal. To better understand the possible nature of this link a brief of the
components of the smoking withdrawal syndrome is in order. DSM-III-R, the diagnostic
manual for the American Psychiatric Association (1987), provides the following criteria for
nicotine dependence: 1) Daily use of nicotine for at least several weeks; 2) at least four of the
following: craving for nicotine, irritability, frustration or anger; anxiety; difficulty
concentrating; restlessness; decreased heart rate; increased appetite or weight gain. Shiffman
(1979), reviewing the literature on the tobacco withdrawal syndrome, also suggests increased
blood pressure, nausea, headache, constipation, diarrhea, hostility. Hughes, Hatsukami, Pickens,
Krahn, Malin, and Luknic (1984) report significant differences between baseline measures and
measures during withdrawal on self-reported irritability, anxiety, difficulty concentrating,
restlessness, impatience, and somatic complaints and on POMS (Profile of Mood States) scores
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of anger, tension, confusion and total mood disturbance. Hughes, Hatsukami, Pickens, and
Svikis (1984) report that the syndrome is consistent across time in the same individual.
although as others have reported (e.g. Shiftman, 1979; West, 1984), it may be quite variable
from one individual to another. Other recent studies of the smoking withdrawal syndrome
seem generally consistent with the above description (e.g. Gross and Stitzer, 1989; Hajek,
Jarvis, Belcher, Sutherland, and Feyerabend, 1989; Hatsukami, Dahlgren, Zimmerman, and
Hughes, 1988).

Caffeinism and Smoking Withdrawal
Benowitz et al. (1989) and his colleagues found that smoking cessation caused the
plasma caffeine level to increase up to two and one-half times. Lee et al. (1986) found two
withdrawal patterns, one connected with fatigue and the other with increased nervousness and
irritability. Gilliland and Bullock (1983) have characterized caffeinism as "a syndrome which
includes increased anxiety, depression, frequency of psychophysiological disorders, and
possibly degraded performance (p. 53)." It is possible that the withdrawal syndrome
characterized by increased nervousness involves the increased anxiety and tension produced by
the increased levels of caffeine in the blood plasma. Thus at least some of the aspects of the
supposed smoking withdrawal syndrome that involve increased tension might be due to high
levels of caffeine in the smokers who continue to use coffee after quitting smoking.
This study compares the withdrawal symptoms from quitting smoking in two caffeine
groups. One group continues to use their nonnal caffeine products and the other abstains from
caffeine (uses decaffeinated products).

4

Detailed Methodology

Subjects
One hundred-sixty-two volunteers (75 male, 89 female) were recruited from 41
American Lung Association "Freedom From Smoking Programs" in the Los Angeles county
(Glendale and West Covina communities). Orange, Riverside and San Bernardino counties of
Southern California. Participants were randomly assigned by clinic to one of two conditions: a
standard care condition (21 clinics, 83 smokers) or a caffeine abstinence condition (20 clinics,
79 smokers). Inclusion criteria were: 1) used caffeinated products in some form: regular coffee,
tea, or soft drinks, and 2) were presently smoking and intending to quit.
Written informed consent was obtained from each subject: the study was approved by
the Loma Linda University Institutional Review Board on Human Research (Loma Linda,
CA.). Each participant was given incentives: $20.00, a "LLU Research Project" T-Shirt at the
end of the Lung Association meetings, and at the end of the 12 month follow-up a mailed
summary of the research findings. In addition, participants in the caffeine abstinence condition
were provided caffeine-free substitutes and decaffeinated coffees, e.g. Sanka, Postum, Pepsi
Free, Caffeine-free Coke.

Experimental design and procedure
The research design was a two condition experimental design. In the "standard care
condition," participants were asked to continue their caffeine use at normal levels for the
duration of the program; in the "experimental condition," participants were asked to try to
avoid drinking any beverage or product that contained appreciable amounts of caffeine for at
least one week and as much longer as possible during the study. All participants were asked
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not to quit smoking until the specified "Quit Day" and not to use nicorette gum or anti
depressant drugs after the targeted "Quit Day", as these drugs would have a detrimental effect
on the research, specifically on withdrawal measurements.
Groups were closely matched in size, then randomly assigned to one of the
experimental conditions. Participants and research assistants were kept blind regarding the
assignment until the actual quit day. Prior to data collection, all research assistants were
trained in data collection protocol and given written guidelines. The project director or one
research assistant presented all enrollment protocol.
A total of seven sessions was utilized in the "Freedom From Smoking Program". All
data was collected at the conclusion of each cessation program. Table 1 (p. 44) shows the
activities that took place at each session.

Instruments
Data was collected using the following instruments:
Intake Questionnaire. The smoking / caffeine history questionnaire was modeled after
the American Lung Association intake questionnaire. Several rating scales were modified to
provide a broader range of choices for data analysis, as suggested by Lando (1983). For
example, the degree of supportiveness of individuals in the environment was recorded on a
nine-point scale, from "no support" to "high support", rather than a simple supportive-not
supportive option.
The questionnaire requested personal data, smoking history, the use of caffeinated and
decaffeinated products, medical questions relating to kidney or liver problems, pregnancy, use
of oral contraceptives, female hormones (e.g. estrogen) and alcohol consumption. The caffeine
section requested information about brand type, product fonn (caffeinated or decaffeinated),
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brewing method (instant, drip, perk, espresso), quantities used (week day verses weekend), cup
size, and portion usually drunk. Queries about other sources of caffeine included caffeinated
and decaffeinated soft drinks, cocoa, chocolate milk, chocolate candy bars, brownies,
prescription and non-prescription drugs. Prescription and non-prescription drugs containing
caffeine, as identified from the 1990 Physicians Desk Reference, were placed into four
categories: 32, 65, 100, 200 mg/caffeine per tablet/capsule. Participants were asked to
designate how many of these drugs were taken daily or weekly. The questionnaire was
pretested on 19 smokers in two cessation clinics to assess clarity and length of time needed for
completion.
Why Do You Smoke? - "Reasons for smoking scale".* The scale was developed using
the items from the Leventhal and Avis (1976) study with additional items to represent a
possible anger reduction dimension. The full scale contained 40 items. It was pretested on 283
smokers and factor analyzed. The scree test suggested between eight and nine factors. The nine
factor solution seemed most interpretable. These factors were: addiction, habit, image,
manipulation of cigarette, negative affect, pleasure, social tension release, stimulation, and
taste. The alpha levels ranged from .73 to .92. These factors were similar to those identified by
Leventhal and Avis (1976). The anger reduction items did not fonn a separate subscale.
Feeling Profile - "Withdrawal symptoms scale".* This sell-report questionnaire was
constructed by examining 43 studies of nicotine withdrawal symptoms and 54 studies of
caffeine withdrawal or caffeinism. Symptoms of caffeinism were included since Benowitz,
Hall, and Modin (1989) found that the serum concentration of caffeine can double in smokers
who cease tobacco use without changing caffeine consumption. For each study we tested all
*Note: some of the material from this section originated from the initial submitted grant proposal
and internal reference reports prepared by J.W. Lee
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the confirmed symptoms. Symptoms found in more than two studies were placed in a second
list. For each symptom a thesaurus was examined for synonyms and at least two synonyms for
each symptom were added. Next, word frequency lists (Carroll, J.B., et al. 1971) were
examined and the frequency of use of each word determined. Two independent reviewers
categorized the words into clusters of similar terms; within each cluster the symptoms were
ordered by frequency of use of the tenns about that symptom. At least four temis in each
symptoms category were selected, with highest priority being given to symptoms which
occurred frequently in word lists. The latter step was required to ensure that the words would
be as easy for our participants to read as possible. This process resulted in a list of 50 items.
We provided 9 scale points for each symptom, since psychometric work suggests that
providing respondents with more points on a scale results in a more reliable scale (Nunnally,
1978).
Thus a question would be stated as follows: Please rate how much each word or
phrase below describes how you have felt today by circling one of the numbers:

irritable

not at all 1 2 3 4 5 6 7 8 9 very much

anxious

not at all 1 2 3 4 5 6 7 8 9 very much

After preliminary testing for fonnat and understandability, the resulting questionnaire was
administered to a sample of 221 smokers attending smoking cessation programs. Results were
entered into an SPSS file, using the double entry procedure. Principal components factor analysis
with varimax rotation was used to detennine groupings of factors. A scree test suggested that
eight, nine or ten factors would adequately explain the data. The ten-factor solution seemed most
interpretable. The items showing the largest factor loadings on each factor were ordered and items
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with low loadings dropped, reducing the length of the scale from 50 to 32 items. Internal
consistency for each subscale was also examined. The ten factors included: caffeine (craving),
craving (tobacco), concentration, fatigue, hunger, muscular activity, negative affect, sensori-motor
disturbances, sleep disturbance and stimulation. Cronbach's Alpha levels in the pretest ranged
from .71 to .93. Table 2 shows the alpha levels in the final study sample for both the initial
testing form and for the shortened form used in the daily-logs.
Daily-log. This was used to detennine when, which, and how much change occurred in
the cessation process. Participants recorded this information in the pocket-size set of daily-logs
three times a day (9 AM, 3 PM, and 9 PM) for seventeen days over a five-week period.
Participants were loaned a watch with alanns preset at the designated times to help them
remember to complete the log.
The daily-log was divided into two sections. Section One included the daily intake of
nicotine products, caffeinated and decaffeinated products (type, amount used and cup size), mood
altering drugs, alcohol beverages, prescription and nonprescription drugs, alcohol, sleep patterns.
and time of first cup of coffee. Section Two measured the symptoms relating to nicotine and
caffeine abstinence and caffeine toxicity. The instrument has a list of 26 symptoms and was
constructed in the same manner as the "Feeling Profile" (see procedure above). It is a shorter scale
(26 items) with nine factors: caffeine (craving), concentration, fatigue, hunger, muscle activity,
negative affect, sensori- motor disturbances, stimulation and tobacco (craving). The alpha levels
for the shorter scale ranged from .71 to .93 during pretesting. The alpha levels during the actual
study are shown in Table 2.
The daily-log presents a different set of demands then does a questionnaire on
caffeine/nicotine-consuming habits. The diary is detailed, specific, ongoing (completed 3 times a
day), allowing for extensive practice and has been shown to have greater self-report accuracy over
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Table 1
Items Composing Withdrawal Symptom Scales
Cronbach’s Alpha
Daily Log1
Pretest
(N=158 to 162) (N=149 to 136)
Caffeine Hunger
desire for something with caffeine*, longing for
something with caffeine*
Concentration Difficulty
can’t concentrate*, confused*
Craving
desire to smoke*, longing for cigarette*
Fatigue
lacking energy*, sleepy*, slowed down*, tired
Hunger
feeling starved*, hungry*
Musculo-Skeletal
headachy*, heart pounding*, muscle ache*, muscle
twitching*
Negative Affect
annoyed*, anxious, depsessed*, gloomy, irritable*,
nervous, tense*
Sensory-Motor
dizzy*, ears ringing*, stomach upset*, vision
blurred*
Stimulation
active*, aroused*, full of energy*
Sleep Disturbance
can’t get to sleep, canl sleep

♦Indicates item used in daily log.
^ean Cronbach’s alpha for measurements summarized in table 1
(Table developed by J.W. Lee)
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.89

.93

.56

.71

.93

.92

.83

.85

.85

.88

.82

.77

.91

.90

.74

.71

.61

.65

.94

time than retrospective questionnaires (James et al., 1989).
Six and Twelve Month Follow-up. At six and twelve months from the actual quit day.
participants were telephoned and a short, five minute, follow-up survey conducted. Questions were
asked regarding nicotine and caffeine use, behavioral substitution for smoking, factors related to
smoking relapse, feelings and symptoms prior to smoking relapse, time of caffeine product
reinstatement, and time of smoking relapse. In addition, the twelve-month follow-up investigated
caffeine product use in relation to smoking (eg. which products, when, how soon used).

Nicotine and Caffeine Saliva Collection and Analysis*
Four saliva samples were collected to measure initial caffeine and cotinine levels. During
saliva collection, participants were instructed through oral and written collection guidelines. The
procedure consisted of rapidly moving the tongue around and against the inner cheek and then
spitting the saliva into a frosted collection cup. Each cup was premarked at 10 mL for adequate
sample determination. Participants were instructed to drink the nonnal intake of fluids (6-8 eight
oz glasses of water or other fluid) on the day of saliva collection. However, 30 minutes prior to
time of collection, they were not to eat any food, candy, or drink any water or beverage, as this
would dilute or alter the saliva sample. After completion of collection, participants filled in the
identification label with the designated infonnation.

All samples were put in an ice chest,

transported to a freezer and kept frozen (-20 °C). At the laboratory, each sample was then
transferred to a glass conical tube and centrifuged at 1500 x g for 10 minutes. The clear supemate
saliva was decanted, transferred to a glass vial and stored at -10 °C until analyzed for cotinine and
caffeine.
Nicotine and caffeine saliva concentrations were assessed using a modification of the high-

*Note: the last paragraph of this section was prepared by L.S. Berk
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performance liquid chromatography (HPLC) method of Machacek and Jiang (1986), Hiriharan,
VanNoord and Greden (1988) and Hartley, Smith and Cookman (1985). The intra-assay (withinday) reproducibility was as follows (N=10): cotinine, mean, 220 ng/mL, relative standard
deviation, 4.9%; caffeine, mean 4.1 pg/mL, relative standard deviation, 4.9%. The inter-assay
(day-to-day) reproducibility data was as follows (N=35): cotinine, mean, 203 ng/mL, relative
standard deviation, 6.4%; caffeine, mean, 3.9 pg/mL, relative standard deviation, 5.1%.
(For a more detailed description see Appendix Q)

Caffeine Assessment
Daily-log. Caffeine intake was calculated for each time period (9 AM, 3 PM and 9 PM)
by applying caffeine estimates (see Table 2/Paper 2, p.55) per ounce (29.5 ml) of liquid type
(caffeinated or decaffeinated coffee, tea, soft drink, cocoa, chocolate milk). The result was
multiplied by a weighted caffeine score for brewing method and product fonn, and then multiplied
by the number of ounces consumed (cup size times number of cups). Finally, the caffeine amounts
for each category (e.g. coffee, tea, soft drinks, cocoa, chocolate milk, chocolate bar) were added
together. Prescription and nonprescription drugs containing caffeine were calculated by multiplying
the number of capsule(s) or tablet(s) used by the caffeine content of that specific drug and adding
it to the total caffeine score for that time period. The total daily caffeine intake was calculated by
summing the score for each of the 3 time periods.
Intake questionnaire. Daily caffeine consumption on the intake questionnaire was
calculated by applying the same caffeine estimates (see Table 2/Paper 2, p. 104) and calculations
as used in the daily-log, with two differences: 1) in calculation, a weighted average for the
"number of cups" used was obtained by multiplying the frequency questions of weekday by five
and weekend by two. The two scores were added together, then divided by seven. 2) Prescription
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and non-prescription drugs containing caffeine were placed into four categories (32, 65, 100, 200
mg per dose). The number of capsules/tablets taken was multiplied by the category and the result
numbers added to the total daily caffeine score.

Nicotine Assessment
Daily nicotine intake (mg) for cigarettes was detemiined by matching the reported brand
name and descriptors (size, filter, menthol, "ultra light", etc.) with the 1991 Federal Trade
Commission Report. The total nicotine alkaloid reported as milligrams of nicotine per cigarette
was multiplied by the number of cigarettes smoked for that day. Nicotine levels for cigar, gum,
snuff, chewing tobacco and nicotine patch, were detemiined by type of product and amount
consumed or used in a day (Benowitz, et al. 1990, Armitage et al., 1978).

Data Analysis
Data was double entered using Data Entry II (SPSS, 1989), examined for outliers and
missing values and violation of distributional assumptions. The data was then cleaned and, if
necessary, appropriate transfomiations were made to reduce violations of distributional
assumptions.
Analysis of saliva samples for cotinine (a primary metabolite of nicotine used to indicate
nicotine intake) and caffeine concentrations, obtained at four different time points, were examined
by using the repeated measures ANOVA with caffeine group (caffeine abstainer versus normal
caffeine user) and time of the caffeine or nicotine saliva samples as factors.
Daily-log estimates of nicotine, caffeine, and withdrawal symptoms were averaged across
the measures for each day. Thirteen time points (two time points one week pre-cessation and 11
time points post-cessation) were measured by repeated measures ANOVA. Caffeine group was the
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first factor, caffeine baseline level (low = 0.4 ug/mL or less, moderate = 0.41 - 2.0 ug/mL, high=
2.1 ug/mL or more) was the second factor, and day of the measurement (13 time points) was the
third.
Success in smoking during the first 16 days post-cessation was examined with survival
analysis (life tables) from SPSS. Six and twelve month followup was analyzed by using simple
chi-squared techniques for the category success versus failure in the two groups.

Power*
For tests of the proportion of subjects who are successful quitters an N of 156 was estimated
to give us 80% power at alpha equal to .05 if there was 30% successful in the caffeine group and
46% successful in the no-caffeine group. However, if the difference was between 30% and 40%
successful then the power was estimated to be only about 55% at an alpha of .10.

Validity Concerns*
1. If large numbers of individuals in the no-caffeine group failed to give up caffeine then
information regarding the comparison of the no-caffeine group and the caffeine group would be
invalidated. The primary concern of this study is whether asking people enrolled in a smoking
cessation program to give up caffeine improves program outcomes. If we found that people were
unwilling to give up caffeine as part of a cessation program even when they were given the added
incentives provided by our study then that question would still have been answered. However, we
would not have been able to say anything meaningful regarding withdrawal symptom differences.
Based on our experience, we expected in excess of 40% initially to give up caffeine as well as
cigarettes at least during the first few weeks of the program. We hoped that due to the demands
*Note: some of the material from this section originated from the initial submitted grant proposal
and internal reference reports prepared by J.W. Lee
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of being in an experiment, the financial incentive, and our statement in the consent form that we
requested that they give up caffeine for at least a week, would give us a high enough number of
participants to at least analyze the effects of caffeine cessation in the first week. Information about
how successful participants were at giving up caffeine in the long term was also of interest. In the
weeks preceding the start of the actual experiment, we monitored self-reports of caffeine cessation
and pretested measures aimed at increasing the percent of individuals complying with the caffeine
restrictions. For example, caffeine cessation could be included in self-contracts at the beginning
of the program.
2. It was impossible in this design to blind participants to whether or not they were getting
caffeine. Thus, some differences between groups in withdrawal symptoms could be due to
expectations about the effects of caffeine withdrawal. While this is true, it was irrelevant to the
main purpose of our study which was to study the impact of asking program participants to quit
caffeine on their smoking cessation success. In any real world attempt to use caffeine cessation
as an adjunct to successful smoking cessation, participants would have to know that they were
giving up caffeine. Therefore, our results would closely mirror the impact of this advice in the
real-world clinic settings and thus would have greater external validity than a study that blinded
participants as to whether they were receiving caffeine or not.
3. Experimenter bias was a potential problem since the same individuals would give both
the non-caffeine and caffeine allowed programs. However, blinding the program presenter to
conditions would appear to be nearly impossible in this setting since the presenter would
eventually know whether a group was to receive caffeine or not. However, since the primary
program presenter was aware of the lack of concrete evidence for the effectiveness of caffeine
cessation and was enthusiastic about the research project, this was not a problem.
*Note: some of the material from this section originated from the initial submitted grant proposal
and internal reference reports prepared by J.W. Lee
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4. Since subjects filled out a smoking motivation scale which would include such
responses as dependent, sedative, and stimulant smoking and then later filled out a questionnaire
measuring craving, stimulant, and sedative type withdrawal symptoms relationships found between
reason for smoking and withdrawal symptoms could be an artifact of an attempt by subjects to
maintain consistency. The reasons for smoking scale was filled out at the early interview session.
on the average two weeks and at least several days, before they filled out the withdrawal scales
at the time of withdrawal. Given the number of other things happening between times of
measurement it was unlikely that any very large correlations would result because of consistency
attempts.

Ethical Issues
Is it ethical to withhold information about caffeine from our caffeine-allowed groups? If
it were well established that caffeine avoidance actually helped smoking cessation this could be
a problem. But there are no studies that demonstrate that caffeine avoidance is helpful in smoking
cessation and many major smoking cessation programs currently mention caffeine only in passing
or not at all. Caffeine-avoidance is not a standard of treatment for smoking cessation, and we do
not yet know whether it is really helpful. Thus, withholding this information does not seem
unethical.
The appendix has a copy of the informed consent that was used in the study.
This study received approval on 3-15-90 from the Loma Linda Ethics Committee.

Significance of The Proposed Research
The results of this study should provide several benefits. It should provide data regarding
the impact of simultaneous caffeine and tobacco cessation on withdrawal symptoms. It should
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provide The Five-Day Plan, The Breathe-free Plan, and other plans which advocate caffeine
restriction, with information as to whether or not the elimination of caffeine is helpful in smoking
cessation. Finally, it will assist the field of health education by enhancing the effectiveness of
intervention programs in reducing smoking. As such, it can contribute to the success of the
"Healthy People 2000" Objectives for the Nation - that of reducing preventable death, disease, and
disability.
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CHAPTER 2: PAPERS
Introduction

The first paper, entitled "Caffeine and Nicotine: A Review of Their Combined Use and
Interactive Effects in Tobacco Withdrawal," reviews the current scientific literature from 1972
through March 1993 on caffeine and nicotine as it relates to non-health effects in smoking
cessation. The sources were Medline and Psychlit searches, references from published articles and
a review of relevant journals up to and including March 1993. Section I reviews 15 studies on the
combined use of caffeine and nicotine. Section II examines 17 studies on the physiological and
behavioral rationales for this combined use. In Section III eighty-six studies are examined to
compare the similarities and differences of withdrawal symptoms of both drugs, and compare
caffeine toxicity symptoms with nicotine withdrawal symptoms. The last section summarizes the
evidence and provides specific suggestions for future research in this area. The second paper.
entitled "The impact of Caffeine Use on Tobacco Cessation and Withdrawal," summarizes the
major findings of this research project. All tables and figures are found at the end of each paper
which is the format of submitted publications.
The first paper was submitted to the journal "Addictive Behaviors" which has the
American Psychological Association specifications. The second paper will also be submitted to
this same journal.
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Abstract

There is a strong significant relationship between coffee consumption and smoking. In
six epidemiological studies reviewed and analyzed here, 86.4% of smokers consumed coffee
versus 77.2% of nonsmokers. Exsmokers use more coffee than nonsmokers but somewhat less
than smokers. Seventeen experimental studies suggest that the pharmacologic effect of caffeine
in coffee may be partially but not totally responsible for the relationship. Conditioning, a
reciprocal interaction (caffeine intake increases anxiety/arousal - nicotine decreases it), or
combined effect of a third variable (e.g., stress, alcohol) may account for the relationship. In
abstinent smokers, plasma caffeine levels increase and remain elevated for as long as six
months. These higher plasma caffeine levels may be sufficient to produce caffeine toxicity
syndrome. A review of 86 studies of nicotine withdrawal, caffeine withdrawal and caffeine
toxicity suggests that the symptoms are similar enough to be confused and reported nicotine
withdrawal symptoms may be a mixture of nicotine withdrawal and caffeine toxicity.
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Caffeine and Nicotine: A Review of Their Relationship

Is it the coffee that makes a cigarette taste good, or is it the cigarette that makes
coffee taste good? Whichever smokers chose, one thing is certain: there is a relationship
between two of America’s major psychotropic drugs.
While the social approval of smoking has declined from 40.4% to 29.1% for the total
U.S. population from 1965-1987 (U.S. Dept, of Health and Human Services, 1989), coffee is
still the beverage of choice in both the United States and Canada (Gilbert, 1976; Barone and
Roberts, 1984). Approximately 80% of the general U.S. population consume caffeine products
regularly (Gilbert, 1986; Marrett 1983), with the average intake per capita around 211 mg per
day (Barone and Roberts, 1984; Gilbert, 1986). Smokers consume more coffee than nonsmokers. At least six epidemiological studies have reported coffee use rate in smokers and
nonsmokers; however, none indicated whether there were significantly more smokers than
nonsmokers using coffee. Table 1 summarizes these six epidemiological studies. Although
Dawber et al. (1974) did not report on the coffee drinking rates of nonsmokers, the results are
included for comparison. When significance tests were perfonned (also reported in Table 1),
smokers were found to drink significantly more coffee than nonsmokers (i.e., never smokers
and exsmokers) in every study. Coffee consumption was approximately 86.4% for smokers
versus 77.2% for nonsmokers (Dawber et al., 1974 data was excluded).
Insert Table 1 about here

This paper reviews the current scientific literature from 1972 through March 1993 on
caffeine and nicotine as it relates to non-health effects in smoking cessation. The sources were
medline and psychlit searches, references from published articles and a review of relevant
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journals up to and including March 1993. Section I, reviews 15 studies on the combined use of
caffeine and nicotine. Section II, examines 17 studies on the physiological and behavioral
rationales for this combined lase. Section III, eighty-six studies are examined to compare the
similarities and differences of withdrawal symptoms of both drugs, and compare caffeine
toxicity symptoms with nicostisne withdrawal symptoms. The last section summarizes the
evidence and provides specific suggestions for future research in this area.

Epidemiological studies showing positive association between use of the two drugs
Epidemiological studies provide evidence for a possible dose response relationship of
smoking and coffee consumpakiii. Table 2 lists nine large studies (>1,000 participants) and six
small studies (<1,000 particijOTts) that provide support for this relationship. Since it was not
the intent of the original studies to measure this association, we performed several %2 test to
help clarify the issue. The remits are shown in the findings and significance column. In each
case increased coffee consumption was associated with increased cigarette consumption.
Insert Table 2 about here

Several of the reported studies provide data allowing comparison of coffee drinking
habits of smokers, exsmokers and never smokers. In these studies, exsmokers consumed
greater quantities of coffee dsasi never smokers, but less than smokers. In the Boston
Collaborative Drug Surveillance Program (1972), a crosstabulation among exsmokers and
nonsmokers demonstrates thag there were twice as many exsmokers (66.7%) consuming 6+
c/day of coffee as non-smokeas, ^2(2, N = 579) = 11.02, p=.004. The percentage consuming
coffee were: 80.2% smokers, 77.9% exsmokers and 71.3% never smokers x2(2, N = 1,104) =
9.74, £=.007. In the Nationafl Research Council twin panel of 10,744 male veterans (Hrubec,
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1973), 95.2% smokers, 90.1% of exsmokers and 79.5% of never smokers used coffee x (2. N
= 10,615) = 515.49, jK-OOOOOS). Thomas (1973), examining 692 physicians and their health
habits, found that current smokers and fonner smokers consumed more cups of coffee per day
than did lifetime nonsmokers.. Mean cups of coffee per day per smoking classification were:
nonsmoker = 1.69, former smoker = 2.43, and current cigarette smoker = 2.96. There was no
significant difference reported between the fonner smoker and the current cigarette smoker. In
a hospital based study of 980 women, non-myocardial infarct controls (Rosenberg et al., 1980),
71.5% of smokers, 63.1% of exsmokers and 55.0% of never smokers drank coffee %2(2, N =
980) = 23.52, 2=.00001. Finally, in the Lutheran Brotherhood Study of 16,911 men (Murray et
al., 1981) and through a personal interview with authors Gibson and Schuman for additional
raw data (Murray et al., 1993), a crosstabulation revealed that 97.0% of smokers, 95.0% of
exsmokers and 88.6% of never smokers used coffee x2(2, N = 16,800) = 353.05, 2<-000005
(17,633 usable questionnaires, less 833 unknown for smoking and coffee consumption).
The relation of tea to cigarette smoking has been investigated with mixed results.
Prineas et al. (1980), in a sysaematic population survey, examined the association between
coffee, tea, cigarette smoking, sleep habits and ventricular premature beats in 7,311 men, ages
35-57 from the Twin Cities m Minnesota. Results from 7,009 men (302 omitted answers to
tea, coffee or alcohol) showed an extremely small negative correlation between cigarette
smoking and tea drinking (r= -0.05, £<.05). Gilbert (1976), in the Ontario study of 1,883
adults, originally reported that smoking and tea consumption were unrelated. Upon further
investigation, Gilbert (1979) neported that lea consumption among non-coffee drinkers was
positively correlated with cigarette smoking (£<.01). However, among coffee users there was a
lack of association between tea and smoking. Interestingly, he noted that heavy smokers were
more likely to consume coffee than tea. Despite the mixed results for tea, it is important to
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consider its contribution to the total daily caffeine intake, since caffeine is found in both tea
and coffee and is associated with cigarette smoking.
In summary:
1) There is a positive relationship between coffee consumption and cigarette
smoking.
2) The relationship exists for both males and females, although Dawber et al.
(1974) found no association among females.
3) Exsmokers consume more coffee than never smokers, but less than smokers.
4) While Prineas et al. (1981) found that tea use alone was not correlated with
cigarette smoking, Gilbert (1979), reported that tea consumption among non
coffee drinkers was positively correlated with cigarette smoking (pcO.Ol). The
finding that some smokers prefer tea over coffee suggests that when
investigating caffeine and its association with cigarette smoking, consideration
of all sources of caffeine and smoker types, not just coffee, is important.
Despite using crude methods for estimating caffeine consumption as did all previous
epidemiological studies, Prineas et al. (1980) noted that caffeine comes from additional sources
other than coffee, and that "unmeasured variability" is introduced in a study when these
sources are not considered. In particular, the brewing method of coffee, brand type, cup size.
product form, amount used, and additional sources eg. soft drinks, tea, medications, are issues
that have plagued earlier studies and recent ones (Leviton, 1991; Schriebner et al., 1988). Such
variability in measurement on a given population sample would result in underestimation when
additional sources of caffeine are not considered, or overestimation when cup size and amount
consumed are not considered. Both conditions would result in corresponding erroneous
conclusions (Barone and Roberts, 1984; James et al., 1989, Schrciber, 1988). Since all the
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aforementioned studies failed to consider these added dimensions and additional sources of
caffeine, its important that future studies have carefully designed instruments to correct for this
problem.

Rationale For Apparent Linkage
The Pharmacokinetics Effect of Caffeine
One explanation for the higher levels of coffee consumption among cigarette smokers
involves the shorter half-life and increase in the metabolism of caffeine when nicotine is also
present (Kalow, 1985; Rotate et ah, 1982; May et ah, 1982; Murphy et ah, 1988; Parsons and
Neims, 1978).
In healthy individuals, the plasma half-life of caffeine varies between 1.5 and 9.5
hours, with a mean average of 5 hours (Busto et ah, 1989). This wide range in the half-life
may be a result of the interindividual variation in volume of distribution and clearance (Busto
et ah, 1989). Other factors influencing the phannacokinetics of caffeine include; age, gender
(oral contraceptives, pregnancy, taking female honnones e.g. estrogens), impaired liver
function, smoking and other drug use (Busto et ah, 1989; Curatolo et ah, 1983; Rail, 1985;
Sawyer et ah, 1982; and Von Borstel, 1983).
Parsons and Neims (1978) studied 13 healthy smokers who continued smoking (M =
20 cig/day) and 13 healthy non-smokers as to the effects on caffeine half-life and metabolism
over a 24 hour period. He reported that the caffeine half-life in smokers (3.5 hr) was less than
in nonsmokers (6.0 hr) and the metabolism of caffeine was greater in smokers (155 ± 16
ml/hr/kg) than in non-smokers (94 ± 18 ml/hr/kg, _p<.05). He also speculated that the greater
caffeine clearance rate by smokers may contribute to the increased coffee intake.
May et ah (1982) investigated the effects of cimetidine (Tagament, which is
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known to impair the elimination of certain drugs including caffeine) on the absorption.
distribution, and elimination of caffeine. They evaluated the effects on twelve participants: six
smokers (M = 20 cig/day) and six non-smokers over four days. They found a 31% decrease in
the total body clearance of caffeine from cimetidine. Among smokers, the total body clearance
of caffeine was 60% higher than nonsmokers (2.49 ± 0.35 versus 1.59 ± 0.19 ml/min/kg.
pc.05) and the elimination half-life was 68% shorter (190 ± 15 versus 276 ± 30 min, pK-OS).
While Parsons and Neims (1978) suggested that the faster caffeine elimination from smoking
may lead to increased coffee consumption. May et al. (1982) found no such increase. May did
suggest, however, that abstinent smokers consuming coffee throughout the day may develop
nervous system toxicity from the accumulated caffeine plasma level because of the increased
caffeine half-life.
Nicotine’s Effect on Caffeine Metabolism and Half-life
The studies reported so far establish that smokers have greater rates of caffeine
clearance than non-smokers. These studies, however, failed to demonstrate whether cigarette or
nicotine use increases caffeine clearance or whether the difference might stem from some other
variable that accompanies cigarette use (e.g. increased fluid consumption, genetic difference in
metabolism). Several studies address this question.
Up to 1988, experimental short-tenn studies had focused primarily on effects resulting
from single doses of caffeine and had failed to look at regular caffeine users who consume
several doses of caffeine throughout the day. In response to this issue. Brown et al. (1989)
conducted a four-day study comprised of multiple and variable daily caffeine dosing (6
cups/day, daily caffeine dose 0, 6, or 12 mg/kg/day). He reported a non-statistically significant
tendency for cigarette smoking and consumption of nicotine to increase during caffeine
consumption. During low dose caffeine intake (1 mg/kg), plasma nicotine levels were slightly
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higher compared with no caffeine intake (611.2 ± 176.5 and 538.9 ± 166.6 ng-hr/ml,
respectively, p=.09). Plasma caffeine levels were significantly higher during non-smoking
conditions. This is consistent with other studies that have shown that smoking abstinence
increases the plasma caffeine levels (May, 1982; Nil, 1984).
Brown et al. (1988) studied the rate and pattern of caffeine metabolism in nine healthy
smokers under smoking abstinence conditions. Each participant received six cups of coffee (1
cup every 2 h, 8 AM - 6 PM) and went through four treatments: placebo or low caffeine dose
(6 mg/kg/day) or high caffeine dose (12 mg/kg/day) while smoking; and high caffeine dose
under abstinent conditions. Each treatment lasted between 3-4 days. They found the peak
plasma caffeine concentrations occurred at 8 PM and were greater during the non-smoking
treatment than during the smoking treatment (3.8 ± 0.9 versus 2.9 ±1.0 pg/ml, p<.05).
Caffeine metabolism was faster under smoking conditions compared to nonsmoking conditions
(36986.1 ± 11095.7 versus 53884.2 ± 17693.3 ng-hr/ml, pc.OOl). After three to four days of
not smoking, the rate of caffeine metabolism was substantially slower, to the point that
caffeine toxicity might occur, if consumption was not reduced. They also suggested that
smokers tend to ingest more caffeine products because of the higher rate of caffeine
metabolism and the desire to achieve certain body caffeine levels.
Benowitz et al. (1989) investigated the plasma caffeine levels and caffeine
consumption patterns of 95 healthy participants in a smoking cessation program at baseline, 12
weeks and 26 weeks. Sixty-eight participants completed the program, sixty-four were in the
evaluation at 12 weeks (34 ex-smokers, 30 smokers) and sixty-one were evaluated at 26 weeks
(24 ex-smokers, 37 smokers). Among smokers who quit, they reported a 269% increase in
plasma caffeine levels from baseline to 12 weeks (6.64 ± 7.41 versus 17.89 ± 20.65 pmol/L,
pc.05) and a 266% increase from baseline to 26 weeks (7.33 ± 8.39 versus 19.54 ± 16.06
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jimol/L, j><-05). Caffeine consumption levels in the cessation group were approximately the
same at baseline and at 12 weeks (2.05 ± 1.66 versus 1.94 ± 1.68 mg/kg/day), but had
decreased from baseline to 26 weeks (2.14 ± 1.55 versus 1.62 ± 1.11 mg/kg/day, 2<-05;
baseline figures changed from a reduction of 3 participants at 26 weeks).
Finally, Oliveto et al. (1991) studied the influence of caffeine on smoking withdrawal
symptoms in ten participants (7 men, 3 women). The study design consisted of six 4-day
weekly trials. In each 4-day trial, participants received 0, 50, or 100 mg/caffeine per cup in
their decaffeinated coffee and were allowed to smoke or were abstinent. Results of the study
showed only a nonstatistically significant increase in plasma levels in the non-smoking
condition. Several reasons were cited for this non-significant finding: (1) the lower caffeine
dose (3.4 and 6.8 mg/kg versus 12 mg/kg in Benowitz et al., 1989 study) was not sufficient to
cause a detectable increase, (2) the participants were lighter smokers (20.2 versus 38.9 cig./day
in Brown et al., 1988 study), (3) the time was not long enough to produce significant increases
(4-days versus 12 and 26 weeks in Benowitz et al., 1989), and (4) the sample size was too
small.
In summary, there is evidence to support the hypothesis that when a person stops
smoking, metabolism of caffeine slows, the half-life of caffeine lengthens and saliva and
plasma caffeine levels increase. Whether the increased caffeine levels remain at elevated levels
for 3 and 6 months, and whether the higher plasma levels contribute to the tobacco withdrawal
syndrome, needs further study.
While smoking and cessation of smoking have a pharmacokinetic effect on caffeine
plasma levels, it also has been documented that ethanol consumption significantly prolongs
caffeine half-life and reduces caffeine clearance (George et al., 1986). Thus, a number of
factors including age, sex (oral contraceptives, pregnancy, taking female honnones e.g.
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estrogens), impaired liver function, and other drug usage may influence caffeine metabolism in
a way that is not easily predictable. Since cigarette smoking and coffee consumption, along
with alcohol, are common habits among smokers, future studies should be directed to see how
caffeine metabolism and half-life are affected in the smoker who quits and who continues to
consume alcohol as compared to those who do not consume alcohol.

Behavioral Association Between The Two Drugs - Conditioned Response
While coffee drinking and smoking have a positive association and smokers have a
tendency to smoke more cigarettes while drinking coffee (Hrubec, 1973; Istvan, 1984;
Marshall, 1980a; Parsons and Neims, 1978), there are several experimental studies that have
failed to show dose-related increases. Kozlowski (1976) reported that differing levels of
caffeine (0, 75, 150 , and 300 mg) had no dose effect on the cigarette consumption. In fact.
the group using decaffeinated coffee actually smoked more than the groups receiving caffeine
(p<.05). Studies by Ossip (1980, 1981) and Chait (1983) also showed no increase in the
number of cigarettes smoked as coffee dose increased.
Brown et al. (1989) suggest that the aforementiontioned brief single-dose caffeine
studies (usually ranging from one hour to three-and-one-half hours in length) "may not be
relevant to cigarette and coffee consumption over the course of the whole day." In response to
the short-term studies. Brown et al. (1989) conducted a four-day, multiple and variable daily
caffeine dosing (6 cups/day, daily caffeine dose 0, 6, or 12 mg/kg/day) study on nine male
subjects. The longer-tenn repeated dosing study revealed only a slight tendency (10% increase)
toward greater cigarette consumption with increased caffeine dose. It appears, then, that the
increase in cigarette smoking is only partially dose related to the phannacologic effect of
caffeine in coffee and that other factors are influencing the relationship.
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Marshall (1980a), in the first of two experiments, investigated the impact of a hard or
easy task on coffee consumption and cigarette smoking. Thirty-two coffee drinking smokers
were randomly assigned to one of four conditions (0, 1, 2 or 3 six-ounce cups of coffee) and
given either easy or difficult crossword puzzles to work on. Any amount of coffee doubled the
amount of cigarettes smoked, independent of crossword puzzle condition (2<.05). In the
second experiment, he found that both regular coffee and decaffeinated coffee significantly
influenced cigarette smoking and that regular coffee influenced puffs taken. Marshall also
demonstrated, however, that any liquid (water or Postum) could influence the number of
cigarettes smoked and puffs taken compared to the no drink situation. This suggests that
liquid, taste and appearance might also be contributors and influence cigarette smoking. In
another study, Marshall (1980b) suggested that the effect of coffee on increased smoking may
not be solely related to a pharmacological effects. A behavioral conditioning stimulus for
smoking may be present from the repeated pairing of the two drugs in the same setting. Coffee
consumption, or other factors may come to act as a cue to trigger cigarette consumption.
Emurian et al. (1982) used an event time series analysis to evaluate the relationship
between cigarettes and coffee use among eight participants. All subjects lived in a laboratory
(efficiency apartment) where their behavior was carefully monitored over seven to twelve days.
Results showed that coffee drinking tended to occur within twenty minutes after drinking
coffee than within twenty minutes before (jx.OOl). This suggests that coffee appears to be a
stimulus which influences cigarette smoking.
Chait et al. (1983) studied the effects of caffeine on cigarette smoking behavior in six
volunteers (3 men, 3 women). Participants received one of the following conditions: placebo.
200, 400 or 800 mg caffeine, or 25 mg d-amphetamine sulfate (known to increase cigarette
smoking) in gelatin capsules and a glass of water prior to the 90-minute daily smoking session.
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All the conditions were repeated 4 times. Results revealed that caffeine doses of 200, 400, or
800 mg had no effect on increased cigarette smoking. Since caffeine dose was unrelated to
cigarette use, Chait et al., su><sgested that the increase in cigarette smoking from coffee
consumption found in other research is more than the pharmacological effect of caffeine, and
that a behavioral association between the two drugs may have resulted in a conditioned
reaction. Thus, coffee drinkii^ smokers, for example, would tend to smoke during or after
their morning cup of coffee or during coffee breaks.
Another explanation fear the behavioral association between caffeine and nicotine may
be an indirect reciprocal interaction, with use of one substance acting as a cue to elicit use of
the second (Gilbert et al., 1919; Marshall et al., 1980a; Marshall et al., 1980b). For instance.
heavy caffeine consumption has been reported to increase the anxiety level (Sawyer et al..
1982), whereas the heightened anxiety levels may be relieved in some persons by the calming
effect of nicotine (Gilbert et aL, 1979).
A third explanation k Shat some third variable (e.g. stress, alcohol use) might influence
both coffee and cigarette use and hence cause the association. Conway et al. (1981) reported
that both caffeine and tobaco© use rose during days when high levels of stress occurred. The
average number of cigarettes smoked and cups of coffee consumed during high occupational
stress versus low periods of stress were 31.2 cig/day versus 27.8 cig/day, (£<.001) and 47.4
cups/week versus 33.6 cups/wsek (£<.04). Friedman et al. (1974), in the Kaiser-Permanente
Multiphasic Health Check-up, found that both coffee and alcohol use were correlated with
cigarette smoking. He reportei 25% of males and 12% of female smokers drank three or more
drinks of alcohol a day, whereas 9% of males and 3% of females nonsmokers consumed that
amount.
Therefore, there are a number of factors interacting with caffeine use which elicit
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smoking. While early studies have shown that alcohol is a strong stimulus for smoking
(Griffiths, 1976), as well as with stress (Conway et al., 1981), caffeine appears to be part of
the behavioral and pharmacological matrix.

Comparison of Caffeine-Nicotine Withdrawal Symptoms and Caffeine Toxicity Symptoms
The combined use of caffeine and nicotine among cigarette smokers may have
detrimental effects. When the smoker decides to quit smoking, plasma caffeine levels rise and
the caffeine half-life increases (Benowitz et al., 1989; Brown et al., 1988; Murphy et al.,
1988). The rise in caffeine plasma levels along with a decrease in nicotine plasma levels may
produce a combined effect of nicotine withdrawal symptoms and caffeine toxicity or
"caffeinism" type symptoms. For instance, symptoms of anxiety, difficulty concentrating.
impatience, insomnia, and restlessness have all been reported in studies of both nicotine
deprivation and caffeine excess (Greden, 1981; Hughes et al., 1990; Sachs et al., 1988). This
dual effect may add another dimension to the difficulty of remaining a quitter. The interaction
of caffeine and nicotine may be important in the cessation process and in the long term
success of the exsmokers who desire to continue their caffeine consumption habits.
The American Psychiatric Association, Revised Diagnostic and Statistical Manual
(APA, DSM III-R, 1987a) classifies nicotine withdrawal symptoms among the organic mental
disorders. The syndrome includes the following:
A. Daily use of nicotine for at least several weeks. B. Abrupt cessation of
nicotine use, or reduction in the amount of nicotine used, followed within 24
hours by at least four of the following signs: 1) craving for nicotine; 2)
irritability, frustration, anger; 3) anxiety; 4) difficulty concentrating; 5)
restlessness; 6) decreased heart rate; and 7) increased appetite or weight gain.
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The symptoms for caffeine toxicity, or "caffeinism" have likewise been identified and
described by the APA, DSM-III-R (1987b) as follows:
A. Recent consumption of caffeine, usually in excess of 250 mg. B. At least
five of the following: 1) restlessness; 2) nervousness; 3) excitement; 4)
insomnia; 5) flushed face; 6) diuresis; 7) gastrointestinal complaints; 8) muscle
twitching; 9) rambling flow of thought and speech; 10) cardiac arrhythmia; 11)
periods of inexhaustibility; 12) psychomotor agitation. C. Not due to any other
mental disorder, such as anxiety disorder.
Currently, caffeine withdrawal symptoms are not included in the APA, DSM-III-R.
Even though caffeine withdrawal headache is well documented, DSM-III-R states that "the
syndrome is usually not severe enough to warrant clinical attention" (APA, DSM-III-R, 1987).
Despite its lack of inclusion, as well as other caffeine withdrawal symptoms, there is current
discussion as to its relevance in the future DSM-IV revision (Hughes et al., 1992).
Table 3 contains a list of survey and experimental studies which have measured a
particular symptom and found evidence of its presence. The table is divided into four columns.
The first column lists the measured symptoms and the next three columns list the studies
which found evidence for supporting each symptom under nicotine withdrawal, caffeine
withdrawal and caffeine toxicity. Each study is represented by a single letter pemiitting a
comparative judging of the frequencies of studies finding each symptom. Appendixes 1A-C list
the source references for each letter used.
In assembling the table, only human survey and experimental studies were included.
While there are a number of case studies relevant to caffeine withdrawal and caffeine toxicity
symptoms, we have purposely excluded these in an attempt to produce a higher quality of
findings. Despite these exclusions, there are still design problems and lack of controls in a
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number of earlier reported caffeine studies (Wells, 1984).
Initial examination of Table 3 reveals that more studies have explored nicotine
withdrawal symptoms than caffeine withdrawal and caffeine toxicity symptoms. This suggests
the need for more well-designed studies to enhance the current database on caffeine.

Similarities
A close observation of Table 3 shows that a number of symptoms are similar in two or
more conditions. They include: 1) anxiety/tension; 2) depression; 3) irritable/frustration/anger/
upset; 4) restlessness/nervousness/jittery/shaky; 5) sleep disruption (insomnia), and
6) gastrointestinal problems.
Anxiety/Tension. Twenty nicotine withdrawal studies (prospective, retrospective and
survey) identify an increase in anxiety/tension symptoms in smoking abstinence (see Table 3,
1A). Hughes et al. (1986a) reported 87% of withdrawal smokers have symptoms of anxiety.
Five caffeine withdrawal studies mention this symptom. Anxiety symptoms from
caffeine withdrawal have been reported in psychiatric inpatients (Winsted, 1976), college
students (White et al., 1980) and in nonnal adults ( Silvennan et al., 1992). However, one
study found a decrease in anxiety scores (DcFreitas et al., 1979) and a second study reported
no increase (Griffiths et al., 1986) during the period of caffeine withdrawal. DeFreitas et al.
(1979) suggest that psychiatric patients may use caffeine to reverse the sedative effects of
tranquilizers and thereby increase anxiety symptoms.
Several problems exist in interpreting many of the caffeine studies. The lack of
consistency in caffeine dosage levels and the lack of control groups make it hard to draw
substantial conclusions. Also, smoking was not measured in most studies; alterations of
smoking behavior during the withdrawal process might bias the results. For instance, the
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higher caffeine excretion rate by smokers may intensify the caffeine withdrawal symptoms.
Symptoms of anxiety/tension were reported in eight caffeine toxicity studies. Greden (1974)
reported that caffeinism can produce symptoms similar to anxiety neurosis. These symptoms
have been reported among psychiatric patients (Greden et al., 1978; Winstead, 1976), among
general hospital patients (Victor et al., 1981) and among college students (Gilliland et al..
1981). The symptoms appears to be dose related (Greden et al., 1978; Victor et al., 1981), with
moderate and high caffeine groups (>750 mg/day or >5 cups/day) reporting significantly
higher anxiety scores (Gilliland et al., 1981; Greden et al., 1978; Victor et al., 1981; Winstead,
1976). However, panic disorder patients have exhibited anxiety symptoms on low doses of
caffeine (<100 mg/day, Lee et al., 1988).
In summary, anxiety symptoms appear to be associated with both nicotine withdrawal
and caffeine toxicity symptoms (Sachs et al., 1988; Oliveto et al., 1991). There may be an
interactive effect taking place between the two drugs. While anxiety has been reported as a
result of heavy caffeine consumption, it may be relieved in some persons by the
pharmacologically leveling effect of nicotine use (Gilbert, 1979). Since caffeine has been
shown to be excreted more rapidly in smokers (Parson and Neims, 1978) and that in nicotine
abstinence conditions caffeine plasma levels rise (Brown et al, 1988), the higher caffeine
plasma levels may be the cause for the increase in anxiety. Sachs and Bcnowitz (1988)
reported a double-blind, randomized, placebo-substitution trial where the participants received
0, 1, or 2 mg of nicotine gum over several weeks. During the placebo treatment, one caffeine
using participant had a five-fold increase in anxiety (jx.Ol). The caffeine plasma levels
increased from 4.5±0.6 (2 mg nicotine) to 12.6±3.5 mg/L (placebo, £<.001). While it appears
that anxiety may be associated with high plasma levels of caffeine and the indirect effect of
nicotine on caffeine metabolism and half-life, additional clinical studies are needed to
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substantiate this.
Depression. Twelve studies suggest depression as a nicotine withdrawal symptom.
Depression in abstinent smokers was described as a significant withdrawal symptom along
with the other core symptoms in 24 hour studies (Hajek et al., 1989; West et al., 1988),
increasing during the first four days then gradually declining (Hatsukami et al., 1984),
becoming significant from baseline at the end of week one and remaining elevated for an
additional two weeks and then declining (West et al., 1987). Twenty-one percent of abstainers
reported depression on the seventh day (Gritz et al., 1991). The gradual rise and peaking at the
end of the first week was similar to other nicotine withdrawal symptoms e.g., irritability.
restlessness, difficulty concentrating and cravings (West et al., 1989a).
While depression was not one of the major symptoms during the first week, by week
four, it was the third most (17%) reported symptom (West et al., 1989a). At the end of one
year, Gritz et al. (1991) reported that 9% of abstainers (n = 59) were still experiencing
depression. In his study, this was the 5th most frequent symptom, only superseded by eating
more (25%); restlessness (19%); impatience (10%) and excessive hunger (10%). Despite its
lack of inclusion in the APA, DSM-III-R (1987), depression appears to be a significant
nicotine withdrawal symptom and may have a increasing impact on recidivism over the long
term abstinent period.
Caffeinism, too, appears to be associated with symptoms of depression. Some
researchers suggest that both depression and anxiety may overlap each other (Cameron et al..
1985; Leeckman et al., 1983; Liebowitz et al., 1984; Uhdc et al., 1984). The symptoms of
depression associated with caffeinism has been reported in six studies (see Table 3:1C). The
study populations include psychiatric patients Greden et al., (1978), panic disorder patients
(Boulenger et al., 1982, 1984), depressed patients (Lee et al., 1988) and college students
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(Gilliland et al., 1981).
While depressed patients were found to be similar in caffeine consumption patterns to
a non-depressed control group (Boulenger et al., 1982, 1984), Neil et al. (1978) reported that
depressed patients may actually increase their daily caffeine intake in an attempt to improve
their mood. Panic disorder patients, who are more sensitive to the effects of caffeine including
depression (Uhde, et al, 1984; Chamey et al., 1985), have a tendency to use less caffeine
compared to control subjects (Boulenger et al., 1982, 1984).
Three caffeine withdrawal studies report this symptom. Higher depression scores on
days of caffeine placebo have been reported among graduate students (Dreisbach and Pfeiffer,
1943) and in normal adults (Oliveto et al., 1991; Silvennan et al., 1992). Silvennan et al.
reported that 11% scored abnormally high in depression during placebo.
Oliveto et al. (1991) looked at the interactive effects of both drugs on depression and
found no significant interactions. They did report an increase in depression under caffeine
placebo conditions. With the administration of 50 mg or 100 mg of caffeine there was a
marginal dose related decrease in depression. Several study design parameters, however, may
not have been adequate to detect an effect. The sample size (10 adults) was small, the caffeine
doses low (50 and 100 mg), only light to moderate smokers (20.2 cig/day) were assessed and
the four study days may not be sufficient to detect an interactive effect between caffeine and
nicotine on depression.
In summary, depression appears to be associated with nicotine withdrawal, caffeine
withdrawal, and caffeine toxicity symptoms. Whether depression is an independent symptom to
each drug situation is not clear. Hughes et al. (1990) suggest that abstinence from prototypic
stimulants (eg. caffeine), can result in clinical depression. The depression associated with
nicotine withdrawal may be distinct from caffeine depression, or there may be an interactive
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effect as in the case of arousal symptoms (Rose et al., 1986, 1991). To our knowledge, there is
only one short term study that has looked at the interactive effects of caffeine and nicotine on
withdrawal symptoms (Oliveto et al., 1991). We found no long tenn studies of interactive
effects.
Irritability, Frustration, Anger, Upset. Thirty-one nicotine withdrawal studies support
this symptom including DSM-III-R. The symptom tends to intensify within the first 24 hours
and peak at the end of the first week before declining (West et al., 1987).
Nicotine replacement studies have documented irritability as a nicotine withdrawal
symptom (Hajek et al., 1989; Hatsukami et al., 1988; West et al., 1984). One observation
study reported that 80% of nicotine withdrawal participants (documented by observer reports
before and after cessation) experienced this symptom (Hughes et al., 1986a). In another study.
however, Hatsukami et al. (1984) mentioned that nurses failed to note an increase in
argumentation with inpatient cessation.
West et al. (1989) list irritability as the second highest reported nicotine withdrawal
symptom (20%) during the first week of abstinence. By week four, it ranked 4th on the list of
most troublesome symptoms (8%). At the end on one year, Gritz et al. (1991) reported that 9%
of abstainers (n=59) were still experiencing symptoms of irritability/frustration and anger.
There are five studies that give support to irrilability/frustration/anger/upset as a
caffeine withdrawal syndrome. The symptoms have been reported in nonnal adult female
participants prior to coffee consumption and under placebo conditions (Goldstein et al., 1969a),
in psychiatric patients (De Freitas et al., 1979) and in a double blind study of normal adults
(Silvemtan, et al., 1992).
Five caffeine toxicity studies have documented this symptom. The symptoms have
been documented in female’s (Goldstein et al., 1969a), psychiatric patients (Greden et al..
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1978) and panic disorder patients (Boulenger et al., 1984).
In summary, nicotine deprivation, caffeine abstinence and caffeine toxicity produces
similar withdrawal symptoms of irritability\frustration\angei^jpset. Hughes et al. (1990), has
stated that there is a commonality of withdrawal symptoms among all drug abstinence
syndromes, of which irritability is just one. Since biological factors, such as rate of metabolism
and half-life, may influence the intensity or severity of the withdrawal effects, further study
looking at the interactive effects of caffeine and nicotine may be illuminating.
Nervousness/Jittery/Shaky/Restlessness. I have combined symptoms
nervousness/jittery/ shaky with restlessness because of their similarity. Twenty-five nicotine
withdrawal studies in Table 3 reported this symptom. DSM-III-R recognizes restlessness as a
tobacco withdrawal symptom. One observational study found that 71% of nicotine withdrawal
participants experienced this symptom of restlessness (Hughes et al., 1986a).
While West et al., (1988) identified this nicotine withdrawal symptom in the initial 24
hour of abstinence, Hajek et al. (1989) reported no significant changes for the same time
period. In another study West et al. (1987) reported a gradual increase in restlessness, peaking
at the end of the first week and then declining. Long tenn studies have identified this effect.
Restlessness/nervousness was the third most reported symptom (17%) during the first week of
abstinence (West et al., 1989). Another study found 47% experiencing this symptom at the end
of one week (n=96) and at the end of one year, 19% of abstainers (n=59) were still
experiencing symptoms of restlessness (Gritz et al., 1991).
Nicotine replacement studies demonstrate the reduction of restlessness/irritability/
jittery/shaky symptom. Two milligrams of nicotine gum appears to be reduce these symptoms
(Gross et al., 1989; West et al., 1984). These symptoms, are increased under low nicotine dose
(.5 mg) nicotine gum (West et al., 1984).
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Two caffeine withdrawal symptoms studies support the occurrence of these symptoms
(Table 3). Two studies reported symptoms of nervousness/restlessness in adult females if the
morning cup of coffee was missed, or a placebo was given (Goldstein et al., 1969a, 1969b).
Four caffeine toxicity studies found these symptoms. Adult females who are light
coffee users (1-2 cups/day) and non-coffee users reported more nervousness/restlessness with
regular coffee (Goldstein et al., 1969a, 1969b). Also, psychiatric patients in the high-caffeine
category (>750 mg/day) exhibited these symptoms (Greden et al., 1978).
In summary, restlessness/nervousness/jittery/shaky appears to associated with nicotine
withdrawal, caffeine toxicity and caffeine withdrawal. The symptom appears to be exhibited in
caffeine abstainers, who may be more sensitive to the initial effects of caffeine, and caffeine
users, who exhibit the same symptom under withdrawal effects. Tolerance to the
pharmacological effects of caffeine may be associated to the individual differences in the
metabolism of caffeine (Abbott, 1986; Levy et al., 1982). Future studies testing both drugs in
various before and after designs may help clarify this issue.
Sleep Disruption/Insomnia. Sixteen nicotine withdrawal studies have identified sleep
disruption as a symptom. Increases in the number of awakenings and duration of awakenings
following smoking cessation have been reported in a number of studies (Hatsukami et al.,
1984, 1987; Hughes et al., 1984; Gunn, 1986). One observational study reported 84% of
participants had symptoms of insomnia (Hughes et al., 1986a).
In nicotine replacement studies, the total cessation group had a significant increase in
the number of awakenings during sleep compared to the partial reduction group (Hatsukami et
al., 1988).
The effects of caffeine on sleep have been well evaluated; nine caffeinism studies
documented this symptom. Caffeine taken prior to sleep may delay the onset of sleep by 33
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minutes and affect the soundness of sleep (Goldstein, 1964). Caffeine’s affect on sleep may be
dose related, affecting the quality of sleep, increasing stage 2 sleep, decreasing stage 3 and 4
sleep, and variations in REM sleep (Karacan et al., 1977).
Impaired sleep or insomnia, as a result of caffeine consumption, has been reported
among psychiatric patients (Greden et al., 1978), general hospital patients (Victor et al., 1981)
and among nomial adults (Karacan et al., 1977). In psychiatric patients, if coffee is consumed
before bedtime, the symptom was higher (53%) among the low caffeine users (0-249 mg/day)
and lower (22%) among high caffeine users (>750 mg/day; Greden, 1978). Insomnia was the
second highest symptom (39%) associated with caffeine use among general hospital patients
(Victor et al., 1981).
Impaired sleep may be due either to the tolerance effect of caffeine (Golton et al..
1968; Greden et al., 1978) or the difference in the phannacokinetics of caffeine metabolism
and half-life among low versus high consumers (Greden et al., 1978). The fatigue effect may
become more pronounced among caffeine toxicity symptoms as the sleep deficit is chronically
established.
In summary, nicotine withdrawal as well as caffeine toxicity appears to affect the
quality of sleep, with effects showing an increase in the number of awakening, the quality of
sleep and the amount of sleep. The association between nicotine withdrawal and caffeine
toxicity symptoms may be due to an interactive effect. The elevated caffeine plasma levels
reported by Sachs and Benowitz (1988), from 4.5±0.6 (2 mg nicotine) to 12.6±3.5 mg/L
(placebo, 2<.001) during the nicotine placebo period, along with the significant five fold
increase in insomnia, suggest a drug interaction taking place (q<.01). Until further clinical
studies are done, no definitive conclusions can be drawn.
Gastrointestinal Problems. Four nicotine withdrawal studies have reported
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gastrointestinal problems. One prospective study reported 11% experiencing stomach or bowel
problems (Gritz et al., 1991) and in a sample survey 3% experienced gastrointestinal
disturbances (Hughes et al., 1987). In a third study, Stuer et al. (1989) stated "that out of 39
withdrawal symptoms, 22 (44%) symptoms varied and included constipation and other physical
symptoms." In contrast, Williams et al. (1982) compared smokers with non-smokers, reporting
that smokers complain of having more gastro-intestinal problems (diarrhea, stomach trouble)
than non-smokers.
Four caffeine toxicity studies demonstrated this symptom. Non-coffee drinking
housewives who were given caffeine in coffee versus decaffeinated coffee reported having an
upset stomach (Goldstein et al., 1969b). In another study, 17.8% of general hospital patients
reported abdominal pain with caffeine use (Victor et al., 1981). Third, Slaby et al., (1981)
found severe abdominal pain sometimes mimicking that of an acute abdomen among high
caffeine users.
In summary, nicotine deprivation and caffeine toxicity are associated with similar
gastrointestinal problems. The effect appears to be small, however, as compared to other
withdrawal symptoms. Future studies may help determine if it is an independent drug effect
or related to caffeine toxicity.

Differences
There are several withdrawal symptoms that arc different among the two drugs. They
include: 1) headache and 2) sleepiness (tired/drowsy/fatigued).
Headache. Three studies reported headache under nicotine withdrawal symptoms
(Gritz et al., 1991; Gunn, 1986; Hughes et al., 1987). In these studies, there was no mention of
a caffeine measurement or of caffeine behavioral changes during the cessation period. Two of
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the studies used the 1981 DSM-III criteria where headache is listed as a tobacco withdrawal
symptom. The 1987 DSM-III-R no longer designates headache as a tobacco withdrawal
symptom.
The most consistent feature of caffeine withdrawal is the headache. Nineteen studies
identify this as a withdrawal symptom. This generally occurs after 12-23 hours of abstinence
(Griffiths et al., 1986). Caffeine withdrawal headache occurs in 73% of postoperative patients
consuming >1,000 mg caffeine/day and 43-46% of the time in patients consuming 210-1000
mg/day (Galletly et al., 1989).
Headache may be related to caffeine’s effect as a cerebral vasoconstrictor and the
subsequent discontinuance of the drug produces a cerebral vasodilation effect and the
withdrawal headache (Diamond et al., 1986). The headache was described as: gradual in
development (Driesbach and Pfeiffer, 1943; Greden et al., 1980; Roller, 1981); throbbing
(Driesbach and Pfeiffer, 1943; Greden, 1974;; Greden et al., 1980; Roller, 1981); and severe
(Driesbach and Pfeiffer, 1943; Greden, 1974; Greden et al., 1980; Naismith et al., 1970;
Rainey, 1985). Other symptoms closely related may include: nausea (Driesbach and Pfeiffer,
1943); vomiting, ((Driesbach and Pfeiffer, 1943; Griffiths et al., 1990; Rainey, 1985);
rhinorrhea (Driesbach and Pfeiffer, 1943; Roller, 1981); and flu-like-feelings (Griffiths et al..
1990; Silverman et al., 1992). Also, caffeine containing analgesics are used by a higher
percentage of patients seeking relief from the withdrawal headache (Saper, 1983).
One study reported a significant interaction taking place between the two drugs and the
headache symptom (Oliveto, et al., 1991). During caffeine placebo, headache was significantly
greater under the smoking condition than under non-smoking conditions. Oliveto et al. reported
that 50 mg or 100 mg caffeine doses decreased the headache under the smoking condition.
This suggest that the headache symptom is brought on by a lack of caffeine and alleviated by
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caffeine. The fact that the headache occurred while smoking rather than not-smoking may be
due to nicotine’s effect in increasing caffeine metabolism. This would have resulted in quicker
reduction of plasma caffeine and, hence, quicker caffeine withdrawal headache.
In summary, headache appears to be associated with caffeine withdrawal, occurs
sooner as a result of smoking, but not usually with tobacco withdrawal.
Sleepy/Tired/Drowsv/Fatigued. Eight nicotine withdrawal studies report sleepy/tired/
drowsy/fatigued as a withdrawal symptom. In one study, eight percent reported feeling tired at
48 hours (Steuer et al., 1989); in another, 61.3% reported the same symptom (Gunn, 1986); in
a third, there was an increase in drowsiness (Hughes et al., 1984). Heavy smokers seem to be
more affected by this symptom than light smokers (Cummings et al., 1985). Despite these
findings, there are a number of nicotine deprivation studies that have failed to show
participants being affected by this symptom (Hatsukami, et al. 1987,1988; Rodin, 1987;
Hughes, et al. 1986; West and Russell, 1987).
In nicotine replacement studies, one study reported that drowsiness was significantly
reduced with nicotine replacement therapy (Gross et al., 1989); a second reported that nicotine
gum had no effect on relieving fatigue (Brantmark et al., 1983).
Seven caffeine withdrawal studies report sleepy/tired/drowsy/fatiguc as a common
symptom. The symptom has been demonstrated in placebo or decaffeinated coffee conditions
for graduate students (Dreisbach and Pfeiffer, 1943), among housewives Goldstein et al.
(1969), in nine adult ad lib smokers (Griffiths et al., 1986) in college students (JohnsonGreene, et al., 1988) and in nomial adults (Silvennan et al., 1992).
In summary, being sleepy, tired, drowsy or fatigued appears to be primarily a symptom
of caffeine withdrawal. Nicotine withdrawal studies, however, also have manifestations of this
symptom. Additional studies are needed to detenuine if the symptom is independent with each
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drug or an interactive effect may be taking place.

Summary and Conclusions
The strong significant relationship of coffee consumption and smoking is apparent
from large epidemiological studies to smaller sample surveys. Analysis of coffee consumption
in six large epidemiological studies (see Table 1) revealed that 86.4% of smokers consume
coffee versus 77.2% for nonsmokers. When you consider the total caffeine intake, however.
these estimates may be low because caffeine from additional sources (e.g. tea, soft drinks.
medications, etc.) usually was not measured.
After coffee drinking smokers quit smoking, they have greater consumption levels than
nonsmokers who never took up smoking (Hrubec, 1973; The Boston Collaborative Drug
Surveillance Program, 1972; Thomas, 1973; Murray et al., 1981, 1993). It is plausible to think
that this may be a continuation of their coffee drinking habit acquired while smoking. We do
not know, however, whether they used coffee prior to taking up smoking or what their caffeine
consumption levels were prior to smoking. It is possible they developed a higher tolerance to
the effects of caffeine independent of cigarette smoking.

Pharmacological Relationship
One explanation for the relationship between coffee consumption among cigarette
smokers may involve an increase in metabolism and the resulting shorter half-life of caffeine
in cigarette smokers (Kalow, 1985; Kotate, et al., 1982; May et al., 1982; Murphy et al., 1988;
and Parsons, and Neims, 1978). The mean half-life of caffeine in a nonnal healthy person is
around five hours (Busto et al., 1989). In smokers, the mean half-life is approximately 60%
shorter than in non-smokers (3.5 h vs 6.0 h; Parsons and Neims, 1978). The increase in
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caffeine metabolism by smokers may contribute to the increase in coffee consumption (Brown
et al., 1988; Parsons and Neims, 1978) as the smoker tries to maintain certain body caffeine
levels. Consistent with this, Benowitz et al. (1988) reported a decrease in caffeine intake
among quitters compared to continuing smokers. Several studies, however, reported no change
(Hughes and Hatsukami, 1986; May et al., 1982; Puddey et al., 1985; Rodin, 1987) and one
study actually showed an increase in caffeine consumption (Olbrisch and Oades-Souther,
1986).
While coffee consumption is strongly associated with cigarette smoking, the
relationship appears not to be dose-related. Several experimental studies have demonstrated no
increase in the number of cigarettes smoked as coffee dosage increased (Chait, 1983;
Koslowski, 1976; Marshall, 1980a, 1980b; Ossip, 1980). Brown et al. (1989) found only a
10% increase in cigarette smoking as caffeine dosage was increased. Thus, there appear to be
other factors in addition to a pharmacological one that is related to the caffeine-smoking
relationship.

Behavioral Relationship
One rationale for the increased cigarette smoking with coffee consumption may be
behavioral. Through repeated associations, coffee consumption may act as a cue to trigger
cigarette consumption or vice versa. Marshall’s (1980a) study showed that any liquid (water or
postum - a coffee substitute) may increase smoking. Despite the fact that regular and
decaffeinated coffee contributed the most, taste, appearance, or use of a liquid also may be
contributing factors.
The fact that smoking is twice as likely to occur after drinking coffee than before
suggests that coffee use stimulates cigarette use (Emurian et al., 1982). Whether the stimulus is
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behaviorally or pharmacologically induced is not clear. However, the weakness of the dose
response relationship mentioned in the previous studies seem to argue against a solely
pharmacological explanation.
The behavioral link between caffeine and cigarette smoking may be the result of a
indirect reciprocal interaction, with one substance acting as a cue to elicit use of the second.
For instance, heavy caffeine consumption has been reported to increase the anxiety level
(Sawyer et al., 1982), whereas the heightened anxiety levels may be relieved in some persons
by the emotional calming effect of nicotine (Gilbert et al., 1979).

The behavioral

association might also be caused by a third variable which affects the nicotine and caffeine
association. Several studies have demonstrated that when the level of stress or alcohol
consumption increases, there is a corresponding increase in both coffee consumption and
cigarette smoking (Conway et al., 1981; Friedman et al., 1974).

Additional Interactive effects
Other interactive effects may be taking place between caffeine and nicotine. In addition
to the interactive effects of both drugs on caffeine withdrawal headache, discussed earlier,
Oliveto et al. (1991) reported a second interactive effect. During caffeine placebo, the severity
of hunger was significantly greater during smoking abstinence than during smoking conditions.
The addition of 50 mg or 100 mg caffeine decreased the hunger symptom relative to the
placebo condition. During smoking, caffeine placebo and both caffeine doses had no effect on
changes in hunger. Two studies by Rose et al. (1986, 1991) showed nicotine actually
decreasing arousal in the presence of caffeine. While both caffeine and small doses of nicotine
have the capacity to increase arousal (Rose et al., 1986, 1991), these studies indicate that one
drug may interact with the second one resulting in a different symptomatic response.
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In abstinent smokers, plasma caffeine levels tend to increase (Benowitz et al., 1989;
Brown et al., 1989; May et al., 1982; Nil, 1984) up to 266% of baseline levels and may stay
elevated for 6 months (Benowitz et al., 1989). The higher plasma caffeine levels in abstinent
smokers may produce a nervous system caffeine toxicity syndrome (Brown et al., 1988; May
et al., 1982). The coffee drinking smoker who quits smoking would be confronted with
nicotine withdrawal symptoms and caffeine toxicity symptoms at the same time. For instance,
symptoms of anxiety/tension, depression, irritable/frustration/ anger/upset, sleep
disruption/insomnia, restlessness/ nervousness/jittcry/shaky and gastrointestinal problems have
all been reported in studies of both nicotine deprivation and caffeine excess (see Table 3).
At the end of one year, abstinent smokers report that they are still experiencing
withdrawal symptoms (Gritz et al., 1991; Silvennan et al., 1992). While one could argue that
this is a behavioral or environmental phenomena, it may be the result of caffeine toxicity from
continued caffeine usage along with other factors which effect caffeine metabolism and halflife (e.g. alcohol, other drug usage, liver problems, etc.).
The rate of drug elimination may also inlluence the severity of the abstinence effect.
Martin (1977) has suggested the faster decline in plasma levels of a drug may be associated
with greater abstinence effects. Hatsukami et al. (1985) reported that smokers with a higher
nicotine metabolism had more confusion and an increase in the number of awakenings after
abstinence than did smokers with longer nicotine half-lives. Since nicotine increases the
metabolism of caffeine and shortens its half-life, could this higher caffeine metabolism
contribute to the an increase in caffeine withdrawal symptoms among smokers?
Of all the experimental studies that have examined the causal effect of caffeine dose
on nicotine use, only one of them has found a relationship (Brown et al., 1989) and it was
weak. Is it possible that the causal link is in another direction; that smoking increases caffeine
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metabolism? If this is true, could this contribute to the heavier caffeine consumption levels
among heavier smokers who may be experiencing greater caffeine withdrawal effects than light
or moderate smokers and who consequently have a greater multi-drug physical dependency,
not to mention the use of additional sedatives and tranquilizers to alter their mood states?

Suggestions for Future Research
In conclusion, a number of factors are both pharmacologically and behaviorally
interacting directly and indirectly in the caffeine and nicotine relationship. While the preceding
concepts on the interactive effects of caffeine and nicotine seem rationale, the current research
data base supporting these concepts are quite scarce. Additional studies are needed to help
clarify these issues.
It is apparent from this review that the interactive effects of caffeine and nicotine are
largely unexplored. Future research is especially needed in several areas:
1) Studies of the abstinence effects of nicotine in caffeine users and non-users
are needed which quantify the magnitude and identify the withdrawal
symptoms most affected.
2) Long term studies are needed that examine how caffeine, alcohol, and other
drugs, affect persistent and annoying withdrawal effects in abstinent smokers.
3) Research is needed to detennine if there is a dose-response relationship
between smoking, caffeine metabolism and its half-life.
4) Studies are needed to detennine if there are drug interactive effects taking
place between caffeine and nicotine which influence the severity of symptoms.
5) We found no studies which have examined the influence of gender on
nicotine and caffeine metabolism (e.g. oral contraceptives, pregnancy and
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female hormones are known to increase caffeine’s half-life), therefore, studies
targeted at women are needed to detennine if the higher caffeine plasma levels
may intensify withdrawal effects and contribute to smoking cessation
recidivism among women.
6) Research is needed to analyze abstinence effects that include baseline.
several postcessation measures, never smoking controls, never caffeine
controls, to determine whether abstinence effects are influenced by behavioral
conditioning or phamiacokinetic interaction.
7) Experimental studies of the effects of nicotine dose on caffeine consumption
would help to clarify the relationship between these drugs.
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Table 1. Summary of Studies Showing Percentage of Smokers and Nonsmokers
(never smoker & exsmoker) Consuming Coffee.
Reference

Sample

Percentage consuming coffee
Smokers

o\
oc

Nonsmokers

Significance

Boston Collaborative Drug
Surveillance Program (1972)

1,104 men
controls

80.2%

73.7%

X2d, N = 1,104) = 6.42
£=.011

Hrubec (1973)

10,615 men

95.2%

83.7%

X2(1,N= 10,615) = 393.6
£<.000005

Dawbcr, Kannel and Gordon
(1974)

1,992 men

91.54%

Rosenberg et al. (1980)

980 women
controls

71.5%

57.4%

X2(l, N = 980) = 20.91
£<.000005

Murray et al. (1981)

16,800 men

97.0%

91.5%

X2G, N = 16,800) = 353.1
£<.000005

Lang et al. (1983)

6,321
(3,704 men, 2,617
women)

90.9%

81.9%

X2(1,N = 6,321) = 104.2
£<.000005

Rosenberg et al. (1988)

955 men controls

83.5%

74.8%

X2(l, N = 955) = 10.95
£=.00094

(no information reported)

Table 2. Summary of Studies Investigating the Relationship of Coffee Use to Nicotine Use (ordered
from earliest to most recent).
Reference

Sample

Measures

Findings and Significance

Boston
Collaborative
Drug Surveillance
Program (1972)

1,104 men
non-myocardial
infarct controls

Caffeine:Coffee
0, 1-5, 6+ cups/day
Nicotine:Nonsmoker
(exsmoker,nonsmoker),
smokers (cigarette, pipe and
cigar)

Smokers per coffee
category: 40.6%, 46.1% &
76.0%, respectively
r(2, N = 1,104) = 37.98,
£<.000005

Hrubec (1973)

10,744 men

Caffeine: Coffee 0, 1-5, >6
cups/day
Nicotine: Nonsmoker
(exsmoker, never smoker),
smoker(pipe, cigar &
cigarettes)

Smokers per coffee
category: 36.4%, 63.8% &
82.4%, respectively
X2(2, N = 10.615) = 683.9,
£<.000005

Thomas (1973)

692 male
physicians
10,744 men

Caffeine: Coffee - number of
cups/day
Nicotine: Lifetime
nonsmokers, former
cig/smokers, continuing
cig/smokers

Mean cups of coffee/day per
nicotine category: 1.69,
2.34, & 2.96, respectively
£<.01

Dawber, Kannel
& Gordon (1974)

1,992 men
2,500 women

Caffeine: Coffee - number of
cups/day (0, 1, 2, 3, 4. 5, 6,
>6)
Nicotine: Number of
cigarettes smoked/day

Men: Number of cigarettes
smoked/day per coffee
category = 8.7, 9.9, 11.5,
13.5, 16.2, 16.5, 18.7, 21.8,
respectively £<.001.
Women: non-significant, no
data reported

Friedman, et al.
(1974)

36,656 adults
(approx. 58%
women)

Caffe ine:Coffee <6 & >6
cups/day
Nicotine: Smokers (current
and past year smoking),
nonsmokers (never smokers)

Percentage of smokers per
coffee category: <6 cups
coffee/day - 48.6%, >6 cups
coffee/day - 76.7%
X2(1,N = 36.610) = 2338.4,
£<.000005

Wingerd &
Sponzilli (1977)

9,547 women

Caffeine: Coffee <6 & >6
cups/day
Nicotine: Never smokers, past
smoker, <1, 1, l1/:, 2+
packs/day

Percentage of smokers
consuming >6 cups of
coffee/day per nicotine
category: 14.3%, 22.6%,
23.9%, 42.6%, 56.8% &
55.8%, respectively
No data on <6 cups per day
reported

69

Coif t Table 2.
Reference

Sample

Measures

Findings and Significance

Prineas, et al.
(1980)

7,009 men

Caffeine: Coffee - number of
cups/day (0, 1-2, 3-4, 5-6,
7-8, 9-10, 11+), Tea - number
of cups/day (0, 1, 2, 3+)
Nicotine: Number of
cigarettes smoked/day

Positive correlation between
smoking and coffee
consumption (r = .34,
£<.05)
No correlation between
smoking and tea
consumption (r = -.052,
£<.05)

Rosenberg, et al.
(1980)

980 women
non-myocardial
infarct controls

Caffeine: Coffee (0,
1-4, 5+ cups/day)
Nicotine: Nonsmokers (never
smokers & exsmokers)
Smokers (1-14, 15-24, 25-34,
35-44 & 45+ cigarettes
smoked/day)

Smokers per coffee
category: 46.2%, 56.7% &
73.2%, respectively
X2(2, N = 980) = 35.45,
£<.000005

Conway, et al.
(1981)

34 male, U.S.
Navy petty
officers

Caffeine: Cups of
coffee/week
Nicotine: Number of
cigarettes, cigars, and pipefuls
smoked /day

Positive correlation between
smoking and coffee
consumption (r = .408,
£<.01)

Kannas (1981)

880 Finish men

Caffeine: "Drinks little
coffee" (0-1 cups/day)
Nicotine: Nonsmoker, 1-9,
>10 cigarettes smoked/day

Percentage from each
nicotine category consuming
0-1 cups coffee/day: 48.0%,
40.0% & 26.0%,
respectively

Murray, et al.
(1981)

16,800 men

Caffeine: Coffee - number of
cups/day (0, <1, 1-2, 3-4,
5-6, >7)
Nicotine: Number of
cigarettes smoked/day (1-19,
20-29, 30+)

Smokers per coffee
category: 13.1%, 16.3%,
19.8%, 28.3%, 39.1%, &
54.2%, respectively
X2(5, N = 16,800) = 976.91,
£<.000005

Cameron &
Boehmer (1982)

272 interviewed
persons
(65% female)

Caffeine: "Currently use"
coffee
Nicotine: "Currently use"
tobacco

Coffee consumption
correlated positively to
cunent tobacco use (r = .14,
£<.02)

Lang et al. (1983)

6,321 salaried
workers
(3,704 men,
2,617 women)

Caffeine: Coffee - number of
cups/day (0, 1-2, 3-4, 5+)
Nicotine: Number of
cigarettes smoked/day
(smokers, nonsmokers)

Smokers per coffee
category: 28.5%, 39.8%,
52.0% & 71.0%,
respectively
X2(3,N = 6,321) = 335.29,
£<.000005
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Con't Table 2.
Reference

Sample

Measures

Findings and Significance

Mathias et al.
(1985)

701 adults
(320 men, 381
women)

Caffeine: Regular coffee &
decaffeinated coffee (0-7, 832, 33+ oz./day)
Nicotine: Number of
cigarettes smoked/day

Cigarettes smoked/day per
regular coffee category;
Men: mean = 2.8, 3.9, &
11.5; Women: mean = 3.0,
5.0, & 6.1 cig/day,
respectively
Decaffeinated coffee; Men:
mean = 3.0, 2.5 & 1.2;
Women: mean = 3.5, 2.1,
5.0 cig. /day, respectively

Rosenberg et al.
(1988)

955 men nonmyocardial
infarct controls

Caffeine: Coffee (0,
1-2, 3-4, >5 cups/day)
Nicotine: Non-smokers &
smokers (0, 81-24, 25-34,
>35 cigarettes smoked/day)

Smokers per coffee
category: 38.5%, 33.9%,
51.2% & 70.0%,
respectively
X2(3.N = 955) = 81.08,
£<.000005

71

Table 3. Studies Which Found Evidence of Particular Symptoms: Nicotine Withdrawal, Caffeine
Withdrawal and Caffeine Toxicity Symptoms, (see appendix 1A-C for reference of each designated
symbol)
Measured
Symptom

Nicotine Withdrawal
Symptom (N=42)

Caffeine
Withdrawal
Symptom (N=24)

Alertness/Aroused

J

DO

Caffeine Toxicity
Symptoms (N=20)

(decrease)

Alertness/Aroused

KLQR

(increase)

Annoyed

N

Anxiety/
Tension

BCDEGMNRSUVXYZ
beklmo

FIKOP

EHIJKLOQ

X

Arms-legs
(heavy feelings)
Blood Pressure

R

(increase)

Blood Pressure

o

MR

(decrease)

Chest (tightness)

J

Concentration (difficult)

AEFGHIMNOPRSTVW
Zabcdfhikm

RU

Confusion/
Bewilderment

FLMQUXYej

ORUX

Coughing

J

Craving
(desire/urge
for product)

ABEFGHJKLMOQRST
UVWXYZabcefiklmnp

RU

Depression

FIMNUWXYacik

AWX

Disoriented

Nk

Diuresis

JO

Dizziness

IJQVk

Dry mouth

Q

Eating more

DRUbkl

Energy/Vigor (decrease)

MRUXYck

DORUX

Ru-like Feelings
Gastrointestinal

EHIKLO

RUX
CVfk

O (iM)

Problems (increase)
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CGJK

Con’t Table 3.
Measured
Symptom

Nicotine Withdrawal
Symptom (N=42)

Caffeine
Withdrawal
Symptom (N=24)

Caffeine Toxicity
Symptoms (N=20)

Headache

QVk

ABCDEGHJLMNO
RSTUVWX

J

Heart Rate (decrease)

FHPYco

MP

Heart Rate
(tachycardia)

GJO

Heart
Palpitations
Hunger/Appetite

N
ACDGIMOQSTVWYZa
bcfijklmop

W

Hunger (desire for
sweets)

o

W

Lightheadedness

A

Impatience

DFGMRSVbdklmo

Irritable/Anger/
Frustration/Upset

ADEGHIJMNOPQRST
UVWXYZabceiklmop

(increase)

GJ

CDIOX

Lassitude (list-less,
weakness, exhaustion)

E

Lethargy/Lazy

ACORUX

Mood Disturbance

GOQ

CEGLQ

RU

No

Muscle (restless legs)

F

Muscle Twitching

G

Muscle Tension/Pain

KRU

Nausea/Vomiting

ARU

Nervousness/
Jittery/Shaky

Qe

CD

BCEG

< Performance
(task related/
productivity)

Dgh

COPUX

IP

> Performance
(psychomotor)

N

Perspiration
(excessive)

Q
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Con’t Table 3.
Measured
Symptom

Nicotine Withdrawal
Symptom (N=42)

Caffeine
Withdrawal
Symptom (N=24)

Restlessness

ABDEGHIMNORSTV
Wabciklmo

C

Rhinorrhea

Caffeine Toxicity
Symptoms (N=20)

A

Respiration
(tachypnea)

GJO
X

Self-confidence
(decrease)
Shakiness

Q

Sleepy/Tired
/Drowsy/Fatigued

HJQXbfjk

ADOQRUX

Q

Sleep Disruption
(insomnia/wakefullness)

ACFGHLMQRUVYbcl
m

N

ABDEJKLQS

Sociable/Friendliness
(decrease)

I

IRUX

Somatic Complaints

GRV

IX

Stimulation

MRT

Talkative

T

Tremors (increase)

N

AV (iGo)

Vision Blurred
Weight (increase)

X
DUY1

Yawning

AX

Appendix 1A: references for nicotine withdrawal symptoms
Appendix IB: references for caffeine withdrawal symptoms
Appendix 1C: references for caffeine toxicity symptoms
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APPENDIX 1A
References of Symbols for Table 3, Column A: Survey and Experimental Studies Relevant to Nicotine
Withdrawal Symptoms in Abstinent Conditions.
Symbol

Reference

A

Larson, & Silvette (1968,
1971)

smokers: irritability, restlessness, tremor, inability to
concentrate, craving, light-headedness, insomnia, hunger

B

Shiffman & Jarvik (1976)

35 adult smokers, M = 23.5 cig/day: anxiety, craving,
restlessness

C

Williams, Hudson, & Redd
(1982)

survey, 50 smokers, 50 non-smokers: anxiety, loss of
sleep, hungry, gastrointestinal symptoms (diarrhea,
stomach trouble)

D

Manley & Boland (1983)

94 adult smokers, M = 23 cig/day: restlessness, tension,
impatience anxious, irritability, appetite, overeating,
weight gain, poor productivity

E

Glassman, Jackson, Walsh,
& Roose (1984)

15 adult smokers, 30+ cig/day: anxiety, irritability,
craving, restlessness, concentration, tension

F

Hatsukami, Hughes, Pickens,
& Svikis (1984)

27 smokers, M = 35.2 ± 12.5 cig/day: craving,
depression-dejection, confusion, increased number of
awakenings, increased duration of awakenings, poor
concentration, decreased heart rate

G

Hughes, Hatsukami, Pickens,
Krahn, Mai in, & Luknic
(1984b)

99 adult smokers, majority = 30 cig/day: craving,
irritability, anxiety, difficulty concentrating, restlessness,
impatience, somatic complaints, anger, tension, hunger,
insomnia, less tremor

H

Hughes, Hatsukami. Pickens,
Svikis (1984a)

? subjects, 15-32 cig/day: irritability, restlessness,
drowsiness, craving, insomnia, difficulty concentrating,
decreased heart rate

I

West, Jarvis, Russell,
Carruthers, & Feyerabend
(1984)

48 adult smokers, 2 groups, 25/26.5 cig /day: irritability,
depression, hunger, restlessness, dizziness, decreased
ability to concentrate, decreased sociability, less
composed when in company

J

Cummings, Giovino, Jaen, &
Emrich (1985)

33 adult smokers, M = 26.7 cig/day: irritability, feeling
sleepy, dizziness, coughing, tightness of chest, craving

K

Hall, Killen (1985)

64 adult smokers, M = 31.7 cig/day: craving (urge
severity)

L

Hatsukami, Hughes, Pickens
(1985a)

20 adult smokers, 36.9 ± 12.2 cig/day: craving, increased
confusion, increased number of awakenings

Measured and Reported Symptom
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APPENDIX 1A (con’t)
Symbol

Reference

M

Hatsukami, Hughes, Pickens
(1985b)
(2 studies)

76 adult smokers, 2 groups: anxiety-tension, confusion,
depression-dejection, less vigor, anger-hostility, craving,
irritability, difficulty concentrating, restlessness,
impatience, hunger, sleep problems,
increased number awakenings, increased duration of
awakenings

N

Schneider, N.G., Javik,
M.E., (1985)

60 adult smokers, 30-35 cig/day: annoyed, hostile,
irritable, fluctuations in mood, frustration, depression, left
out, anxiety, concentration, disorientation, restlessness

O

West, Russell (1985a)

29 smokers, M = 23.9 cig/day: craving, irritable, hunger,
restlessness, inability to concentrate

P

West & Russell (1985b)

6 female smokers, 34 cig/day: irritability, difficulty
concentrating, decrease heart rate

Q

Gunn (1986)

285 adult smokers: nervous, hungry, sad, tired, confused,
sleep problems, dizzy, dry mouth, headaches, shakiness,
angry, irritable, craving

R

Hughes, & Hatsukami
(1986a)

50 adult smokers, M = 29 cig/day: anxiety, irritability,
craving, difficulty concentrating, restlessness, increased
eating, impatience, somatic complaints, less vigor, anger,
tension, increased sleep disturbance

S

Hughes, Hatsukami, Skoog
(1986b)

8 adult exsmokers & nicotine gum users, median 25
cig/day & 9.5 pieces nicotine gum/day, respectively:
irritability, anxiety, restlessness, impatience, difficulty
concentrating, hunger, craving

T

McNeil, West, Jarvis,
Jackson, & Bryant (1986)

survey, 597 girls ages 11-17, 191 were current smokers:
craving (strong need to smoke), irritable, unable to
concentrate, hungry, restless, miserable

U

Hatsukami, Gust, & Keenan
(1987)

two groups: 16 smokeless tobacco users & 11 cigarette
smokers, M = 2.06 tins/wk & 26.27 cig/day, respectively:
craving, confusion, increased eating,
increased number of awakenings, anger-hostility, tensionanxiety, less vigor, increased weight, increased number of
awakenings, depression-dejection

V

Hughes, Gust, Pechacek
(1987)

survey, 1,006 male smokers: craving, irritability, anxiety,
difficulty concentrating, restlessness, increased appetite,
impatience, somatic complaints (headache, dizziness,
tremor, stomach or bowel problems), insomnia

W

West, Hajek, & Belcher
(1987)

84 adult smokers, two groups, M = 24.7 & 25.3 cig/day:
depressed, irritable, restless, hungry, poor concentration,
craving (time spent w/urges)

Measured and Reported Symptom
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APPENDIX 1A (con’t)
Symbol

Reference

X

Killen, Fortmann, Telch, &
Newman (1988)

two groups, 259 adult smokers (>25 cig/day), 121 adult
smokers (<15 cig/day): anxiety, depression, anger, vigor,
fatigue, confusion, craving

Y

Hatsukami, Dahlgren,
Zimmerman, & Hughes
(1988)

32 adult smokers, 3 groups, M = 26.3 ± 5.4, 26.2 ± 7.2,
25.7 ± 8.3 cig/day: decreased heart rate, increased weight,
increased number of awakenings, anger-hostility, craving,
hunger (eat),
tension-anxiety, depression-dejection, confusion, less
vigor

Z

Stitzer & Gross (1988)

40 adult smokers, two groups: anxiety, impatience,
irritability, impatience, craving, difficulty concentrating,
hunger, weight gain

a

West, Russell (1988)

21 adult smokers, M = 23 ± 6.3 cig/day: irritability,
depression, hunger, difficulty concentrating, restlessness,
craving, feeling physically less well

b

Gross and Stitzer (1989)

40 adult smokers, 2 groups, 35.5 & 33.9 cig/day:
irritability, anxiety, impatience, restlessness, excessive
hunger (appetite), difficulty concentrating, drowsiness,
sleep disturbance, craving, excessive eating

c

Hajek, Jarvis, Belcher,
Sutherland, & Feyerabend
(1989)

40 adult smokers, 24.4 cig/day: depressed, irritable, less
energetic, restless, poor concentration, hungry, poor sleep,
urge to smoke, cravings,
decreased heart rate

d

Hughes, Keenan, & Yellin
(1989)

16 adult male smokers, 23.2 ± 6.7 cig/day: difficulty
concentrating (slow reaction time & inconsistent
responding), impatience (inability to inhibit responding)

e

Shiffman (1989)

47 adult smokers, 2 groups, 26.48 & 4.27 cig/day:
craving, tension, confusion, nervous, negative affect
(tense, angry, bored)

f

Steuer & Wewers (1989)

29 adult smokers: craving, difficulty concentrating/
mental clouding, appetite, feeling tired, constipation

g

Snyder, Henningfield (1989)

6 adult male smokers, M = 27 ± 5.2 cig/day: decreased
performance

h

Snyder, Davis, &
Henningfield (1989)

7 adult male smokers, 35.7 ± 9.8 cig/day: decreased
performance (attention, concentration, & memory)

West, Hajek, & Belcher
(1989)

147 adult smokers: craving, irritability, hunger,
restlessness, depression, difficulty concentrating

Zacny & Dewit (1990)

7 adult smokers, M = 23 cig/day: fatigue, confusion,
arousal, hungry

J

Measured and Reported Symptom
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Symbol

Reference

k

Gritz, Carr & Marcus (1991)

554 adult smokers. 19.3 - 24.4 cig/day: craving, restless,
eating more, anxious/tense, impatient, irritable/ angry,
difficulty concentrating, hunger, depressed, disoriented,
loss of energy, fatigue, dizziness, stomach or bowel
problems, headaches (11%)

1

Hatsukami, Skoog, Huber, &
Hughes (1991)

48 smokers, 3 groups, 30.1, 27.0, 27.7 cig/day: craving,
irritable, anxious/tense, impatient, excessive hunger,
increased eating, insomnia, number of awakenings, poor
quality sleep, weight, restless

m

Hughes, Gust, Skoog,
Keenen, & Fenwick (1991)

315 adult smokers, two groups, M = 29.2 ± 12.0 & 29.8
± 10.7 cig/day: anger-irritable, impatient, restlessness,
anxiety, difficulty concentrating, hunger, craving,
insomnia

n

Killen, Fortmann, Newman,
& Varady (1988)

1,218 adult smokers, female = 23.1 ± 10.7 cig/day &
male = 26.6 ± 12.9 cig/day: craving

o

Oliveto, Hughes, Terry,
Bickel, Higgens, Pepper, &
Fenwick (1991)

10 adult smokers, M = 20.2 ± 5.7 cig/day: anxiety, desire
for sweets, hunger, impatience, initability, mood swings,
restlessness; decrease in heart rate, blood pressure and
tremor

P

West, & Hack (1991)

29 college student smokers, two groups, 14.6 & 1.4
cig/day: irritability, hunger, craving (time spent w/urge,
difficulty not smoking, & strength of urge)

Measured and Reported Symptom
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APPENDIX IB
References of Symbols for Table 3, Column B: Survey and Experimental Studies Relevant to Caffeine
Withdrawal Symptoms in Abstinent Conditions.
Symbol

Reference

Prior caffeine use and reported withdrawal
symptom in abstinence

A

Dreisbach & Pfeiffer (1943)

22 graduate students (given 0.12-0.78 Gm/day
prior to abstinence): lethargy, headache, nausea,
vomiting, rhinorrhea, mental depression,
drowsiness, yawning

B

Goldstein (1964)

230 students (>5 cups/day): headache

C

Goldstein & Kaizer (1969)

239 women; >3 cups/day: headache, lethargy,
irritability, inability to work effectively,
nervousness, restlessness

D

Goldstein, Kaizer & Whitby
(1969)

56 housewives; >5 cups/day: less alert, active,
energetic, relaxed & content; more sleepy,
irritable, and jittery/nervous/shaky; headache

E

Naismith, Akinyanju, Szanto &
Yudkin (1970)

20 healthy adults; 560 mg/day: lassitude, severe
headache within 12 hrs

F

Winstead (1976)

135 psychiatric inpatients; >500 mg/day: anxiety

G

Shorofsky & Watson (1977)

7 adults; 180-240 mg/day: headache

H

Greden, Fontaine, Lubetsky &
Chamberlin (1978)

83 psychiatric inpatients; survey: headache (no
significant difference for light, moderate, & heavy
user)

I

De Freitas & Schwartz (1979)

14 Psychiatric patients; anxiety, tension, hostility,
excitement, somatic concern, irritability, neatness,
social competence

J

Greden, Victor, Fontaine &
Lubetsky (1980)

205 patients; p=616 mg/day: headache

K

White, Lincoln, Pearce, Reeb &
Viada (1980)

36 college students (p=376 mg/day): muscle
tension, anxiety

L

Victor, Lubetsky & Greden (1981)

124 general hospital patients; survey: 24%
reported withdrawal headache (non-significant
difference between low, moderate, or heavy users)

M

Edelstein, Keaton-Brasted & Burg
(1983)

18 psychiatric inpatients: increased headache,
decreased BP, decreased HR. less gastro-intestinal
complaints.

N

Shirlow & Mathers
(1985)

4558 participants; 240 mg/day; palpitations,
tremor, headache, insomnia
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APPENDIX IB (con’t)
Symbol

Reference

Prior caffeine use and reported withdrawal
symptom in abstinence

O

Griffiths, Bigelow, & Liebson
(1986)

9 adult smoking males; p=1.25 g/day: sleepy, less
alert, increased lethargy/lazy, less active, 100%
reported headache, increase anxiety/tension,
confusion, bewilderment, more fatigue,
gastrointestinal complaints, more irritability,
decreased psychomotor performance, less
vigor/activity

P

Risso, Stamps & Fehr (1988)

40 students (200-600 mg/day):
decreased heart rate, poor performance - increase
in reaction time (decreased speed to accomplish
task)

Q

Johnson-Greene, Fatis, Sonnek &
Shawchuck (1988)

270 students; >300 mg/day: fatigue

R

Ratliff-Crain, O'Keffee & Baum
(1989)

40 nonsmokers (600 mg/day):
decreased systolic & diastolic BP,
poor concentration, desire for coffee (craving),
headache, lethargic/fatigue/tired/sluggish, less
vigor, muscle pain/stiffness, flu-like feelings,
nausea/vomiting, confusion-bewilderment, mood
disturbance, decreased friendliness

S

Baumgartner, Wessely, Bingol,
Maly & Holzner (1989)

54 neurological patients: headache

T

Galletly, Fennelly & Whitwam
(1989)

42 post-operative patients (210-1000 mg/day): 4346% had headache, (>1000 mg/day) 73% had
headache

U

Griffiths, Evans, Heishman,
Preston, Sannerud, Wolf &
Woodson (1990)

7 normal adults; p = 384 mg/day: headache, flu
like symptoms, nausea/vomiting, craving for
coffee, less vigor, less friendliness, increased
mood disturbance, greater confusion-bewilderment,
poor concentration, decreased performance, muscle
pain/ stiffness, lethargy/fatigue/tired/ sluggish

V

Fennelly, Galletly
& Purdie (1991)

287 post-operative patients: headache

W

Oliveto, Hughes, Terry, Bickel,
Higgens, Pepper & Fenwick
(1991)

10 adults (502.2 ± 300.6 mg/day): headache,
depression, desire for sweets, hunger
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Symbol

Reference

Prior caffeine use and reported withdrawal
symptom in abstinence

X

Silverman, Evans, Strain &
Griffiths (1992)

62 adults (p=235 mg/day): fatigue, depression, less
vigor, headache, greater indecisiveness, poor work
difficulty, decreased performance, decreased
friendliness, irritable/ cross/grumpy, decreased
well-being, less desire to socialize/talk, decreased
urge to do task\work-related, drowsy/ sleepy,
increased yawning, confusion\bewilderment, less
energy /active, increased lethargy/
fatigued/tired/sluggish, foggy/not clearheaded, flulike feelings, blurred vision, hot & cold spells, less
content/ satisfied, less self-confidence, heavy
feelings in arms & legs
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APPENDIX 1C
References of Symbols for Table 3, Column C : Survey and Experimental Studies Relevant to Caffeine
Toxicity Symptoms.
Symbol

Reference

Measured and Reported Symptom

A

Goldstein (1964)

230 students; wakefulness (increased time to fall
asleep), slept less soundly

B

Goldstein & Kaizer (1969)

239 housewives; 1-2 C/day; more wakefulness at
bedtime & more nervousness in AM from coffee;
5+ C/day: less wakefulness at bedtime & less
nervousness in the AM from coffee.

C

Goldstein, Kaizer
& Whitby (1969)

56 housewives; (0, 150, 300 mg/day) non-coffee
users: felt jitteriness, nervousness, upset stomach,
cross, irritable, grumpy after coffee

D

Karacan, Thomby, Anch, Booth,
Williams & Salis (1977)

18 males: insomnia

E

Greden, Fontaine, Lubetsky &
Chamberlin (1978)

83 psychiatric patients: anxiety (felt tired, blue,
like crying, tension, worrying), anxious, nervous,
upset; impaired sleep; depression, frequent use of
minor tranquilizers & sedative-hypnotics; use more
ethanol and cigarette

F

Lutz (1978)

62 patients: restless legs (crawling, creeping,
aching sensations in the lower legs)

G

Greden (1979)

3 adults: jitteriness, tremulousness, agitation,
muscle twitching, light-headedness, rapid breathing
(tachypnea), rapid heart beat (tachycardia), cardiac
palpitation (skipped beat), upset stomach, loose
stools, epigastric distress (heart burn)

H

Greden, Victor,
Fontaine & Lubetsky (1980)

205 patients; p=616 mg/day; anxiety, depression

I

Gilliland, & Andress (1981)

159 college students; moderate & high consumers
had: increased depression, anxiety, poorer physical
health, lower performance (academic)

J

Victor, Lubetsky & Greden (1981)

124 general hospital patients
(0-249 mg/day; 250-749 mg/day;
>750 mg/day): diuresis, insomnia, withdrawal
headaches, dianhea, anxiety, tachycardia,
tremulousness, abdominal pain, headache, and
light-headedness;
250-759 mg/day group reported less: headaches,
light-headedness, tachypnea, & tachycardia than
other groups
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APPENDIX 1C (con'l)
Symbol

Reference

Measured and Reported Symptom

K

Boulenger & Uhde (1982)

32 patients (16 anxiety, 16 matched non
psychiatric controls): anxiety, depression,
alertness, insomnia, tremors, diarrhea

L

Boulenger, Uhde, Wolf
& Post (1984)

53 outpatients, 53 controls: depression, insomnia,
anxiety, alertness, anger/hostility

M

Griffiths, Bigelow
& Liebson (1986)

9 adult men (p=12 cups/day): stimulant effect

N

Kuznicki & Turner
(1986)

70 male nonsmokers (50 consumed regular coffee
3-5 cups/day): increased psychomotor performance

O

Lee, Flegel, Greden
& Cameron (1988)

281 patients ( 127 depressed. 30 panic disorder,
124 nonpsychiatric patients); 0-249 mg/day; 250749 mg/day, & >750 mg/day:
Panic disorder: more anxiety, tachypnea,
palpitations, & tachycardia; Depressive and panic
disorder: more anxiety, diuresis, & tremulousness
than nonpsychiatric group

P

Foreman, Barraclough, Moore &
Madon (1989)

32 male students: decreased performance.

Q

Mackay & Rollins (1989)

1,000-1500 mg/day: tense, agitated, hyperalert,
disturbed sleep, fatigue, tremor, sweating,
palpitations, anxiety state, paranoid delusions after
4 days.
60 inpatients; 43% >500 mg/day

R

Ratliff-Crain, O'Keeffe & Baum
(1989)

40 healthy adults (u=5.7 cups/day): stimulant
effect, increased concentration, increased BP, task
less stimulating

S

Dusseldorp & Katan (1990)

45 normal adults (420 mg/day): decrease in quality
of sleep

T

Oliveto, Hughes, Terry, Bickel,
Higgens, Pepper, & Fenwick

10 adults (502.2 ± 300.6 mg/day): more
stimulated, talkative
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Abstract
Continuous caffeine consumption with smoking cessation has been associated with
more than doubled caffeine plasma levels. Such concentrations may be sufficient to produce
caffeine toxicity symptoms in smoking abstinence conditions. To test whether caffeine
abstinence influences smoking cessation, 162 caffeine using smokers were enlisted from
American Lung Association smoking cessation programs. Volunteers were randomly assigned
by clinic to caffeine use and caffeine abstinence conditions and measured for three weeks post
smoking cessation, at six months and one year. Results showed a significant linear increase in
caffeine sputum levels across four time points for those who quit smoking and continued using
caffeine. Three weeks after cessation, concentrations reached 203% of baseline for the caffeine
user. Typical nicotine withdrawal symptoms occurred during the first 16 days of cessation.
Caffeine abstinence significantly increased headache, fatigue, muscle aches/twitches, tobacco
craving, and decreased stimulation immediately following tobacco cessation. There were no
differences between the groups on other withdrawal symptoms. Finally, no significant
difference in success existed in either group at 16 days, 6 months or 12 months.
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Impact of Caffeine Use on Tobacco Cessation and Withdrawal

In a review of the caffeine-tobacco use relationship, Swanson, Lee and Hopp (1993)
found fifteen epidemiological studies which reported a positive association between coffee
drinking and cigarette smoking. In addition, 86% of smokers were found to drink coffee versus
77.2% for nonsmokers (never smokers and exsmokers).
Cigarette smoking increases the metabolism of caffeine and reduces its half-life
(Parsons and Neims, 1978; May, Jarboe, VanBakel, and Williams, 1982). When the coffee
drinking smoker quits smoking, caffeine plasma levels increase and remain elevated for up to
six months if caffeine consumption levels remain constant (Brown, Jacob. Wilson and
Benowitz, 1988; Benowitz, Hall and Modin, 1989). The higher caffeine plasma levels may
produce caffeine toxicity symptoms possibly making it harder for the smoker to quit smoking.
A recent review of nicotine withdrawal symptoms and caffeine toxicity symptoms suggest that
some of the nicotine withdrawal symptoms reported may be a combination of nicotine
withdrawal and caffeine toxicity symptoms (Swanson et al., 1993). The phamiacokinetic
interactions of caffeine and nicotine may be important in detennining the success of the
abstinent smoker as well as the withdrawal effects from continued use or nonuse.
There are some smoking cessation programs (e.g. Five-Day Plan and Breathe-Free
Plan) that emphasize the importance of eliminating caffeine consumption when one is trying to
quit smoking (McFarland & Folkenberg, 1978; Proctor & Proctor, 1985). For example.
McFarland and Folkenberg (1978) state: "it will help them get over the craving much quicker
if they drop off the caffeine," and Proctor and Proctor (1985) slate: "giving up caffeine will
probably help you get off and stay off cigarettes." Programs run by the American Lung
Association (1986 - "Freedom from Smoking") and American Cancer Society (1982 - "Fresh
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Start") do not have such an emphasis. While there are a number of epidemiological studies that
support the relationship between caffeine consumption and cigarette smoking, we found no
research that provides direct evidence that elimination of caffeine is helpful in smoking
cessation or that have measured the impact of simultaneous caffeine and tobacco cessation on
withdrawal symptoms.
The present study was designed to test whether continued caffeine use affects the
success of the smoker during smoking cessation. Our second objective was to detemiine
whether simultaneous caffeine cessation influences the withdrawal symptoms of the abstinent
smoker.
METHODS
Subjects One hundred-sixty-eight volunteers (65 male, 103 female) originally signed up for 41
American Lung Association "Freedom From Smoking Programs" in Southern California. Six
people dropped out after the first session, prior to the randomized group assignment. The
remaining 162 participants were randomly assigned by clinic to one of two conditions: a
standard care condition (21 clinics, 83 smokers) or a caffeine abstinence condition (20 clinics.
79 smokers). Inclusion criteria were: 1) use of caffeinated products in some form (e.g. regular
coffee, tea, or soft drinks), and 2) present use of cigarettes and intention to quit. Written
informed consent was obtained from each subject: the study was approved by the Loma Linda
University Institutional Review Board on Human Research (Loma Linda, CA.). Each
participant was given incentives: $20.00, a "LLU Research Project" T-Shirt at the end of the
Lung Association meetings, and a mailed summary of the research findings at the end of the
12 month follow-up. In addition, participants in the caffeine abstinence condition were
provided caffeine-free substitutes and decaffeinated coffees, e.g. Sanka, Kaffree-Roma, PepsiFree, Caffeine-free Coke.
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Experimental Design and Procedure The research design was a two condition experimental
design. In the "standard care condition" participants were asked to continue their caffeine use
at normal levels for the duration of the program; (2) in the "experimental condition,"
participants were asked to try to avoid drinking any beverage or product that contained
appreciable amounts of caffeine for at least one week and as much longer as possible during
the study. All participants were asked not to quit smoking until the specified "Quit Day" and
not to use nicorette gum or anti-depressant drugs after the targeted "Quit Day." Clinics were
closely matched by number of participants in each, then randomly assigned to one of the
experimental conditions. Participants and research assistants were blinded regarding the
assignment until the actual quit day. Prior to data collection, all research assistants were
trained in data collection protocol and given written guidelines. The project director or one
research assistant presented all enrollment protocol.
Seven sessions in the eight session "Freedom From Smoking Program" were used for
data collection. All data were collected at the conclusion of each cessation program. Table 1
shows session by session activities.
Insert Table 1 about here

Instruments Data were collected using the following instruments:
Intake questionnaire. The smoking / caffeine history questionnaire was modeled after
the American Lung Association intake questionnaire. Several rating scales were modified to a
nine-scale to provide a broader range of choices for data analysis, as suggested by Lando
(1983).
The questionnaire requested personal data, smoking history, use of caffeinated and
decaffeinated products, medical infonnation relating to kidney or liver problems, pregnancy,
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use of oral contraceptives, female honnones (e.g. estrogens) and alcohol consumption. The
caffeine section requested infonnation about brand type, product form (caffeinated or
decaffeinated), brewing method (instant, drip, perk, espresso), portion used (week day versus
weekend), and cup size. Queries about other sources of caffeine included caffeinated and
decaffeinated soft drinks, cocoa, chocolate milk, chocolate candy, brownies, prescription and
non-prescription drugs. Participants were asked to designate how many of these items were
taken daily or weekly. The questionnaire was pretested on 19 smokers in two cessation clinics
to assess clarity and length of time needed for completion.
"Feeling profile" (self-reported withdrawal symptoms scale). This questionnaire was
constructed by examining 43 studies of nicotine withdrawal symptoms and 54 studies of
caffeine withdrawal or caffeinism. After preliminary testing for word frequency (Carroll,
Davies, and Rickens, 1971), fonnat and understandability, the resulting questionnaire was
pretested in a sample of 221 smokers attending smoking cessation programs, then factor
analyzed. The thirty-two item, ten factor questionnaire included symptoms in the following
categories: caffeine craving, tobacco craving, poor concentration, fatigue, hunger, muscular
activity, negative affect, sensori-motor disturbances, sleep disturbance and stimulation.
Cronbach’s Alpha levels in the pretest ranged from .71 to .93.
Daily-log. This was used to detennine when, which, and how much change occurred in
the cessation process. Participants recorded this infonnation in a pocket-size set of daily-logs
three times a day (9 AM, 3 PM, and 9 PM) for seventeen days over a five-week period.
Participants were provided with a watch with alanns preset at the designated times to help
them remember to complete the log. The daily-log was divided into two sections. Section One
included the daily intake of nicotine, caffeinated and decaffeinated products (type, amount used
and cup size), mood altering drugs, alcohol beverages, prescription and nonprescription drugs.
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alcohol, sleep patterns, and time of first cup of coffee. Section Two measured the symptoms
relating to nicotine and caffeine abstinence and caffeine toxicity. The instrument is a shorter
version of the "Feeling Profile" described previously. It has a list of 26 symptoms with nine
factors: caffeine craving, tobacco craving, poor concentration, fatigue, hunger, muscle activity.
negative affect, sensori-motor disturbances and stimulation. The alpha levels for the shorter
scales ranged from .65 to .93 during pretesting.
The daily-log presents a different set of demands then does a questionnaire on
caffeine/nicotine-consuming habits. The log is detailed, specific, and ongoing (completed 3
times a day), allows for extensive practice. This type of data collection has produced greater
self-report accuracy over time than retrospective questionnaires (James, Bruce, Lader, and
Scott, 1989).
Six and twelve month follow-up. At six and twelve months from the actual quit day.
participants were telephoned and a short, five minute, follow-up survey conducted. Questions
were asked regarding nicotine and caffeine use, behavioral substitution for smoking, factors
related to smoking relapse (if it occurred), feelings and symptoms prior to smoking relapse,
time of caffeine product reinstatement, and time of smoking relapse. In addition, the twelvemonth follow-up investigated caffeine product use in relation to smoking (e.g. which products,
when, how soon used).
Cotinine and caffeine saliva collection. Four saliva samples were collected to measure
initial caffeine and cotinine levels. During saliva collection, participants were instructed
through oral and written collection guidelines. The procedure consisted of rapidly moving the
tongue around and against the inner check and then spitting the saliva into a frosted collection
cup. Each cup was premarked at 10 mL, and participants were asked to try to produce that
much saliva. Participants were instructed to drink the nonrial intake of fluids (6-8 eight oz

90

glasses of water or other fluid) on the day of saliva collection. Thirty minutes prior to time of
collection, they were not to eat any food, candy, or drink any water or beverage. All samples
were put in an ice chest, transported to a freezer and kept frozen (-20° C) until analyzed.

Caffeine and Nicotine Assessment
Daily-log. Caffeine intake was calculated for each time period (9 AM, 3 PM and 9
PM) by applying caffeine estimates (see Table 2) per ounce (29.5 mL) of liquid type
(caffeinated or decaffeinated coffee, tea, soft drink, cocoa, chocolate milk). The result was
multiplied by a weighted caffeine score for brewing method and product form, then multiplied
by the number of ounces consumed (cup size times number of cups). Finally, the caffeine
amounts for each category (e.g. coffee, tea, soft drinks, cocoa, chocolate milk, chocolate bar)
were added together. Prescription and nonprescription drugs containing caffeine were
calculated by multiplying the number of capsule(s) or tablet(s) used by the caffeine content of
that specific drug and adding it to the total caffeine score for that time period. The total daily
caffeine intake was calculated by summing the score for each of the three time periods.
Insert Table 2 about here

Intake questionnaire. Daily caffeine consumption on the intake questionnaire was
calculated by applying the same caffeine estimates (see Table 2) and calculations as used in
the daily-log, with two differences: 1) in calculation, a weighted average for the "number of
cups" used was obtained by multiplying the frequency questions of weekday by five and
weekend by two. The two scores were added together, then divided by seven. 2) Prescription
and non-prescription drugs containing caffeine were placed into six categories (32, 40, 65, 100,
140, and 200 mg per dose). The number of capsules/tablcts taken was multiplied by the
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category and a summation of these categories were added to the total daily caffeine score.
Daily nicotine intake (mg) for cigarettes was determined by matching the reported
brand name and descriptors (size, filter, menthol, "ultra light", etc.) with the 1991 Federal
Trade Commission Report. The total nicotine alkaloid reported as milligrams of nicotine per
cigarette was multiplied by the number of cigarettes smoked for that day. Nicotine levels for
cigar, gum, snuff, chewing tobacco and nicotine patch, were detennined by type of product
and amount consumed or used in a day (Benowitz, et al. 1990, Annitage et al., 1978).
Saliva caffeine/cotinine analysis.
At the laboratory, each sample was transferred to a glass conical tube and centrifuged at 1500
x g for 10 minutes. The clear supemate saliva was decanted, transferred to a glass vial and
stored at -20 °C until analyzed for cotinine and caffeine.
Cotinine and caffeine saliva concentrations were assessed using a modification of the
high-performance liquid chromatography (HPLC) method of Machacek and Jiang (1986),
Harlharan, VanNoord and Greden (1988) and Hartley, Smith and Cookman (1985). The intra
assay (within-day) reproducibility was as follows (N=10): cotinine, mean, 220 ng/mL, relative
standard deviation, 4.9%; caffeine, mean 4.1 pg/mL, relative standard deviation, 4.9%. The
inter-assay (day-to-day) reproducibility data was as follows (N=35): cotinine, mean, 203
ng/mL, relative standard deviation, 6.4%; caffeine, mean, 3.9 ug/mL, relative standard
deviation, 5.1%.
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Dala Analysis
Analysis of saliva samples for cotinine (a primary metabolite of nicotine used to
indicate nicotine intake) and caffeine concentrations, obtained at four different time points.
were entered into a 2 x 4 repeated measures ANOVA with caffeine group (caffeine abstainer
versus normal caffeine user) and time of the caffeine or nicotine saliva samples as factors.
Daily-log estimates of nicotine, caffeine, and withdrawal symptoms were averaged
across the measures for each day (9 am, 3 pm, and 9 pm). The resulting 13 time points were
entered into a 2 x 3 x 13 repeated measures ANOVA. Caffeine group was the first factor.
caffeine baseline level (low = 0.4 ug/mL or less, moderate = 0.41 - 2.0 ug/mL, high= 2.1
ug/mL or more) was the second factor, and day of the measurement (2 days baseline, 11
measurement days after cessation) was the third. For participants with an occasional missing
value that occurred between two complete data points, a value was interpolated by use of
linear regression analysis of the other two values. Mauchly’s sphericity test was used to assess
violation of the sphericity assumption. If this test was significant the Huynh-Feldt Epsilon
adjustment to ANOVA degrees of freedom was applied.
Although the best understanding of the effects of asking individuals to abstain from
caffeine involved all individuals randomly assigned to the two groups, withdrawal effects
might be obscured by participants returning to caffeine or tobacco use or by use of other
drugs. Therefore, a second analysis was carried out to examine the initial withdrawal effects
only in participants who had not smoked, used alcohol or any mood altering drug, and, in
addition for the abstainer group, used no caffeinatcd products after the quit day. In this
analysis, symptoms on the two days after cessation were averaged and compared to the
average level of symptoms on the same two days of the week before cessation. The full
thirteen day period was not examined for this analysis because this would have decreased
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sample size too much. Caffeine user and abstainer groups were than compared in a 2 x 2,
group by time repeated measures ANOVA.
Self-reported days of first cigarette smoked was entered into a survival analysis (life
tables) test comparing the probability of continued cessation at each day following cessation in
the two experimental groups.

RESULTS
Table 3 shows characteristics of the subjects including baseline cigarette and caffeine
consumption.
Insert Table 3 about here

Figure 1 shows sputum caffeine and cotinine, self-report caffeine and nicotine levels
throughout the different time points. Caffeine sputum concentrations in the caffeine user group
gradually increased after cessation of smoking (linear trend: (F(l,49)= 7.71 jp-OOS). The
caffeine abstainer group had a sharp decrease followed by an increase (quadratic trend:
F(l,49)= 12.59 £=.001). After three weeks the caffeine user group exhibited increased caffeine
concentrations to 203% that of baseline levels. This interaction of caffeine group by time was
highly statistically significant (F(3,294)= 5.46 £=.001, £(Huynh-Feldt Epsilon)=.005).
Insert Figure 1 about here

Caffeine self-report remained unchanged for the caffeine user group and showed a
significant decrease (F(l,78)= 71.08 £<.0005) for the abstainer group after smoking cessation.
The interaction was highly statistically significant for the abstainer group by time of
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measurement (F( 12,1920)= 10.85 j><-0005, ^(Huynh-Feldt Epsilon)<.0005). After day seven.
the caffeine abstainer group shows a gradual increase in sputum caffeine and self-report
caffeine. It was at this time that many of the abstainers, who were initially encouraged to
abstain from caffeine for at least one week, returned to their normal caffeine drinking habits.
Nicotine self-report and sputum cotinine showed decreases from baseline in both
groups. The reduction in self-report nicotine and sputum cotinine was statistically significant
for both groups across time (self-report nicotine (F(12,1920)= 89.88 jk.OOOS, ]2(Huynh-Feldt
Epsilon)<.0005), and sputum cotinine (F(3,381)= 111.45 2<.0()()5, ^(Huynh-Fcldt
Epsilon)<.0005).
There was a statistically significant interaction found for the self-reported fatigue
withdrawal symptom for caffeine abstainers upon cessation of smoking. The interaction of time
of measurement and caffeine abstainer group was significant (F( 12,1452)= 2.34 jp .006,
2(Huynh-Feldt Epsilon)= .017). Figure 2 shows that the interaction appears to be due to
greater withdrawal fatigue in the caffeine abstainer group during the first four days of
cessation.
Finally, a statistically significant interaction was found for self-reported hours slept.
The interaction of time of measurement and baseline caffeine use (low, moderate and high)
was significant (F(24,1620)= 1.99 2=-003, ^(Huynh-Feldt Epsilon)= .005). Figure 2 shows that
the low and high caffeine users slept longer than moderate caffeine users in both caffeine
group conditions for days three through seven. Since this interaction occurred in both groups.
it appears to be a result of nicotine abstinence, with the low and high users possibly being
more sensitive to the withdrawal effects.
Insert Figure 2 about here
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Self-reported caffeine craving, cups of coffee/day, concentration, headache, hunger.
negative effect, sensori-motor, showed statistically significant changes across time, but the
pattern of change did not differ across caffeine group or caffeine baseline use conditions.
There were no significant interactions in self-reported daily alcohol intake, time to bed, or time
awakened.
Analysis was repeated on the immediate pre-and-post cessation measures, as indicated
in the data analysis section, eliminating all individuals who had returned to smoking before the
end of the second day of cessation, all users of psychoactive drugs and, in the abstainer group.
those who used caffeine (>30 mg/day) in the first two days after cessation were eliminated.
Five significant interactions were found in the first two days of smoking cessation.
Compared to the caffeine user group, the caffeine abstainer group had a significant increase in
self-reported fatigue (F(l,54)=5.88 £=.019), headache (F( 1,55)= 12.79 £=.001), muscle aches
and twitches (F(l,54)=9.54 £=.003), tobacco craving (F(l,54)=5.45 £=.023), and a significant
decrease in stimulation (F(l,54)=4.03 £=.050). Table 4 shows the means for each experimental
group in the before and after cessation.
Insert Table 4 about here

When all individuals were considered in the immediate pre-and-post cessation
measures, the caffeine abstainer group had a significant increase in self-reported fatigue
(F(l,142)=8.56 £=.004) and headache (F(l,143)=5.08 £=.026), approached significance for
muscle aches/twitches (F(l,142)=3.76 £=.054) and stimulation (F(l,142)=3.83 £=.052), and no
significant difference for tobacco craving (F(l,142)=2.39 £=.124).
There were no significant differences between the experimental groups on success in
quitting. Data were available on all 162 subjects at six months, and 161 subjects at 12 months.
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but was only available on 150 subjects at 16 days post-cessation. This was a result of
incomplete data from participants missing clinic sessions.
Figure 3 shows the success rate for both caffeine groups in the first 16 days post
cessation. On day sixteen, 41.1% (n=30/73) of the abstainer group and 38.9% (n=30/77) of the
user group were still not smoking. At six months, the telephone follow-up interview revealed
that 24.1% (n=19/79 abstainer group, n=20/83 user group) of both groups were successful and
at one year, 24.1% (n= 19/79) of the abstainer and 19.5% (n= 16/82) of the user group were still
not smoking. None of these differences were significant.
Insert Figure 3 about here

Discussion
Our results validate previous findings regarding the increase in plasma caffeine levels
after people give up smoking (Brown et al., 1988; Benowitz et al., 1989). This study,
however, demonstrated the effect on caffeine sputum levels. The significant finding shows a
gradual increase of sputum caffeine concentrations from baseline to 162% of baseline at 2
days, 174% at 7 days, to 203% at 3 weeks post-cessation from smoking. Benowitz et al.
(1989) reported concentration of 269% at 12 weeks and 266% at 26 weeks. Our results suggest
a linear increasing trend which might have demonstrated a similar caffeine concentration if a
12 week sputum sample had been taken.
Five interactions were found in the study of withdrawal symptoms. During the first
two days of smoking cessation, the caffeine abstainer group had increased muscle aches and
twitches, tobacco craving, fatigue, and decreased stimulation. While caffeine is known for its
stimulatory effects, abstinence appears to intensify tobacco craving and muscular skeletal
effects.
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Low and high caffeine users (for both caffeine use groups) showed an increase in the
hours of sleep while the moderate caffeine users had a decrease. The reason for this difference
is unclear but suggests that low and high caffeine users might be more sensitive to the effects
of nicotine abstinence.
Our study shows a linear and two fold increase in caffeine sputum concentrations at
three weeks cessation; however, we found no evidence that this increase affected symptoms of
those who continued to use caffeine immediately after cessation. For example, there was no
significant increase in stimulation. Possibly the lack of effect occurs because caffeine levels
did not reach a maximum concentration until at least 3 weeks following cessation and our
withdrawal measures ended at 16 days. Or perhaps our instruments were not sensitive enough
to detect these effects.
Continued caffeine use or abstaining from caffeine does not appear to influence the
success of the smoker during the first week of abstinence. While measurements were taken
over a longer time period, study participants were asked only to abstain for at least one week.
During that first week, 72% had consumed more than 30 mg of caffeine (the amount one
would get from 10 cups of decaffeinated coffee) on at least one day. Most of this group.
however, did restrict their caffeine consumption during the entire week. Of the 53 in the
abstainer group who had consumed more than 30 mg of caffeine during any one day of the
first week, 60% used less than 30 mg on the seventh day and 75% used less than 100 mg of
caffeine. Figure 1 shows that the abstainer group had approximately 16% of their nonnal
baseline caffeine self-report levels and 30% of their baseline sputum caffeine levels through
the first seven days. After one week, there is a gradual increase in both sputum caffeine
concentrations and self-report caffeine. On the 16th day post-cessation, the abstainer group is
still 66% below their baseline caffeine self-report and 30% below baseline caffeine sputum
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levels on day 21. The caffeine users had approximately two and one-half times the sputum
concentration of the abstainer group on day 21. Thus, even though 72% of the abstainers
exceeded the 30 mg per day of caffeine on at least one day during the first week, most of the
group continued to restrict their caffeine intake. Since the abstainer group, however, had a
definite increase in their caffeine consumption levels after day seven, we cannot determine
whether longer term abstinence would affect success in smoking cessation.
It was the intent of this research to simulate as closely as possible the real clinic
setting of smoking cessation, thus, no attempt was made to blind participants as to whether
they were abstaining from caffeine or not. In a real clinic setting participants would know. One
potential problem of this setting, however, is that differences between coffee abstainers and
non-abstainers on success or withdrawal symptoms could be due to conditioning effects. For
example, the coffee cup or the act of drinking coffee might produce conditioned withdrawal
reactions rather than pharmacological determined reactions. Marshal, Epstein, and Green
(1980) and Ossip and Epstein (1981) reported an increase in cigarette smoking when the
number of cups of coffee was increased. Marshall, et al. (1980) suggested that this may be due
to the stimulus control properties of coffee drinking. In our study, abstainers may have used
decaffeinated coffee or other coffee substitute. Thus for some, the stimulus control properties
of coffee drinking would continue.
A similar issue involves expectancy effects. It can be argued that the abstainer group
might have reported more withdrawal symptoms (e.g. fatigue) because they expected that
caffeine withdrawal would produce such symptoms. The differences in success, therefore.
might be due to differences caused by expectations rather than by any direct effect of the
caffeine abstinence. The argument that differences between groups on success could be due to
conditioning effects or expectancy does not apply because there were no differences in success
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between the groups. Withdrawal differences could be due to expectancies or a conditioning
effect but we were not attempting to examine this question. Our major point is that the
withdrawal effect differences we found are the ones that practitioners can reasonably expect to
find, since our setting is similar to the setting used by typical practitioners. Again, in such a
setting, expectancy and conditioning effects would be expected. Nevertheless, both the
psychological conditioning response and the issue of expectancy effects needs to be addressed
in subsequent experimental studies.
Future research is, also, needed to determine whether different levels of caffeine use
during smoking cessation and long term cafieine cessation affect withdrawal symptoms and
long term success. Since caffeine sputum levels did not double until three weeks post-cessation
and our measurements stopped at 16 days, additional studies are needed to sec whether
caffeinism effects are present at three weeks or more, or whether caffeine plasma levels have
to be higher. Finally, study is needed to see if there is a difference between the low, moderate
and high caffeine users relative to the elevated caffeine plasma and sensitivity to caffeine
toxicity over a longer period of abstinence.
This study, however, provides no support for requesting short-tenn caffeine abstinence
or reduction in smoking cessation programs. Health educators and smoking cessation
facilitators, therefore, need to be careful in recommending a reduction of caffeine use
concurrently with smoking cessation. If this practice is still to be continued, it should not
involve short-term caffeine reduction occurring concurrently with smoking cessation.
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Table 1. Research Program Event and Questionnaire
Week

Session

Event

0

Baseline

Orientation

a) Introduction of "Tobacco Related Research Program"
b) Incentives: t-shirt, $20.00, summary result
c) Informed consent
d) "Intake" questionnaire
e) Participant address and follow-up information
0 Saliva collection #1
g) "Feeling profile" questionnaire

1

1

Pretesting

a) Daily-log handed out (2.3-day) with instruction
b) Research watch assigned with loan form

2

2

Quit Night

a) Daily-log collected and new given (2.3-day)
b) Group assigned: standard or experimental
c) Experimental group given decaffeinated coffee
substitutes

2

3

48 Hours

a) Daily-log collected and new given (3-day)
b) Saliva collection #2
c) Research summary envelope addressed

3

4

One Week

a) Daily-log collected and new given (2-day)
b) Saliva collection #3
c) Incentive request form completed

4

5

Second Week

a) Daily-log collected and new given (2.3-day)
b) Change of address request form

5

6

Third Week

a) Collect daily-log, research watch, and credit
watch loan form
b) One time daily-log measurement (.3-day)
c) Saliva collection #4
d) Incentives distributed ($20.00/ t-shirt)

Activity

24

6 Month

Telephone follow-up survey

48

12 Month

Telephone follow-up survey
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Table 2. Caffeine Content of Various Sources
Coffee by brewing method0 (mg/1 oz)
Drip
Instant
Percolated
Decaffeinated

22.4 mg
12.0 mg
17.0 mg
.6 mg

Tea* (mg/1 oz)

Instant
leaf or bag
decaffeinated

8.0 mg
6.0 mg
0.3 mg

Soft Drinks" (mg/ 1 oz)
caffeinated
decaffeinated

3.0 mg
.05 mg

Other* (mg/1 oz)
cocoa
chocolate milk
milk chocolate (plain)
dark chocolate

0.8 mg
0.6 mg
6.0 mg
20.0 mg

Prescription/Non-prescription Drugsc
(mg/per capsule or tablet)
Anacin, Bromo-Seltzer, Cope, Coryban-D, Damason-P, Darvoncompound, Easy-Mens, Emprin, Gelpirin, Midol, Norgesic,
Orphengesic, Propoxphene, Sinarest, Synalgos-DC, Vanquish

32 mg

Amaphen, Fiorinal, Fioricet, Mcdigesic, Pacaps. Triad. Two-Dyne

40 mg

Excedrin, Migral, PreMens Forte

65 mg

Appedrine, Aqua-ban, Cafergot. Migralarm, NoDoz, Wingraine

100 mg

Prolamine

140 mg

Aqua-Ban Plus, Dexatrim, Dictac. Permathene H2 Off, Vivarin

200 mg

"Based on Dews, P.B., (1984) Caffeine: Perspectives from Recent Research, and other
publications.
*Based on B.L. Zoumas et al., (1980) Theobromine and Caffeine Content of Chocolate
Products.
‘Based on The Physicians Desk Reference, 1981, and 1990, and other publications.
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Table 3. Participant Characteristics (n = 162)
Mean ± SD

Range

Age (yr)

46.2 ± 13.1

13-75

Weight (kg)

72.5 ± 19.2

38.5-149.7

Demographics

Men

63

Women

99

Smoking habits
Cigarettes/day

24.1 ± 8.1

1-65

Nicotine yield
(mg/cigarette)*

.86 ± 0.32

0.05-1.7

0.18 ± 0.15

0.01-1.001

323.9 ± 164.4

30-773

Caffeinated coffee
(cups/day)

3.7 ± 3.0

0-16.4

Caffeinated tea
(cups/day)

.61 ± 1.4

0-8.8

Total caffeine (mg/day)

550.0 ± 539.9

0-2887.2

Caffeine levels (mg/kg)

7.9 ± 7.5

0-37.5

Initial saliva caffeine
levels (pg/mL)

2.1 ± 2.8

0-17.3

Nicotine level (mg/kg)
Saliva Cotinine (ng/mL)
Caffeine habits

*FTC, US Federal Trade Commission (1991)
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Table 4. Self-report Withdrawal Symptoms Seven Days Before and Two Days After Smoking
Cessation by Experimental Group (n=56)
Baseline

Post-Cessation

Analysis of

Mean ± SD

Mean ± SD.

Variance £
Value

Before

After

G xT

n

Abstainer

2.80 ± 1.59

3.83 ±1.61

.019

31

User

2.66 ± 1.51

2.51 ± 1.83

Abstainer

1.28 ± 1.69

2.81 ± 2.25

User

0.87 ± 1.36

0.67 ± 1.33

Abstainer

0.86 ± 1.15

1.49 ± 1.43

User

0.66 ± 0.83

0.51 ± 0.66

Abstainer

5.24 ± 1.90

6.45 ± 1.72

User

5.39 ± 1.88

5.27 ± 2.31

Abstainer

3.29 ± 1.20

2.89 ± 1.41

User

3.32 ± 1.09

3.46 ± 1.45

Fatigue

25

Headache
.001

31
26

Muscle ache/twitches
.003

31
25

Tobacco craving
.023

31
25

Stimulation
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.050

31
25

FIGURE CAPTIONS

Figure 1. Mean self-report caffeine and nicotine (in milligrams per measurement day), sputum
caffeine (in ng/mL) and cotinine concentrations (in pg/mL) during baseline, and days post
cessation.

Figure 2. (Top) Mean self-report fatigue by experimental groups with baseline values (-7, -6)
and after cessation. (Bottom) Mean self-report hours of sleep by baseline caffeine use during
baseline and post-cessation.

Figure 3. Survival function for experimental groups to first self-reported use of cigarette.
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CHAPTER 3: OTHER FINDINGS

The following additional findings are relevant to the research project:

1. Several epidemiological studies provide data allowing comparison of coffee drinking
habits of smokers, exsmokers and never smokers. Table 1 provides a summary of four studies
showing the percentage of smokers, exsmokers and never smokers consuming six or more cups
of coffee each day. A crosstabulation was perfonned in each study and demonstrates that there
were almost twice as many smokers (21.4%) consuming 6+ c/day of coffee as ex-smokers
(11.5%), and almost twice as many exsmokers as never smokers (6.5%) consuming this same
amount.
Thomas (1973), examining 692 physicians and their health habits, found that current
smokers and fomier smokers consumed more cups of coffee per day than did lifetime
nonsmokers. Mean cups of coffee per day per smoking classification were: nonsmoker = 1.69,
former smoker = 2.43, and current cigarette smoker = 2.96. While the study did not
specifically report on the higher (6+ cups/day) coffee consumption levels, it still demonstrates
clearly that both smokers and exsmokers consume greater quantities of coffee than
neversmokers. This finding was not included in the first paper because the data was not
accumulated and analyzed until after the first article had been submitted for publication.
2. Research findings in Paper 2 validate previous findings regarding the increase in
plasma caffeine levels after people give up smoking (Brown et al., 1988; Benowitz et al..
1989). In paper 2 we reported a linear increase of sputum caffeine concentrations from
baseline of 162% at 2 days, 174% at 7 days, to 203% at 3 weeks post-cessation from smoking.
Figure 1 shows the mean sputum caffeine levels by caffeine experimental groups and caffeine

112

user (low, moderate and high) during baseline, two, seven and twenty-one days post-cessation.
The high caffeine user group had a two-fold increase in sputum caffeine levels, between days
seven and day 21. This interaction among the high caffeine user by time of measurement was
highly statistically significant compared to the low and moderate caffeine user (F (6,282)=
3.68 p=.002, ^(Huynh-Feldt Epsilon)=.003). The reason for this difference is unclear but
suggests that the high caffeine users might be more sensitive to the effects of nicotine
abstinence. This finding was not included in the second paper because it does not contribute to
answering either of the two purposes of the study.
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Table 1. Summary of Studies Showing Percentage of Smokers, Exsmokers and Never Smokers Consuming Six or
More Cups of Coffee Each Day.
Reference

Sample

Percentage consuming 6+ cups/day coffee
Smoker

4^

ExSmoker

Never
Smoker

Significance

Boston
Collaborative Drug
Surveillance
Program (1972)

1,104 men
controls

14.5%

7.4%

2.2%

X2(4, N = 1,104) = 44.58
£<.0005

Hrubec (1973)

10,615 men

30.1%

16.6%

9.7%

X2(4, N = 10,615) = 814.15
£<.0005

Rosenberg et al.
(1980)

980 women
controls

24.4%

13.8%

0.3%

X2(4, N = 980) = 38.15
£<.0005

Murray et al.
(1981)

16,800 men

16.6%

8.4%

4.0%

X2(10, N = 16,800) = 1,434.72
£<.0005
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CHAPTER 4: SUMMARY

Paper one reviews the current scientific literature from 1972 through March 1993 on
caffeine and nicotine as it relates to non-health effects in smoking cessation. The sources were
Medline and Psychlit searches, references from published articles and a review of relevant
journals up to and including March 1993. Section I, reviews 15 studies on the combined use of
caffeine and nicotine. Section II, examines 17 studies on the physiological and behavioral
rationales for this combined use. Section III, eighty-six studies are examined to compare the
similarities and differences of withdrawal symptoms of both drugs, and compare caffeine
toxicity symptoms with nicotine withdrawal symptoms. The last section summarizes the
evidence and provides specific suggestions for future research in this area.
There is a good epidemiologic support to suggest a strong significant relationship
between coffee consumption and smoking. In six epidemiological studies reviewed and
analyzed in paper 1, 86.4% of smokers consumed coffee versus 77.2% of nonsmokers. An
additional finding showed that both smokers and exsmokers use more coffee than
neversmokers. A crosstabulation was perfomied in four epidemiological studies that
demonstrated there were almost twice as many smokers (21.4%) consuming 6+ c/day of coffee
as ex-smokers (11.5%), and almost twice as many exsmokers as never smokers (6.5%).
Seventeen experimental studies suggest that the phannacologic effect of caffeine in coffee may
be partially but not totally responsible for the relationship. The behavioral relationship appears
to be supported by a simple conditioning response, a reciprocal interaction (caffeine intake
increases anxiety/arousal - nicotine decreases it), and possible combined effect of third
variables (e.g., alcohol, stress).
In abstinent smokers, plasma caffeine levels increase and remain elevated for as long
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as six months. These higher caffeine plasma levels may be sufficient to produce caffeine
toxicity syndrome. A review of 86 studies of nicotine withdrawal, caffeine withdrawal and
caffeine toxicity suggests that the symptoms are similar enough to be confused and reported as
nicotine withdrawal and may be a mixture of both.
Several studies reported a drug interaction was occurring between caffeine and nicotine
causing a different symptomatic response. During caffeine placebo, headache was significantly
greater under the smoking condition than under non-smoking conditions. The addition of
caffeine doses decreased the headache under the smoking condition. This suggest that the
headache symptom is brought on by a lack of caffeine and alleviated by caffeine. The fact that
the headache occurred while smoking rather than not-smoking may be due to nicotine’s effect
in increasing caffeine metabolism. During caffeine placebo, the severity of hunger was
significantly greater during smoking abstinence than during smoking conditions. The addition
caffeine decreased the hunger symptom. While both caffeine and small doses of nicotine have
the capacity to increase arousal, two studies showed nicotine actually decreasing arousal in the
presence of caffeine.
In this research project we wanted to test whether caffeine abstinence influences
smoking cessation and if high caffeine plasma levels would be sufficient enough to produce
caffeine toxicity symptoms in smoking abstinence conditions.
One-hundred sixty-two caffeine using smokers were enlisted from American Lung
Association cessation programs. Volunteers were randomly assigned by clinic to caffeine use
and caffeine abstinence conditions and measured for three weeks post-smoking cessation, at six
months and one year. Paper 2 describes in detail the complete methodology of the study.
Results showed a significant linear increase in caffeine sputum levels across four time
points for those who quit smoking and continued using caffeine. At 21 days post-cessation,
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sputum caffeine levels increased 200% of baseline levels. Caffeine abstinence significantly
increased headache, fatigue, muscle aches/twitches, tobacco craving, and decreased stimulation
immediately following tobacco cessation. There were no differences between the groups on
other withdrawal symptoms.
These elevated withdrawal symptom effects over the first few days of smoking
cessation would seem to suggest that caffeine abstinence at the point of smoking cessation
would be counter productive in facilitating the process of smoking cessation. Finally, we found
no significant difference in success of quitting in either group at 16 days, 6 months or 12
months.
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CHAPTER 5: RECOMMENDATIONS

Significance and Recommendations for Public Health Education

The result from this study suggest that short tenn reduction of caffeine or using
decaffeinated products does not facilitate smoking cessation. Health educators and smoking
cessation facilitators, therefore, need to be careful in recommending a reduction of caffeine use
concurrently with smoking cessation. If this practice is still to be continued, it should not
involve short-term caffeine reduction and should not come concurrently with smoking
cessation. Either prior to tobacco cessation or at three weeks post-cessation, when nicotine
withdrawal symptoms have abated and sputum caffeine levels are increasing to the point of
potential caffeine toxicity effects, caffeine reduction might be useful. There is, however, no
scientific evidence suggesting that such caffeine abstinence or caffeine reduction would be
helpful.
It was the intent of this research to simulate as close as possible the real clinic setting.
however, the psychological conditioning phenomena may have been a potential problem. This
study did not measure the conditioned response from various stimuli (e.g. cup of coffee and
cigarette), which may have contributed to the recidivism rates in smoking cessation. This issue
should be addressed in subsequent studies.
With the high level of interest in health refonn in the United States and the emphasis
on Total Quality Improvement on the delivery of health care, there is a new commitment to
provide the best possible in health care and health education for all Americans. The following
recommendations can assist the field of health education by enabling the health educator in
future smoking cessation interventions:
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1) Avoid concurrent abstinence (reduction) of caffeine products while quitting
smoking. Short temi caffeine abstinence significantly increased headache.
fatigue, muscle aches/twitches, tobacco craving, and decreased stimulation
during the first several days immediately following tobacco cessation. Despite
these increased withdrawal effects, there was no significant difference in the
success of quitting between those who continued to use caffeine and those
abstaining from caffeine. Health educators should not advocate the use of
procedures which have unpleasant effects and produce no measurable results or
success (but see "Recommendations for Future Research").

2) Be aware that continued caffeine consumption and cessation of smoking has
been shown to increase caffeine plasma/sputum concentrations. At three weeks
post-cessation caffeine concentrations can double and may produce caffeine
toxicity effects, possibly contributing to smoking recidivism. If toxicity effects
occur (see paper 1 for effects), it would be advisable to encourage the person
to see a physician and to reduce the caffeine consumption levels. In addition.
there are some individuals who are more susceptible to caffeine toxicity. These
include: high caffeine users, pregnant women, women taking oral
contraceptives or female honnones, users of alcoholic beverages and people
with liver and kidney problems (Busto et al., 1989; Curatolo et al., 1983; Rail,
1985; Sawyer et al., 1982; & Von Borstel, 1983).

120

Recommendations for Future Research

How to help smokers quit smoking and maintain long term abstinence are key factors
in the research literature. The following list are recommendations for future research based on
the results of this study:

1) Long term studies of the abstinence effects of nicotine in caffeine users and
non-users are needed which quantify the magnitude and identify the
withdrawal symptoms most affected. The present study only measured
symptomatic effects lor the first 16 days post-cessation. Since sputum caffeine
concentrations did not double until 3 weeks post-cessation, caffeine toxicity
effects may not be problematic until this concentration is reached or later.

2) Research on the long term effects of caffeine abstinence among smokers
attempting to quit smoking, which analyzes the long-tenn success rates and the
potential conditioning response effects of coffee substitutes, decaffeinated
coffee, etc. Our study did not measure the stimulus control properties of coffee
drinking. Thus, withdrawal symptoms for the coffee abstainer or user may
have been affected by the conditioned response effect. Nor did our study
examine the effects of long tenn caffeine abstinence.

3) Laboratory studies that detennine the influence of expectancy effects on
withdrawal symptoms in caffeine abstinence and caffeine user conditions
during smoking cessation. The present study did not consider whether
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withdrawal symptoms were influenced by caffeine abstinence or reduction
expectations (e.g. caffeine abstainers might have expected more fatigue from
past experience). While such expectations appear to be a normal clinic
phenomena, the laboratory setting will provide a more suitable environment to
measure their influence on withdrawal symptoms and success in smoking
cessation.

4) Long term studies are needed that examine how caffeine, alcohol, and other
drugs produce persistent and annoying withdrawal effects in abstinent smokers.
Alcohol is known to decrease the metabolism of caffeine, resulting in increased
plasma caffeine levels. The resulting effect in the smoker who continues to use
caffeine and alcohol may produce interactive effects between the drugs as well
as caffeine toxicity syndrome from the high caffeine plasma levels.

5) Since there appears to be no studies which have examined the influence of
gender on nicotine and caffeine metabolism (e.g. oral contraceptives.
pregnancy and female hormones are known to increase caffeine’s half-life).
studies targeting women are needed to determine if the higher caffeine plasma
levels intensify withdrawal effects and contribute to smoking cessation
recidivism among women.

6) Research is needed to analyze abstinence effects that include baseline,
several post-cessation measures, never-smoking controls, and never-caffeine
controls, to determine whether abstinence effects are influenced by behavioral
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conditioning or pharmacokinetics interaction. The inclusion of never smoking
controls and never caffeine controls along with smokers and caffeine users in
pre-and-post abstinence conditions will help clarify how much of the
abstinence effect is related to the phannacologic interaction of caffeine with
nicotine (or vice versa) and how much of the effect is behavioral. These
include: conditioning, reciprocal interaction (caffeine intake increases anxiety nicotine decreases it), or a combined effect of a third variable (e.g. stress.
alcohol).

7) Experimental studies of the effects of nicotine dose on caffeine consumption
would help to clarify the relationship between these drugs. The majority of
research studies have focused on caffeine’s effect on nicotine. This study
would determine if there is a dose related effect of nicotine on caffeine
consumption and whether different doses of nicotine effect caffeine
metabolism. Faster caffeine metabolism may show greater dependency and
stronger withdrawal effects.

8) Experimental studies conducted to determine if there is a difference between
the low, moderate and high caffeine user relative to the elevated caffeine
plasma and sensitivity to caffeine toxicity. Our study found that high caffeine
users had significantly increased sputum caffeine levels at 3 weeks compared
to low and moderate caffeine users, however, no symptoms were measured at
that time. This study would detennine if there is a sensitivity effect among the
caffeine users to the higher caffeine plasma/sputum concentrations.
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APPENDIXES A

See Paper 1, pages 75 - 83 for Appendix A: 1A - 1C

1A: References of Symbols for Table 3, Column A: Survey and Experimental
Studies Relevant to Nicotine Withdrawal Symptoms in Abstinent Conditions

75

IB: References of Symbols for Table 3, Column B: Survey and Experimental
Studies Relevant to Caffeine Withdrawal Symptoms in Abstinent Conditions

79

1C: References of Symbols for Table 3, Column C: Survey and Experimental
Studies Relevant to Caffeine Toxicity Symptoms
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APPENDIX B

Date:__________ Group:
Loma Linda University / American Lung Association
of the Inland Counties Research Project Impact of
Caffeine Use on Tobacco Cessation and Withdrawal

Gender: [ ], Male

[ ]2 Female

Last four digits identification:
SS #

Informed Consent

:IC

___

__

___

_

PHONE#

People who participate in an American Lung Association smoking cessation program are not usually
asked to give up caffeine at the same time that they give up cigarette smoking. However, some
smoking cessation professionals believe that giving up caffeine at the same time as I give up cigarettes
will make it easier for me to stop smoking. However, this has never been experimentally tested and it
is possible that giving up caffeine could actually make it harder for me to quit. I have been asked to
participate in an experiment which will study how caffeine use affects smoking cessation.
If I choose not to participate It will have no effect on my relationship to the American Lung
Association or Loma Linda University.
If I choose to participate I may be assigned to one of two groups: an experimental group, or a
standard care group. As part of the research I will try to do the following:
If I am assigned to the:
1)

standard care group I will try to continue my caffeine use (if I am using caffeine) at its
normal levels for the duration of the experiment.

2)

experimental group Starting on the quit date, I will try to avoid drinking any beverages that
contain appreciable amounts of caffeine for at least one week and as much longer as possible
during the study. This means that I will try to avoid coffee, tea, and caffeine containing
soft-drinks like Dr. Pepper, Mr. Pibb, Mt. Dew. Coca-Cola, Pepsi-Cola, and other Cola
beverages. Caffeine free substitutes like Sanka, Postum, Pepsi Free, Caffeine-free Coke are
allowed and some will be provided at no cost to me by the researchers if I choose to use them.
Chocolate is also allowed. I also will try to avoid caffeine-containing over-the counter
medicine like NoDoz and Anacin unless my doctor asks me to take something containing
caffeine. The researchers understand that I might lapse occasionally but the research will be of
higher quality if I abstain completely, especially during the first two weeks.

INSTRUCTION FOR BOTH GROUPS
I will also try to do the following:
1)

I will not quit smoking until the actual quit date:

2)

Fill out the research questionnaires at the end of each class session, over the next several
weeks. The questionnaires will include questions about my current tobacco use, my reasons for
smoking, my current level of withdrawal symptoms, and will include a short questionnaire
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intended to measure some things about my personality. It should take no more than 15 to 20
minutes.
3)

Provide a sample of my saliva at the end of this session. This is a simple procedure which
consists of rapidly moving your tongue around and against the inner cheek and then spitting the
contents into the frosted collection cup. This saliva sample will allow the researchers to
determine what amount of caffeine and nicotine (the active ingredient in cigarette smoke) are
currently in my body. At a later date the saliva may also be analyzed to determine how
smoking cessation effects hormonal function or immune system components. Collecting the
saliva sample should not take more than three minutes.

4)

Provide a saliva sample at the third, fourth, and sixth week of the smoking cessation program at
the conclusion of the smoking cessation class session.

5)

I will not use nicorette gum or anti-depressant drugs after the targeted "Quit Night", including
the next two weeks following this quit date. I am fully aware that the American Lung
Association allows the use of these substances, but understand such usage will have a
detrimental effect on the research, specifically withdrawal measurements.

6)

Fill out a withdrawal symptoms and daily log questionnaire beginning with week two, and
thereafter, each time I attend a smoking cessation class session. This should not take more than
five minutes.

7)

Take home a "Daily Log" diary consisting of questions of caffeine-nicotine usage and
withdrawal symptoms. I will try to fill out this diary once each morning, afternoon and evening
during the first nine days after the "Quit Night", and two additional logs during weeks four
and five. This should not take more than about five minutes each time I fill out the form or no
more than 15 minutes in any one day. I will use the "research wrist watch", loaned to me, to
assist in a consistent reporting of the dairy infonnation. I understand the watch will be used at
other clinic sites. Therefore, it must be returned on the sixth week/last session of the American
Lung Association - "Freedom From Smoking" program, or on the last day of attendance.

8)

Answer questions about my caffeine and tobacco use when the researcher phones me six
months and also twelve months after the program ends.

Possible Benefits of this research to others and to me:
If the researchers are able to determine whether caffeine use helps or hinders smoking cessation, people
who later try to stop smoking will benefit from this knowledge and may be able to stop smoking more
easily because of my participation in the study.
If I am in the group that turns out to be the better one I may have an easier time quitting smoking than
would normally be the case.
If I choose to participate, and maintain a current address with the research program, I will be sent a
summary of the research findings when they are ready. This probably will be sometime during the last
half of 1992.
If I attend all the sessions and miss no more than two of the days filling out the Daily-log diary I will
receive $20 and a "LLU Research Project" T-Shirt.
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If I am in the no-caffeine group, the researchers, at no cost to me. will provide me with a choice of
decaffeinated and caffeine-free beverages which I may use during the experiment if I choose.

Possible risks:
I might have more difficulty quitting smoking if it turns out that caffeine use hinders smoking cessation
and I am in the group that is using caffeine or if it turns out that caffeine use helps cessation and I am
in the group not using caffeine. There are no known risks of being in this study compared with not
being in this study.
If I wish to stop participating:
If I wish to stop participating in this research, I may stop anytime I wish. The researchers and the
program leaders understand that there are many good reasons why an individual might want to quit
participating in a research project and if I stop participating this will not affect my relationship with
them, with the American Lung Association, or with Loma Linda University in any way.
Confidentiality:
All of my data will be kept confidential. Only the researchers listed below or research assistants
designated by them will have access to my data. My name will not be disclosed in connection with this
or any study or in any published document.
Impartial third party contact:
If I wish to contact an impartial third party not associated with this study regarding any complaint I may
have about the study, I may contact Jean Fankhanel at 714-824-4648.
I have been given a copy of this consent form.
I have read the contents of this consent form and have listened to the verbal explanation given by the
investigator. My questions concerning this study have been answered to my satisfaction. I hereby give
voluntary consent to participate in this study. I may call Jerry W. Lee, Ph.D. at (714)824-4994 or John
Swanson, M.P.H., at (714)796-7975 if I have any additional questions or concerns about the study.

Signature of subject

Date

Signature of witness

Date

RESEARCHERS LISTED IN RESEARCH PROJECT:
Jerry W. Lee, PhD, Principal Investigator
John A. Swanson, MPH, Co-Investigator
Joyce W. Hopp, PhD, MPH, Co-Investigator
Lee S. Berk, DHsc, MPH, Co-Investigator
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APPENDIX C

PARTICIPANT ADDRESS AND FOLLOW-UP
INFORMATION

Date:___________
Gender:

[ ], Male

Group:.

:02

[ ]2 Female

Last four digits identification:
SS #
PHONE #
CURRENT ADDRESS INFORMATION:

Name:

Address:
City:

State

Zip

Phone: (
Social Security Number ( Last 4 digits ) __ __
other questionnaires you turn in)

__ (This number will be used to match up

FOLLOW-UP INFORMATION: In this study, it will be important to maintain contact for at least one
year.
I. Alternate Contact: Please indicate the name of someone at a different address who would know
how to contact you. We will contact this person only if we are unable to contact you:
Name:
Address:
City:
Phone: (

State

Zip

State

Zip

)

II. Place of Employment:
Name:
Address:
City:
Work Phone: (

)
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APPENDIX D

INTAKE QUESTIONNAIRE
All information given on this questionnaire will be kept
confidential
1.

Date:___________ Group:

Gender:

At what age did you begin to smoke?

[ ], Male

[ ]2 Female

Last four digits identification:
SS #

2.

:IQ-1

What brands of cigarettes do you usually smoke now?

___________

HM PHONE #

(FULL BRAND NAME),
3.

What type is your current brand? (CHECK ONE IN EACH COLUMN.)

[
[
[
[
[
4.

SIZE ? A
] i Regular
] 2 King Size
] 3 Long /100's
] a Extra Long /120’s
] s Super Slims

MENTHOL ? r
[ ] i Menthol
[ ] 2 Non-Menthol

Are any of these words on your cigarette pack? (CHECK ONE)
[]
[]2

5.

FILTER ? B
[ ] . Filter
[ ] : Non-Filtered

Lights/Low Tar/Milds
Ultra/Ultra Lights/Ultra Low Tar

[]3
[]<

How many cigarettes do you smoke per day now, and how many did you smoke, when you were smoking
at your heaviest rate? (CHECK ONE IN EACH COLUMN)
SMOKING NOWa

Cigarettes per day

SMOKING AT HEAVIEST RATE n

Less than ten a week
1-3

No

N
[]2
[]3

4-7

N<

11-15
16-20 (pack a day)
Pack and a half a day
Two packs a day

No
[]
[]2
[ ] 3

8-10

[]3

N«

IN

N<
[]5
[]6
[]7

Two and a half packs a day
Three packs or more a day
[]9
How soon after you awake do you smoke your first cigarette?

N

6.

[]
[]2

7.

Within less than 5 minutes
Within 6-30 minutes

[ 3 3

[3<

N
[ 3 9

Within 31-68 minutes
After 60 minutes

How often do you inhale the smoke from your cigarette?

[3
8.

Extra Milds/Extra Lights
None of these words are on my pack

Never

[ 3 2

Sometimes

[33

When you smoke cigarettes, how deeply do you draw in the smoke? (CHECK ONE)

N
[32
[33

As deeply into the chest as possible [ ] 4
Only partly into the chest
• []5
As far back as the throat
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Well back into the mouth
Do not inhale at all

Always

9.

What is the average number of drags or puffs you smoke per cigarette? (ENTER NUMBER)
] Drags or puffs per cigarette

[
10.

How many times have you tried to stop smoking?
[ ] i Never

11.

12.

[ ] 3 Twice

]
]
]
]
]

A
,
e
D
,

Clinic or group,
Other written materials,
Gradual reduction,
Nicotine Gum,
Stop with a friend ("Buddy System"),

]
]
]
]
]

p
o
„
,
,

Special filters,
Hypnosis,
Nicotine Patch,
Other Self-Help programs
Other (specify),_________

[
[

Do you use nicorette gum, chewing tobacco, or snuff?
]
]
]
]

* No2
, Yes, nicorette gum,-—
D Yes, snuff,—..............
p Yes, chewing tobacco,

-----Pieces chewed daily?
Number of dips per day?
................ Chews per day?

[

]c
]t

Are your spouse, family, or others encouraging you or discouraging you from trying to stop smoking?
If the category does not apply, check column one. (CHECK ALL CATEGORIES)

Husband or WifeA
ChildrenB
Friendsc
Co-workersD

16.

[
[
[
[
[

-Number of pipes smoked daily?
Number of cigars smoked daily?

Does Not
Apply

ParentSg

[ ] 6 Five or more times

Do you currently smoke a pipe or cigar?

[
[
[
[
15.

[ ] 5 Four times

One Month to 6
More than a year
One Week or
One Week to one
Six months to a
Less [ ]
month [ ] 2
months [ ] 3
year [ ] 4
[]5
Have you ever tried to stop before now using the following methods? (PLEASE CHECK ALL THAT
APPLY.)

[ ] * No2
[ ] , Yes, a pipe,[ ] D Yes, a cigar,
14.

[ ] 4 Three times

What is the longest period of time you have gone without smoking since you first started smoking
regularly?

[
[
[
[
[
13.

[ ] 2 Once

[]
[]
[]
[]
[]

Encouraging
Me

Discouraging
Me

Neither

[]2
[]2

[]3
[]3
[]3
[ ] 3
[] 3

[]<
[]<
[]<
[]<
[]<

[]2
[]2
[]2

They Don’t
Know I am
Stopping
[]s

[]5
[]5
[]5

Do your family, friends or co-workers smoke? (CHECK ALL CATEGORIES)
No

Yes, a few

FamilyA
[]
FriendsR
N
Co-worker sr
[]
17A.
How sure are you that you are ready to stop smoking at this
[ ] 1 Not too sure [ ] 2 Fairly sure

[]2
[]2
[)2
time?

[ ] 3 Quite sure
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Yes, many
[ ] 3
[ ] 3
[ ] 3

[ ] 4 Extremely sure

17B.

Are you currently under a physicians care for KIDNEY or LIVER problems?
[ ] i Yes

[ ] 2 No

18.

Are you: [ ] i Male

19.

How old are you?
Height:
(with shoes off)

20.

21.

inches

feet
B

Weight:

C

D

(in light clothing)

African/Black
American
American
White
Asian
Hispanic
Indian
[)2
[]3
[]5
[]
[]<
Please indicate the HIGHEST level of education you have completed?
(CHECK ONE BOX ONLY)

[]2
[]3
[]4

lbs.

Some high school or less
High school graduate
Technical, vocational school
Some college

[]5
[]<[]7

Other (Specify)

[K

College graduate
Post college
Graduate degree

Which of these groups best describes your occupation? If you are retired, check your former occupation.
(CHECK ONE BOX ONLY)
[]o

[]
[)2
[ ] 3

[]<
23.

YEARS OLD.

Which of these best describes your race or ethnic group?

[]

22.

[ ] 2 Female

Housewife
Student
Service worker. Laborer
Factory worker. Machine Operator
Craftsperson or Supervisor

[]5

[]*
[]7

[]
[]9

Clerical or Office
Sales
Managerial
Professional or Technical
Other (specify)________

Are you now:
Married
[]

Single/Never
Married

Separated

Widowed

[]2

[ ] 3

[]4

Divorced
[]5

CAFFEINE USE
These next questions are about drinking and using caffeinated beverages and products.
24.

Are you currently using any caffeinated, decaffeinated beverages and products? (e.g. coffee, tea, cocoa,
chocolate and soft drinks - such as: Pepsi, Coke, Dr. Pepper, Mountain Dew, Tab and Cola beverages)
[ ] i Yes
[ ] 2 No (If No, skip to question 41)

25.

Have your coffee drinking habits changed over the past two years? (CHECK ONE IN EACH COLUMN)
DECAFFEINATED COFFEE? t
[ ] i Yes, drink more
[ ] 2 Yes, drink less
[ ] 3 Drink the same
[ ] 4 Don’t use

REGULAR COFFEE? B (caffeinated)

[
[
[
[
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]
]
]
]

i
2
3
4

Yes, drink more
Yes, drink less
Drink the same
Don’t use

26.

What brand of coffee do you usually drink now? (INDICATE: REGULAR, OR DECAFFEINATED,?),
LIST BRAND NAME:a

27.

Indicate the most frequent brewing methods used. For each method used, please indicate
the percentage of use.
[ ] ai
[ ] bi
[ ] ci

28.

%A2

[ ]D.

%B2

[ ] E‘

espresso
oilier (list)_

%D2
%E2

%C2

What size coffee/tea cup do you normally use?
[ ]
[ ]2
[ ]3

29.

Percolator
Instant
drip

5 oz cup (standard)
8 oz cup (medium)
Mug (10 oz)

[ ]<
[ ]5
[ ]6

12 oz cup (large)
16 oz cup (extra large)
Other (list)________

What portion of the coffee cup/mug do you usually drink.
[ ]
[ ]2

All
3/4 or most

[ ] 3

[ ]<

2/3
only 1/2

SERVINGS OF CAFFEINATED AND DECAFFEINATED BEVERAGES AND PRODUCTS
(Coffee, Tea, Soft Drinks, and. Chocolate)
INSTRUCTIONS: Indicate the NUMBER OF SERVINGS you use on a typical day and weekend (Saturday or
Sunday). Items used less than daily should be marked under the week column. Use decimals to indicate partial
servings e.g., .5 for 1/2 or 1.5 for 1-1/2.
Number of servings per:
WEEK DAY
30.

[

]a

31.

[

32.

SAT or SUN

{leave BLANK if it does not apply)

1b

Regular Coffee - cups (based on question 28)

1a

1b

Decaffeinated Coffee - cups (based on question 28)

[

1a

1b

Hot Tea - cups (not herbal tea, based on question 28)

33.

[

1a

1b

Iced Tea (12 oz glass or cup)

34.

[

1a

1b

Caffeinated Soft Drinks, 12 oz. can (e.g. Aspen. Big Red, CocaCola, Cherry Cola, Diet Coke, Diet Rite, Dr. Pepper, Jolt, Kick,
Mountain Dew, Mello Yello, Mr Pibb, Pepsi, RC Cola, Shasta
Cola’s, Sunkist Orange, Tab, etc.)

35.

[

1a

1b

16 oz. caffeinated soft drinks

36.

[

1a

1b

2-liter, caffeinated soft drinks

37.

[

1a

1b

Decaffeinated soft drinks, 12 oz can

38.

[

1a

[

1b

Chocolate bars or pieces, e.g. Hershey’s, M&M’s, (1 oz)

39.

[

1a

[

1b

Cocoa, Chocolate milk (8 oz glass)

40.

[

1a

[

1b

Chocolate Brownies

[

[
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PRESCRIPTION AND NON-PRESCRIPTION DRUGS CONTAINING CAFFEINE
INSTRUCTIONS: Please indicate the numher of TABLETS and CAPSULES taken each day or week from
each question and CIRCLE products used (e.g. 3 Aqua-ban + 2 NoDoz = 5 entered in daily column and circle
Aqua-Ban, etc.).
PER DAY
41.

[

1a

42.

[

1a

43.

[

Ja

44.

[

]a

PER WEEK
[

(leave blank if it does not apply)

Jb

Appedrine, Aqua-ban, Cafergot, Migralarm, NoDoz, Prolamine,
Wingraine

Jb

Amaphen, Anacin, Bromo-Seltzer, Cope, Coryban-D, Damason-P,
Darvon-compound, Dristan, Easy-Mens, Empirin, Fiorinal, Fioricet,
Gelpirin, Medigesic, Midol, Norgesic, Orphengesic, Pacaps,
Propoxphene, Sinarest, Synalgos-DC, Triad, Two-Dyne, Vanquish
Aqua-Ban Plus, Dexatrim, Dietac, Vivarin

[

1b
Excedrin, Migral, PreMens Forte
]B

ALCOHOL USE
These next several questions are about alcoholic beverages, such as beer, wine, or liquor.
45.

Do you currently use alcoholic beverages?
[ ] . Yes
[ ] 2 No (If No, women skip to question 50, men are finished with the questionnaire)

INSTRUCTIONS: Indicate the NUMBER OF DRINKS you use on a typical day. Items used less than daily
should be marked under the week column. Use decimals to indicate partial drinks, e.g.,.5 for 1/2 of 1.5 for 1-1/2.
Number of drinks per:
DAY

WEEK

(leave blank if it does not apply)

46.

[

]A

[

]B

Beer 12 oz. (e.g. 1 can)

47.

[

)a

I

)b

Wine 4 oz. (e.g. 1 glass)

48.

[

1a

[

1b

Liquor 1.5 oz (e.g. 1 shot glass of whiskey, gin, etc.)

49.

A. Was the amount of your drinking during the past week typical of your drinking during the past 12
months?
[ ] i Yes

[ ] 2 No

B. Was the amount of your drinking during the past week more or less than your drinking during the
past 12 months?
[ ] i More

[ ] 2 Less

[ ] 3 The same
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WOMEN ONLY
The next three questions are for women only. The impact of caffeine has been shown to be influenced by oral
contraceptives, pregnancy and by use of estrogens. Therefore, it is important for us to know if you are taking these,
or are currently pregnant
50.

Are you currently taking oral contraceptives?
[ ]i Yes
[ ]2 No

51.

Are you currently taking any female hormones (such as: estrogens)?
[ ]i Yes
[ ]2 No

52.

Are you currently pregnant?
[ ]i Yes
[ ]2 No

137

APPENDIX E - Reasons for Smoking Questionnaire

Why do you smoke?

Gender:
Here are some statements made by people to describe what they
get out of smoking cigarettes. How often do you feel this way
when smoking them? Circle one number for each statement.
Important: Please answer every question!

:WS2

Group:

Date:
[ ], Male

[ ]2 Female

Last four digits identification:
SS #
PHONE #

Always . . . Never
7 6 5 4 3 2 1

1. I smoke to be sociable.

7 6 5 4 3 2 1

2. Smoking cigarettes is pleasant.

7 6 5 4 3 2 1

3. I find cigarettes pleasurable.

7 6 5 4 3 2 1

4. I use cigarettes as a "pick-me-up".

7 6 5 4 3 2 1

5. When with other people, I am more at ease if I am smoking.

7 6 5 4 3 2 1

6. Smoking makes me feel more awake.

7 6 5 4 3 2 1

7. I smoke cigarettes to help control my temper.

7 6 5 4 3 2 1

8. Smoking gives me something to do with my hands.

7 6 5 4 3 2 1

9. I smoke cigarettes automatically without even being aware of it.

7 6 5 4 3 2 1

10. I find I smoke cigarettes for their taste alone.

7 6 5 4 3 2 1

11. If I am without cigarettes for some time, I am bothered or uncomfortable.

7 6 5 4 3 2 1

12. I get a real gnawing hunger for a cigarette when I haven't smoked for a while.

7 6 5 4 3 2 1

13. Smoking seems to help when I feel embarrassed.

7 6 5 4 3 2 1

14. When something makes me mad I smoke to calm down.

7 6 5 4 3 2 1

15. I smoke to have something in my mouth.

7 6 5 4 3 2 1

16. I smoke cigarettes to stimulate me, to perk myself up.

7 6 5 4 3 2 1

17. I’ve found a cigarette in my mouth and didn’t remember putting it there.

7 6 5 4 3 2 1

18. I smoke when I feel nervous.

7 6 5 4 3 2 1

19. When I find I’m out of cigarettes, I immediately buy another pack.

7 6 5 4 3 2 1

20. Handling a cigarette is part of the enjoyment of smoking it.

7 6 5 4 3 2 1

21. lam very much aware of the fact when I am not smoking a cigarette.

7 6 5 4 3 2 1

22. When I have run out of cigarettes I find it almost unbearable until I can get them.

7 6 5 4 3 2 1

23. I smoke a lot at parties when I hardly know anyone.

7 6 5 4 3 2 1

24. When I’m nervous in social situations, I smoke.

7 6 5 4 3 2 1

25. When I am anxious 1 smoke to help me relax.

7 6 5 4 3 2 1

26. Part of the enjoyment of smoking a cigarette comes from the steps I take to light up.

7 6 5 4 3 2 1

27. When I am annoyed by someone, I smoke.

7 6 5 4 3 2 1

28. I smoke to appear more sophisticated.

(Please continue on the other side.)
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Page 2

Why do you smoke?
Always . . . Never

+
7 6 5 4 3 2 1

29. I smoke because I like the look of a smoker.

7 6 5 4 3 2 1

30. Flicking ashes is one of the pleasures of smoking.

7 6 5 4 3 2 1

31. I smoke cigarettes in order to keep myself from slowing down.

7 6 5 4 3 2 1

32. I smoke with my friends to be one of the crowd.

7 6 5 4 3 2 1

33. I find it very unpleasant to be without cigarettes for some time.

7 6 5 4 3 2 1

34. I like the taste of tobacco.

7 6 5 4 3 2 1

35. When I feel uncomfortable or upset about something. I light up a cigarette.

7 6 5 4 3 2 1

36. When I feel "blue" or want to take my mind off cares and worries, I smoke.

7 6 5 4 3 2 1

37. I light up a cigarette when I feel angry about something.

7 6 5 4 3 2 1

38. I want a cigarette most when I am comfortable and relaxed.

7 6 5 4 3 2 1

39. I light up a cigarette without realizing I still have one burning in the ashtray.

7 6 5 4 3 2 1

40. I smoke cigarettes to give me a lift.
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APPENDIX F - Withdrawal Symptoms Questionnaire

Feeling Profile

Date:

Group:___

:FP1

Below are a list of words and phrases related to how
Gender: [ ], Male [ ], Female
you might feel when you go without a cigarette for
Last four digits identification:
any length of time. For each word or phrase please
SS#
_ ___ ___ __
indicate how you have felt when you have gone
PHONE #
without a cigarette by circling a number on each
scale below. For example, if you do not feel at all
active when you go without a cigarette you would
circle the number 0 on the same line as the word
active. If you feel extremely active when you go without a cigarette you might circle the 8. If
you feel somewhere between these extremes you would circle one of the numbers between 0
and 8.

a lot

not at all

I
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.

How you feel when you have gone
without a cigarette.

►

012345678.
O l" 2 3 4 5 6 7 8 T
0 1 2 3 4 5 6 7 8.
0.. 1.....2 3... 4 5 6 7 8 .
0 1 2 3 4.. 5...6...7 8 .
0 T 2 3 4 5 6 7 8.
0 i 2 3 4 5 6 7 8.
0 1 2 3 4 5 6 7 8.
6 1.... 2 3 4 5 6...7 8 .
0 1 2 3 4 5 6 7 8!
0 1 2 3 4 5... 6 7 s'.
0 1 2 3 4 5 6 7 s’".
012345678.
012345678.
0 1 2 3 4 5 6 7 8.
0 1 2 3 4 5... 6...7 8 .
0.. 1.... 2.. 3... 4.. 5...6...7..8"'.'
0 1 2 3 4 5 6 7 8.
0 1 2 3 4 5 6 7 8.
0 1 2 3 4 5 6 7 8.
0 1 2 3 4 5... 6...7..8 ”
6 1 2 3 4 5 6 7 8.
0 1 2 3 4 5 6 7 8.
0 1 2 3 4 5 6 7 8.

active
can’t concentrate
annoyed
anxious
aroused
can’t sleep
confused
can’t get to sleep
depressed
desire for something with caffeine
desire to smoke
dizzy
ears ringing
feeling starved
full of energy
gloomy
headachy
heart pounding
hungry
irritable
lacking energy
longing for cigarette
longing for something with caffeine
muscle ache
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not at all

t
25.
26.
27.
28.
29.
30.
31.
32.

a lot

How you feel when you have gone

►

without a cigarette.

012345678
0.... 1... 2....3...4....5....6 7 8

muscle twitching
nervous
sleepy
slowed down
stomach upset
tense
tired
vision blurred

0 1 2 3 4 5 6 7 8
0 1 2 3 4 5 6 7 8
012345678
6.... 1....2 3 4 5 6 7 8
0 1....2 3 4 5 6 7 8
0

1

2

3 4

5

6

7 8
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APPENDIX G

Daily Log
Property of:.
Date:.

Group:.

Gender: [ ], Male

;DL/FL 2-1

[ ]2 Female

SS #

_____ (Last four digits)

Home Phone #

______(Last four digits)

Soft Drinks Containing Caffeine:
Aspen, Big Red, Coca-Cola, Cherry Cola, Diet Coke, Diet Pepsi, Diet Rite, Dr
Pepper, Jolt, Kick, Mellow Yellow, Mountain Dew, Mr Pibb, Pepsi-Cola, Pepsi
Light, RC Cola, Shasta Cola, Shasta Cherry Cola, Shasta Diet Cola, Sunkist Orange,
Tab,
Prescription and Nonprescription Drugs Containing Caffeine:
Amaphen, Anacin, Appedrine, Aqua-ban, Aqua-Ban Plus, Bromo-Seltzer, Cafergot,
Cope, Coryban-D, Damason-P, Darvon-compound. Dcxatrim, Dietac, Dristan,
Easy-Mens, Empirin, Excedrin, Esgic, Fioricct, Fiorinal, Gelpirin, Mcdigesic, Midol,
Migral, Migralarm, NoDoz, Norgesic, Orphengesic, Pacaps, PrcMens forte.
Prolamine, Propoxyphene, Sinarest, Synalgos-DC, Triad,
Two-Dyne, Vanquish, Vivarin, Wingraine.
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1. Indicate the number of tobacco products used between the specified time periods
(example: 3 1/2 = 3.5). If no product was used, leave blank.
3:00 P.M.B

9:00 A.M.a

(9 A.M.- 3:00 P.M.)

(9 PAi. - 9 A.M.)

]a
]b
]c
]d
]e

[
[
[
[
[

Cigarettes.....................
Pipes............................
Cigars ..........................
Snuff \ Chewing tobacco
Nicotine gum ..............

[
[
[
[

9:00 P.M.C
(3:00 P.M.- 9 P.M.)

la
lb
1c
Id

le

2a. What time did you go to bed?.

[
[
[
[
[

1.
lb
1c
]d
1c

.( Circle: A.M. or P.M. )
( Circle: A.M. or P.M.)

b. What time did you awaken from sleep?

3. Did you take any drugs to alter your mood in the past 24 hours?
( such as: clonadine patch, librium, valium, etc. )
[ ]i

No

[ ]2 Yes, (List type and amount).

4. Write in name and amount of prescription and nonprescription drugs used between
specified time periods (see back of front page for list of drugs qualifying).
9:00 A.M.a
(9 P.M. - 9 A.M.)

[
[
[

1:
k
k

3:00 P.M.b
(9 A.M- 3:00 P.M.)

i
.[
-[

la

9:00 P.M.C
(3:(X) P.M9 P.M.)

[

la

lb
1c

1c

5. Write in the amount of alcoholic beverages used during the same time periods?
[
[
[

]a Beer 12 oz. can
]b Wine 4 oz glass
]c Liquor 1.5 oz. shot glass

[
[
[

la
lb
1c

6. What time did you drink your first cup of coffee?
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[
[
[

la
lb
1c

.( Circle: A.M. or P.M.)

7. Indicate the number of servings of caffeine or decaffeinated products used
between the specified time periods.
3:00 P.M.b

9:00 A.M.a

(9 A.M.- 3:00 P.M.)

(9 P.M. - 9 A.M.)

[
[
[
[
[
[
[
[
[
[
[
[
[

]a
]b
]c
]d
]e
]f

Coffee, 6 oz cup .
Coffee, 10 oz Mug
Coffee, 12 oz cup
Coffee, 16 oz cup
Decaff-coffee,____
Tea, not herbal___

]g

Tea, iced 12 OZ glass (not herbal) . . . .

]h
\
]j
]k
]j
]m

Caffeinated soft drink, 12 oz can
Caff-soft drink,_____ oz cup?
Caff-soft drink, 2 liter
Decaff-soft drink, 12 oz can
Chocolate Bar, 1 oz............
Cocoa, Chocolate Milk, 8 oz

_oz cup?
oz cup?
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[
[
[
[
[
[
[
[
[
[

[

9:00 P.M.C
(3:00 P.M.- 9 P.M.)

]a
]b
1c
Id
le
1f
1
lh
li
ll
]k
],

[
[
[
[

1.
lb
]c
Id

[

L

[
[

]f
]g

[
[
[

]h
1.
Ij

[
[

]k
].

L

[

L

9 AM Feeling LogA
Please circle a number indicating how you have
been feeling since you got up.
Not at all....... A lot
012345678
012345678
012345678
012345678
012345678
012345678
012345678

1.
2.
3.
4.
5.
6.
7.

012345678 8.
012345678 9.
01234567810.
01234567811.
01 2345678 12.
01234567813.
012345678 14.
012345678 15.
012345678 16.
01234567817.
oi 234567818.
19.
012345678
012345678 20.
0 1 234567 821.
012345678 22.
012345678 23.
012345678 24.
012345678 25.
012345678 26.
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active
can’t concentrate
annoyed
aroused
Confused
depressed
desire for something
with caffeine
desire to smoke
dizzy
ears ringing
feeling starved
full of energy
Headachy
heart pounding
hungry
irritable
lacking energy
longing for cigarette
longing for something
with caffeine
muscles aching
muscle twitching
sleepy
slowed down
stomach upset
tense
vision blurred

3 PM Feeling Log,
Please circle a number indicating how you have
been feeling between 9 AM and 3 PM.
Not at all.......A lot
012345678
012345678
012345678
012345678
012345678
012345678

1.
2.
3.
4.
5.
6.
012345678 7.
012345678 8.
012345678 9.
012345678 10.
01234567811.
012345678 12.
012345678 13.
012345678 14.
012345678 15.
o i 2 3 4 5 6 7 8 16.
01234567817.
01234567818.
19.
012345678
012345678 20.
01234567821.
012345678 22.
012345678 23.
012345678 24.
012345678 25.
012345678 26.
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active
can’t concentrate
annoyed
aroused
COIlfused
depressed
desire for something
with caffeine
desire to smoke
dizzy
ears ringing
feeling starved
full of energy
Headachy
heart pounding
hungry
irritable
lacking energy
longing for cigarette
longing for something
with caffeine
muscles aching
muscle twitching
sleepy
slowed down
stomach upset
tense
vision blurecd

9 PM Feeling Logc
Please circle a number indicating how you have
been feeling between 6 PM and bedtime.
Not at all.......A lot
012345678
012345678
012345678
012345678
012345678
012345678

1.
2.
3.
4.
5.
6.
012345678 7.
012345678 8.
012345678 9.
01234567810.
01234567811.
012345678 12.
012345678 13.
012345678 14.
012345678 15.
01234567816.
0 1 234567 8 17.
012345678 18.
012345678 19.
012345678 20.
0 1 234567 821.
012345678 22.
012345678 23.
012345678 24.
012345678 25.
o i 2 3 4 5 6 7 8 26.
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active
can’t concentrate
annoyed
aroused
confused
depressed
desire for something
with caffeine
desire to smoke
dizzy
ears ringing
feeling starved
full of energy
Headachy
heart pounding
hungry
irritable
lacking energy
longing for cigarette
longing for something
with caffeine
muscles aching
muscle twitching
sleepy
slowed down
stomach upset
tense
vision blurred

APPENDIX H

PARTICIPANT SIX-MONTH
FOLLOW-UP QUESTIONNAIRE

Date:

c:swanson\smoke\question\follow6\revised, June 23, 1993

/

Gender:

/9

Group:____ :FQ6

[ ]j Male[ ]2 Female

Last four digits identification:
SS #
PHONE #
CODE:

[ ], E

[ ]2 S

1A.

HAVE YOU SMOKED CIGARETTES AT ALL IN THE PAST SIX MONTHS?

[ ]i

Yes
No

[ ]2

(SKIP TO QUESTION 2)
IB.

HOW SOON AFTER THE END OF THE LAST CLINIC SESSION DID YOU

BEGIN
SMOKING?
Response:,
1C.

WHEN DID YOU SMOKE YOUR LAST CIGARETTE?

Response:,

2.

days (0 = didn’t quit or last through clinic)

days (0 = smoked today)

ARE YOU NOW USING ANY OF THESE TOBACCO/NICOTINE PRODUCTS?

Per DAY
Number of cigarettes smoked? . . [
] B
Number of pipes smoked?
[
] E
Number of cigars smoked? ... [
] H
Pieces chewed?...................
] K
[
M. [ ], [ ]2 Snuff
Number of dips?...................
[
1N
P. [ Jj [ ]2 Chewing tobacco Number of chews?.................
[
]Q
s. []i
[ ]2 Nicotine patch Patch nicotine level (mg). . . .
[
]T

A.
D.
G.
L

U.

Yes No
[ ], [ ]2 Cigarettes
[ ], [ ]2 Pipes . . .
[ ], [ ]2 Cigar . . .
t It [ L Nicorette gum . .

[ ]

W. [
X. [
Y.

[

[ ]2
]
]
]

Per WEEK
]c
[
[
[
[

]F
]I
] L

[
[

] o
]R

Smoke w/patch Amount smoking w/patch
] V
[
Patch Brand: ( 1 = Habitrol, 2 = Nicoderm. 3 = Nicotrol, 4 = Pro Step, 5 = Other)
How long have you been using the patch? (measured in days)
When did you begin smoking again? (measured in days since first began using patch)

3. OUT OF THE LAST 180 DAYS OR SIX MONTHS, APPROXIMATELY HOW MANY DAYS
DID
YOU SMOKED?

If ZERO days in question 3, skip to question 8A
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4A.

DURING THE LAST SIX MONTHS, HAVE YOU TRIED QUITTING SMOKING AGAIN ?

[
[

Yes.................
No (SKIP TO QUESTION 5)

Ji
]2

4B. IF YES, HOW MANY TIMES HAVE YOU TRIED QUITTING?
[

]

4C. WHAT IS THE LONGEST TIME YOU HAVE BEEN OFF SMOKING?
[

5.

(measured in days, use decimals for hours: 0.33 = 8 hours)

WHAT EVENTS OR FACTORS INFLUENCED YOUR GOING BACK TO SMOKING?
(CHECK ALL THAT APPLY)

□a

Alcohol i
Caffeine i
Stressful event,
Job related.
Family related,
Social event 1
Other, (list):

[]B

□c
No

□e

[]F
□g

6.

]

WERE YOU DRINKING ALCOHOL AT THE TIME YOU RESUMED SMOKING?
Yes
No

[ ]i
[ ]2

7. WERE YOU DRINKING CAFFEINATED BEVERAGES, SUCH AS: REGULAR COFFEE, TEA,
AND CAFFEINATED SOFT DRINKS AT THE TIME YOU RESUMED SMOKING?
Yes
No

[ 1i
[ ]2

8.

ARE YOU CURRENTLY DRINKING REGULAR COFFEE, HOT OR ICED TEA, AND SOFT
DRINKS CONTAINING CAFFEINE?

Yes
A- Mi
B. [ ],
c- Mi

No
[ L Drinking regular coffee
[ ]2 Drinking hot/iced tea
[ ia Drinking caffeinated soft drinks
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9.

ARE YOU CURRENTLY USING DECAFFEINATED PRODUCTS?

[ ]i
[ ]2

Yes
No

10.

[ I EXPERIMENTAL GROUP ONLY: (WHO ABSTAINED FROM CAFFEINE)
HOW SOON AFTER THE "FREEDOM FROM SMOKING PROGRAM"-"QUIT NIGHT"
DID YOU RESUME USING REGULAR COFFEE, TEA, AND CAFFEINATED SOFT
DRINKS?

□o

Use only decaffeinated products
1-2 days
3-4 days
<1 week
1-2 weeks
2-3 weeks

[] i
[]2

[L
[]4

[]5

N*
[]7
[] 8

u

<1 month
1-2 months
3-4 months
Other (iist)_

11A

[ ] EXPERIMENTAL GROUP: DO YOU FEEL THAT ABSTAINING FROM
CAFFEINATED BEVERAGES AND PRODUCTS MADE IT EASIER FOR YOU TO QUIT?

[ ]i

Yes
No
Don’t know

[ 12
[ ]3

11B

[ ] STANDARD CARE GROUP: DO YOU FEEL THAT CONTINUING TO USE
CAFFEINATED BEVERAGES AND PRODUCTS MADE IT EASIER FOR YOU TO QUIT?

[ ]i
[ ]2
[ ]3

Yes
No
Don’t know

12A.

NON-SMOKERS ONLY; SINCE YOU'VE QUIT SMOKING, HAVE YOU
SUBSTITUTED YOUR SMOKING HABIT WITH ANOTHER HABIT ?

[] i
[]2
[ ] 3

Yes (IF YES, WHAT?)
No
Still smoking or on the nicotine patch

12B.

Habit #1 :

12C.

Habit #2 :

END QUESTIONNAIRE FOR NON-SMOKERS
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13.

WHAT FEELING OR SYMPTOMS WERE YOU EXPERIENCING PRIOR TO GOING
BACK TO SMOKING?

LIST:

A:
B:
C:

14. THE NEXT QUESTION I WANT YOU TO ANSWER WITH A YES OR NO RESPONSE.
DID YOU EXPERIENCE ANY OF THESE SYMPTOMS PRIOR TO GOING BACK TO
SMOKING?
Yes
A.
B
C.
D.
E.
F
G.
H.
I.
J.
K.

[
[
[
[
[
[
[
[
[
[
[

]i
]i
]
]i
]i
]i
]i
]i
1i
]i
]i

No
[ ]2
[ ]2
[ ]2
[ ]2
[ ]2

ANXIETY OR TENSION
RESTLESSNESS
TREMORS (SHAKY HANDS)
HEADACHES
IMPAIRED SLEEP (INSOMNIA)

[ ]2 IRRITABILITY
[ ]2 DEPRESSION
[
[
[
[

]2
]2
]2
]2

LETHARGIC (LACK ENERGY, TIRED)
LOSS OF APPETITE
NERVOUSNESS
EXCESSIVE PERSPIRATION

15.

DO YOU THINK CAFFEINE PLAYED A PART IN YOUR GOING BACK TO SMOKING?

[ Ji

Yes
No
Don’t know

[ ]2
[ ]3

END QUESTIONNAIRE
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APPENDIX I

SIX-MONTH FOLLOW-UP QUESTIONNAIRE (FQ6)
CODES AND NOTES
c:swanson\research\FQ6NOTES

QUESTION 5G (Other): FACTORS/EVENTS INFLUENCING SMOKING
CASE NUMBER

DESCRIPTION
ILLNESS

58
108
76
96
22
102
56
1,63,74,118
16
70
38
18,138

asthma
bad news about lower back
2nd breast biopsy (1 breast already removed)
broke venicular bone
chest pains
chemo-therapy reaction
diagnosed with lung cancer
death in family (? , mom, spouse, brother, spouse)
husband in hospital
melanoma (cancer)
pancreatitis (developed diabetes)
surgery (ovarian cancer, wife)
WITHDRAWAL SYMPTOMS

19
2,142,146
106,151
51
97,104,152,157
33
73

after taken off nicorette gum
addiction problem / felt uncomfortable
anxiety
climbing walls
craving
nervousness
tense
BEHAVIORAL PROBLEMS

11,118
11,43,118

101
55,155
35,53,56,61,75,90,93,97
64
20,47
54
67,104
61,65,78,81,89,95,113
15,39
12,24,64
91
148
158

depression
boredom
don’t like to confront people
felt like it
habit
I like smoking
it didn’t take
just on a whim
missed it
never really quit
no support
not ready to quit
I smoke less (have less ill effects)
wanting one
did not participate in cessation program
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QUESTION 5G (Other): FACTORS/EVENTS INFLUENCING SMOKING
CASE NUMBER

DESCRIPTION
SOCIAL PROBLEMS

92
60,63,117
73,154
105
109
103
127,137,159
143

dating a smoker
finances, estate problems
husband smokes and availability
joined in w/daughter
laid off work
quit drinking alcohol
family stress, being around smokers, job pressures
alcoholic husband (non-resolved)

QUESTION 10 (Other)
9
41
120

have not resumed caffeine
never quit - dropped out early
never quit using coffee

QUESTION 11A:
88
"1st two days was like hell" (previous use: 5-6 16 oz C/day - regular coffee, 2-3 48 oz
C/day of Big Gulp - Dr Pepper); current use: 1 C - 16 oz coffee in A.M., and 1 C 16 oz coffee in P.M.)
89
91
101
100
73

very dependent on caffeine
cig and coffee go together
sets you up for cig.
hard to deal w/both drugs at same time
missed the something else (coffee)

QUESTION 12B and 12C: HABITS SUBSTITUTED
0
1
2
3
4
5
6
7
8

snack
eating more
biting nails
was on morphine for a while
lost weight
gained weight
drink more alcohol
used nicorette gum
took up hobby (ceramic painting)

9
10
11
12
13
14
15
16
17

activity
chew straws (plastic stirrers)
exercising
use toothpicks
sunllower seeds
chewing gum
eating hard candy
drink less coffee
pregnant

REPORTED WEIGHT GAIN 12B AND 12C
1-5 lbs.
57,63,97,104,

6-10 lbs.
13,80,85,86,
131,140

16-20 lbs.

11-15 lbs.
14,28,38,107,
114,116,143,
147,156

27,40,115,134
149,161
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21-25 lbs.

26-30 lbs.

30,66,125,144

112,124,151,
162

QUESTION 13: FEELINGS OR SYMPTOMS
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

never quit
anxiety
tired of not smoking
tired of fighting it
remorse
disgust
guilt
fatigue
stress
irritable
nervousness
worried
cravings
tension
jittery/edgy
hopelessness
depressed
anger (from lack of support)
anger
frustration
rebellion (retaliation)
going in circles
feel like in a knot
headaches
dizziness
hyper
pushed for time
no reason
family pressures
restlessness
panicky

Coffee methods: Uses toddy method (125)
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missed enjoyment of smoking
disappointed w/family
sadness
upset
pregnant at the time
boredom
disappointment
sleep (interrupted)
concentration (lack of)
felt free/daring
shock
fear
urge to smoke
none
high stress (LA riots)
agitated

APPENDIX J
PARTICIPANT TWELVE-MONTH
FOLLOW-UP QUESTIONNAIRE

Date:

/

/9

Group:_____ :FQ12

Gender:

[ ], Male

[ ]2 Female

c:swansonXsmoke'Nquestion^ollow 12Vevised, June 23, 1993

Last four digits identification:
SS #
PHONE #

1A. HAVE YOU SMOKED CIGARETTES AT ALL
IN THE PAST SIX MONTHS?
[ I,
[ ]2

Yes
No

CODE:

[

], E

[ ]2 S

STATUS 6M:

I

], S

[ ]2 NS

(SKIP TO QUESTION 2)
B. WHEN DID YOU SMOKE YOUR LAST CIGARETTE?
Response:

days (0 = smoked today)

six month non-smokers only
C. WHEN DID YOU BEGIN SMOKING?
Response^

days

2.

ARE YOU NOW USING ANY OF THESE TOBACCO/NICOTINE PRODUCTS?

A.
D.
G.
J.
M.
P.
S.

Yes
[ ]j
[ ],
[ ],
[ ],
[ ],
[ Ii
[ Ii

No
[ ]2
[ ]2
[ ]2
[ ]2
[ ]2
[ ]2
[ ]2

Cigarettes
Pipes
Cigar
Nicorette gum
Snuff
Chew tobacco
Nicotine patch

U.
W.
X.
Y.

[ ],
[
[
[

[ ]2
]
]
]

Smoke w/patch Amount smoking w/patch
[
J V
Patch Brand: ( 1 = Habitrol, 2 = Nicodemi, 3 = Nicotrol, 4 = Pro Step, 5 = Other)
How long have you been using the patch? (measured in days)
When did you begin smoking again? (measured in days since first began using patch)

2Z

Per DAY
Number of cigarettes smoked?
Number of pipes smoked?
Number of cigars smoked? ...
Pieces chewed?
Number of dips?
Number of chews?....................
Patch nicotine level (mg). ...

[
[
[

[
[

] B
] E
] H
]K

3N
3 Q
3T

Per WEEK
[

[
[
[
[
[

] C
] F
] L

] o
3 R

WHAT SYMPTOMS HAVE YOU EXPERIENCED WHILE ON THE PATCH?
1.
2.
3.

3.

OUT OF THE LAST 180 DAYS, APPROXIMATELY HOW MANY DAYS DID YOU SMOKED?

If ZERO days in question 3, skip to question 5
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4A. DURING THE LAST SIX MONTHS, HAVE YOU TRIED QUITTING SMOKING AGAIN ?
[
[

]i
]2

Yes..................
No (SKIP TO QUESTION 5)
4B. IF YES, HOW MANY TIMES HAVE YOU TRIED QUITTING?
]

[

4C. WHAT IS THE LONGEST TIME YOU HAVE BEEN OFF SMOKING?
[

]

(measured in days, use decimals for hours: 0.33 = 8 hours)

THESE NEXT QUESTIONS ARE ABOUT DRINKING AND USING CAFFEINATED BEVERAGES AND
PRODUCTS.
5.

ARE YOU CURRENTLY USING ANY CAFFEINATED OR DECAFFEINATED BEVERAGES AND
PRODUCTS? (SUCH AS: REGULAR COFFEE, TEA, AND SOFT DRINKS - LIKE: PEPSI, COKE, DR.
PEPPER, MOUNTAIN DEW, TAB AND COLA BEVERAGES)

A.
B.
C.
D.
E.
F.

Yes
[ ],
[ li
[ ]i
[ ],
[ ],
[ ]i

No
[ ]2
[ ]2
[ ]2
[ ]2
[ ]2
[ ]2

6.

HAVE YOUR COFFEE DRINKING HABITS CHANGED OVER THE PAST YEAR?

Use regular coffee
Use decaffeinated coffee
Use regular tea (w/caffeine, not herbal)
Use decaffeinated tea
Use caffeinated soft drinks
Use decaffeinated soft drinks

DECAF. COFFEE ,
Drink more
[]
Drink less
[]2
Drink the same
[]3
Don’t use
[]<
Quit using
[]5

REG. COFFEE B (caffeinated)
Drink more
N
Drink less
[] 2
Drink the same
[]3
Don’t use
[]4
Quit using
[]5

OTHERr (iist)_
[]

[]2
[]3

[]<
[]5

Drink more
Drink less
Drink the same
Don’t use
Quit using

7. WHEN YOU QUIT SMOKING OR ABSTAIN FROM SMOKING, DOES YOUR CONSUMPTION OF
CAFFEINATED BEVERAGES CHANGE?
[ ],

[ h

Drink more
Drink the same

[ ]2

[ L

Drink less
Don’t know

BA. NON-SMOKERS ONLY: SINCE YOU'VE QUIT SMOKING, HAVE YOU SUBSTITUTED YOUR
SMOKING
HABIT WITH ANOTHER HABIT ?
[ ] i Yes (IF YES, WHAT?)
[ ] 2 No
[ ] 3 Still smoking or on the nicotine patch
8B. Habit #1 :
8C. Habit #2 :

END QUESTIONNAIRE FOR NON-SMOKERS /
SIX-MONTH SMOKERS TO QUESTION 14
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9.

WHAT EVENTS OR FACTORS INFLUENCED YOUR GOING BACK TO SMOKING?

□a
Nb
Nc
Nd

□e
[]f
No

Alcohol!
Caffeine,
Stressful event,
Job related,
Family related,
Social event.
Other, (list):__

10. WERE YOU DRINKING ALCOHOL AT THE TIME YOU RESUMED SMOKING?
[ ],
[ ]2

Yes
No

11. WERE YOU DRINKING CAFFEINATED BEVERAGES. SUCH AS: REGULAR COFFEE. TEA,
CAFFEINATED SOFT DRINKS AT THE TIME YOU RESUMED SMOKING?
[ ],
[ ]2

AND

Yes
No

12. WHAT FEELING OR SYMPTOMS WERE YOU EXPERIENCING PRIOR TO GOING BACK TO
SMOKING?

LIST:

A:
B:
C:

13. THE NEXT QUESTION I WANT YOU TO ANSWER WITH A YES OR NO RESPONSE.
DID YOU EXPERIENCE ANY OF THESE SYMPTOMS PRIOR TO GOING BACK TO SMOKING?
Yes
No
A. [ ],
[ ]2 ANXIETY OR TENSION
RESTLESSNESS
B [], [ ]2
C- [ ],
[ ]2 TREMORS (SHAKY HANDS)
D- [ ],
[ )2 HEADACHES
£■[],[ ]2 IMPAIRED SLEEP (INSOMNIA)
F
[ ],
[ ]2 IRRITABILITY
G. [ ], [ ]2 DEPRESSION
H. [ ],
[ ]2 LETHARGIC (LACK ENERGY, TIRED)
LOSS OF APPETITE
i- Mi [ ]2
NERVOUSNESS
J.
[ ]i
[ ]2
K. [ ],
[ ]2 EXCESSIVE PERSPIRATION
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REPEAT QUESTION FROM SIX-MONTH FOLLOW UP
14. DO YOU THINK CAFFEINE PLAYED A PART IN YOUR GOING BACK TO SMOKING?
[ ], Yes
[ L No

Don’t know
I am still not smoking

[ h
[ ]4

15. DO YOU SMOKE WHILE DRINKING YOUR COFFEE OR CAFFEINATED BEVERAGE?
[ ], Yes

[ Ja
[ 1b
[ Ic

[ ]2 No

IF YES, WHICH BEVERAGES?

Regular coffee
Decaffeinated coffee
Regular tea

[ ]D
[ ]E
[ If

Decaffeinated tea
Caffeinated soft drinks
Other beverage (list)__

16. WHAT PERCENT OF THE TIME DO YOU SMOKE WHILE DRINKING YOUR COFFEE OR
CAFFEINATED BEVERAGE?
[

]

Percentage

17. IS THIS PERCENTAGE MAINLY IN THE MORNING, AFTERNOON, EVENING OR ALL DAY
LONG?
[ 1a
[ 1b

Morning
Afternoon

Evening
All day long

[ ]c
[ Id

18. HOW SOON DO YOU SMOKE YOUR CIGARETTE AFTER DRINKING YOUR COFFEE OR
CAFFEINATED BEVERAGE?
[ ^ At the same time
[ ]2 Within 5 minutes
[ ]3 5-15 minutes

[ ]4
[ ]5
[ ]6

16-30 minutes
31-60 minutes
>61 minutes

[ ]7 I smoke before drinking coffee

END QUESTIONNAIRE
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APPENDIX K

TWELVE-MONTH FOLLOW-UP QUESTIONNAIRE (FQ12)
CODES AND NOTES
c:swanson\research\FQ12NOTE

QUESTION 2X - (5) OTHER: PATCH BRAND
bootleg: 3,
QUESTION 2-Z (1-3):
0
1
2
3
4
5
6
7
8
9

none
constipation
headaches (severe)
dreams (abnormal)
hand-mouth behavior hard to break
crave
sick to stomach
pain at the sight
craving for cigarette
very hyper

10
11
12
13
14
15
16
17
18
19

waking up at night
oral fixation
blisters
allergic
agitation
nervousness
dizziness
felt like arms being pierced
skin irritation
faster heart beat (140)

QUESTION 6C:
tea: 28,42,70,83,92,102
tea and soft drinks: 36,103,104
soft drinks: 44,55,59,60,62-64,68,69,71,73,82,85,87,88,90,91,93,94,96-98,106-108,110,111,116,117,
121,122,131,133,136,141,147,148,150,152,153,156,158,159,160,161
QUESTION 7:
Coffee inspires me to smoke, so I cut down (31)
QUESTION 8B AND 8C: HABITS SUBSTITUTED
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

16
17
18
19
20
21
22
23

eating/snack more
biting nails
was on morphine for awhile
lost weight
gained weight
drink more alcohol
used nicorette gum
took up hobby (ceramicpainting)
partially lost - previously gained weight
have urges to eat
used coffee as a substitute for smoking
argue w/self
now pregnant
gained/lost/regained weight (4)
more tense
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chew pencils
started walking program
no weight gain
oral fixation
is dying of lung cancer (56)
chewing gum
taking deep breathes
exercise

REPORTED WEIGHT GAIN 8B AND 8C
1-5 lbs.
47,87,118

6-10 lbs.

11-15 lbs.

4,57,85,92,
131,143

7,14,21,33,
49

16-20 lbs.

21-25 lbs.

27,28,86,
114

60,66,122

26-30 lbs.
115,125,
151

31-40 lbs.
88

Note: case 10 - quit using coffee, colas, tea, etc., last attempt to quit 3/17/92 (33 days off),
prior to quitting used: 3-4 cups regular coffee, 10 cig/day

QUESTION 9G (OTHER): FACTORS/EVENTS INFLUENCING SMOKING
CASE NUMBER

DESCRIPTION

9,22
14

financial
weight gain

15

boredom

71

litigation

156

nothing in particular

QUESTION 12: FEELINGS OR SYMPTOMS
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

never quit
anxiety
tired of not smoking
tired of fighting it
remorse
disgust
guilt
fatigue
stress
irritable
nervousness
worried
cravings
tension
jittery/edgy
hopelessness
depressed
anger (from lack of support)
anger
frustration
rebellion (retaliation)

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

going in circles
feel like in a knot
headaches
dizziness
hyper
pushed for time
no reason
family pressures
restlessness
panicky
missed enjoyment of smoking
disappointed w/family
sadness
upset
pregnant at the time
boredom
disappointment
sleep interrupted
concentration, lack of
felt free/daring

QUESTION 15:F OTHER BEVERAGE

QUESTION 18:

alcohol (24)
caffeinated soft drink (63)
decaffeinated soft drinks (43,58)
iced tea (46,47,48,81)

I smoke outdoors immediately following (11)
Drink coffee in house and then go outside to
smoke (2, 18)
CASE MISSING: 65
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APPENDIX L

TOBACCO-RELATED RESEARCH PROJECT
SIX-MONTH FOLLOW-UP TELEPHONE
QUESTIONNAIRE PROCEDURES
Hello! is (name)
there please?
This is (your name)____________________________________________.

I am calling on behalf of the Loma Linda University Tobacco-Related
Research Project. This project was held in conjunction with the
American Lung Association’s - "Freedom From Smoking Program" which
you attended six months ago at:
m
(site location)

(city)

Do you remember participating?

(wait for response)

We are conducting a short, five minute, follow-up survey regarding your
smoking history since you attended the program.
Am I calling at an awkward time for you: (name).

IF YES. WHEN WOULD BE THE BEST DAY AND TIME TO CALL?
(set up another appointment time)
(phone)

(date)

(best time to call)

IF NO, (continue with survey): Good! It is important to the research that you
answer all the questions to the best of your knowledge. Your answers
will be held in strict confidence.
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CLOSING REMARKS:
That concludes this portion of the survey (name).

Let me remind you that we have one more appointment.

I will be

contacting you by phone in six-months for the final follow-up survey.
Thank you very much for your help, and support for medical research.
And if we can be of any assistance to you here at Loma Linda University,
School of Public Health, don’t hesitate to call: Dr. Jerry Lee or myself, at
824-4300 (ext. 7256)!

Have a nice day / evening!
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TOBACCO-RELATED RESEARCH PROJECT
TWELVE-MONTH FOLLOW-UP TELEPHONE
QUESTIONNAIRE PROCEDURES
Hello! is (name)
there please?
This is (your name)

I am calling on behalf of the Loma Linda University Tobacco-Related
Research Project. This project was held in conjunction with the
American Lung Association’s "Freedom From Smoking Program" which
you attended one year ago at:
m
(site location)

(city)

Do you remember participating?

(wait for response)

Do you remember us calling you six-months ago regarding your smoking
history? (wait for response)

Now, we are conducting the final or one year follow-up survey. Am I
calling at an awkward time for you: (name)_______________________
IF YES. WHEN WOULD BE THE BEST DAY AND TIME TO CALL?
(set up another appointment time)

(phone)

(best time to call)

(date)

IF NO, (continue with survey): Good! Again, it is important to the research
to answer all the questions to the best of your knowledge. Your answers
will be held in strict confidence.
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CLOSING REMARKS:

That concludes our follow-up survey (name).

On behalf of Loma Linda University, I want to thank you very much for
your help and support for medical research. And if we can be of any
assistance to you here at the School of Public Health, don’t hesitate to call
Dr. Jerry Lee or myself at: 824-4300 (ext. 7256)!
(evening)!
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Have a nice day

INCENTIVE REQUEST FORM

(print name)
______________ ^ am requesting a check for
twenty dollars ($20.00) and a "Loma Linda University Research Project - T-shirt". I understand
these will be given to me, on the final class session, for participating in the Loma Linda University
/ American Lung Association of the Inland Counties "Freedom From Smoking" - Tobacco Related
Research Project. The following information is needed for processing the check.
I

>

m

§

ON

Ol

Address

X

City

State

Group

Social Security Number

Date

Zip

Signature

c:\swanson\Licentvcjevisedjuit 23, 1993

Circle T-Shirt Size
Desired: M L XL

£

, acknowledge receiving a Casio
research wrist watch, model number AE20W, from the Loma Linda University - Tobacco Related
Research Project. I understand this watch is loaned to me, to assist in a consistent reporting of the
Daily-log information. I will return the watch on the sixth week / last session of the American Lung
Association Freedom From Smoking” program, or on the last day of attendance.

I (print name)

On
ON

>

na
tn

o
Signed:
Watch ID: LLU #
Date Returned:

c:Nswansoii\watchlonVcviscd, June 23, 1993

Date:
Group #
Recipient Signature:

2

APPENDIX O
LOGO FOR LLU RESEARCH PROJECT T-SHIRT

^4*ch
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APPENDIX P

CLINIC AND RESEARCH PARTICIPANT
Beginning Date

ATTENDANCE SHEET

Group ______

cNiee-cwansonNatteiKtoevised, June 23, 1993

/

/

: ATT

Site Name ___
Address

City
CA

Instructor

Session

Date

Total number

Number

Number not

Number

Number

people in

participating

using

using

completing

clinic (*)

in research

caffeine

caffeine

program

1
2
3
4
5
6
7
6 Month
12

* This number should not reflect support people
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Table 2. Mean self-report caffeine/nicotine and sputum caffeine/cotinine concentrations in caffeine groups at 7 days pre
cessation (baseline) and two, seven, 21 days post-cessation.
Baseline

ON
VO

Nicotine (mg/day)
Abstainer
User

Post-cessation
Mean ± Standard Deviation

-7 days

2 days

7 days

14.03±10.86
12.28111.25

2.4115.87
1.2313.78

3.2617.58
1.1312.95

21 days

N

%
3.0817.22
1.5713.70

79
83

m

§
X

o

Sputum cotinine (ng/ml)
Abstainer
User

338.771176.77
323.611148.05

97.291128.70
88.231100.14

93.331131.52
107.241119.10

Caffeine (mg/day)
Abstainer
User

567.031584.54
512.921483.49

91.421284.17
437.641458.29

96.701274.90
401.701453.42

2.0412.91
1.88+2.47

0.6111.57
3.05+5.44

0.57+1.35
3.27+3.71

Sputum Caffeine (ug/ml)
Abstainer
User

16 days

167.471194.08
160.461171.15
218.821381.63
426.301519.07

65
64
79
83

1.43+3.06
3.83+6.57

50
50

APPENDIX R
The Analysis of Saliva for Caffeine and Cotinine Simultaneously by Liquid/Liquid Extraction
and Gas Chromatography With a Wide Bore Capillary Column (by L.S. Berk).

Materials
Materials for standard and buffer were secured from the following sources: (-cotinine,
caffeine, and l-phenyl-2-pyrrolidinone, Aldrich Chemical Co.; ketamine hydrocholoride
(Ketalar, 10 mg/ml, Inj, NF), Parke-Davis; sodium tetraborate, decahydrate, EM Science.
Water and methanol for the preparation of solutions and chlorofonn for extraction were liquid
chromatography grade from EM Science. Blank saliva was secured from an individual who
had abstained from smoking and the use of caffeine-containing beverages. The pooled saliva
samples were frozen, thawed, and centrifuged (3000 rpm for 10 minutes). The clear
supernatant saliva was decanted and stored in a freezer at about -10 °C.

Apparatus
The gas chromatograph, a Perkin-Elmer model 910, was equipped with a flame ionization
detector and a strip chart recorder. The carrier gas was helium. A glass insert for the packed
column glass liner of the injection port was made from 2 mm o.d. borosilicate tubing. This
insert was 30 mm long, flared slightly at both ends and constricted about 10 mm from the end
leading to the column. This constriction was small enough to prevent the passage of the fusedsilica lead attached to the front end of the capillary column. In use, the back end of the small
insert was flush with the back end of the larger packed column glass liner. Make-up gas
(helium) for the detector was routed through an empty glass column (2 mm i.d.) mounted in
the lower column positions were combined with a T-fitting in the oven-detector interface. The
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glass capillary column (Alltech) was 60 m x 0.75 mm i.d. The stationary phase was OV-1 with
a film thickness of 1 um. Fused-silica open tubular leads, 0.53 mm i.d., were attached with
shrinkable Teflon to both ends of the glass capillary column. The reducing ferrules (Restek
Corp.) were graphite, XA in. -0.8 mm i.d. and were predrilled to accommodate the capillary
column leads. The column was mounted so that the front lead just touched the constriction in
the small injection port liner.
Samples were extracted in 2 mL vials with tapered bottoms (Regis Reaction Vials). The
screw caps had Teflon-faced liners. Agitation was provided by a Eberbach platfomi shaker. A
rainin electronic pipettor was used for pipetting.
Samples were injected into the gas chromatograph with a 10 pL syringe from Hamilton.

Standards, Control, and Buffer
Stock standards of cotinine (0.66 mg/mL) and caffeine (2 mg/mL) were prepared
gravimetrically in 50% by volume methanol in aqueous solution. Working standards of 5
pg/mL cotinine, and 200 pg/mL caffeine were prepared by dilution of aliquots of the stock
standards. The dilution was made with 20% by volume methanol in aqueous solution. A stock
solution of the internal standard for cotinine was prepared gravimetrically at 2 mg/mL. 1Phenyl-2-pyrrolidinone was weighed out and dissolved in 50% by volume methanol in aqueous
solution. A stock standard of the internal standard for caffeine was prepared by dilution of
Ketalar (Parke-Davis) with 20% by volume methanol in aqueous solution; concentration of
ketamine as free base, 1 mg/mL. A combination working internal standard of 3 pg/mL 1phenyl-2-pyrrolidinone and 70 pg/mL ketamine was prepared by dilution of aliquots of the
stock solutions with 20% by volume methanol in aqueous solution.
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A control solution was prepared by spiking blank saliva with suitable aliquots of cotinine
and caffeine stock standards. Nominal concentrations were 200 ng/mL for cotinine and 4
pg/mL for caffeine.
Borax buffer (0.1 M) was prepared by dissolving 3.8 g of sodium tetraborate decahydrate
in about 95 mL of water and adjusting the pH to 9.5 by the dropwise addition of 12.5 N.
sodium hydroxide. The buffer was then diluted to 100 mL with water.
The borax buffer was stored at room temperature. All other solutions were stored at
about -10 °C.

Sample Preparation and Chromatography
To a 2 mL vial was added 60 pL of cotinine working standard, 15 pL of caffeine working
standard and 1 mL of blank saliva. Standard concentrations: 300 ng/mL cotinine and 3 pg/mL
caffeine. To additional appropriately labeled vials was added 1 mL of control and 1 mL of
saliva from test subjects. To all vials was then added 70 pL of the combination working
internal standard, 200 pL of borax buffer, and 600 pL of chloroform. The vials were capped.
placed on their sides on the Eberbach shaker platfonn and shaken horizontally for 5 minutes at
about 150 cycles per minute. The vials were then centrifuged at 3000 rpm for 5 minutes. By
use of a 1 mL HPLC syringe equipped with an 8 cm blunt needle the chloroform layers were
transferred to small vials (55 mm long, 6 mm o.d.) with tapered bottoms. The vials were
placed in a heat block (55 °C) and the chlorofonn evaporated just to dryness with a gentle
stream of air. Immediately before chromatographic analysis each sample was dissolved in 8 pL
of chloroform and mixed by vortexing several times. Generally, injections of about 1.5 pL in
the chromatograph proved satisfactory.
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Chromatographic conditions were as follows: oven, injector and detector interface
temperatures, 190, 210, and 220 °C, respectively; carrier and make-up helium, 7 and 14
mL/min., respectively; detector hydrogen, 22 psig (35 mL/min), and detector air, 50 psig (550
mL/min); attenuation, generally X8 or XI6 for cotinine and X64 or XI28 for caffeine, range
1; recorder response, 1 mV full scale and chart speed 30 cm/hr.
Quantification was based on peak heights. Measurements were made to the nearest
millimeter with a stainless steel ruler, and these data applied to the usual formulas for
quantification by the internal standard technique.

Results Approximate retention times were as follows: l-phenyl-2-pyrrolidinone (internal
standard for cotinine), 7 min.; cotinine, 8 min.; caffeine 12 min.; ketamine (internal standard
for caffeine), 14 min.
The within-day reproducibility data for the control were as follows (n = 10): cotinine,
mean, 220 ng/mL, relative standard deviation, 7.7%; caffeine, mean, 4.1 pg/mL, relative
standard deviation, 4.9%. The day-to-day reproducibility data were as follows (n = 35):
cotinine, mean, 203 ng/mL, relative standard deviation, 6.4%; caffeine, mean, 3.9 pg/mL,
relative standard deviation, 5.1%.
The standard curve for cotinine was linear to 1000 ng/mL. Linearity was not checked
above this concentration. The standard curve for caffeine was linear to about 8 pg/mL. Levels
of cotinine below about 50 ng/mL were only semiquantitative at best because of the difficulty
in measuring small peaks on a sharply sloping baseline. Caffeine could be detected as a
concentration of about 0.2 pg/mL, a level with little significance for the purposes of this study.
The stock standards of cotinine and caffeine were stable for at least two years at -10 °C;
the working standards at -10 °C were stable for at least a year.
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APPENDIX S

TOBACCO RELATED RESEARCH PROGRAM
American Lung Association Clinic Site Information
c:\let-jwanjon\clinsite\revised, June 23, 1993

Site

Location

Instructor

Begin Date
and Time

Research
Assistant

01

02

03

04

05

Josyln Senior Center
21 Grant St.
Redlands, CA 92373
(Between Center & Eureka, S
of Brookside)

Penny Mitchell

3/11/91
Tuesday

J. McDonough

6:30 P.M.

(End Total)

Date for
6 & 12
Month
Follow
up (*)

2/4

10/1/91

Research
Participants/
Total Group

Design:
(Standard

or Experi
mental

S
(2/2)

4/1/92

Corona Community Hospital
Business Center
819 S. Belle St., Corona, CA
(91 to Main St exit, go S)

Estelle Shay/
Taree Fleege

3/18/91

Chino Community Hospital
5451 Walnut
Chino, CA
(215 - 60 (w), exit Central (S),
Walnut (Left) follow sign)

Janet Ferren

4/22/91
Monday

4/5

7 P.M.

(2/3)

5/6/92

Kaiser Permanente
Park Sierra Medical Offices
10800 Magnolia Ave, Riverside,
La Sierra Exit to Magnolia turn
Rt., Conference 2A (2nd floor,
across from Lab)

Shirlee Shirley

3/18/91
Monday

7/14

10/8/91

canceled

Jorma
Rasanen

J. Swanson

11/6/91
E

E

6:30 P.M.

Inland Valley Medical Center
36485 Inland Valley Drive
Wildomar, CA (located next to
hospital) (91 - 15 (s) to Lake
Elsinore, exit Clinton Keith rd.,
(L) over hwy, paved rd to dirt
rd, Hospital on right. Clinic is
in bldg, next to Hospital,
basement Rm 50)

Teresa Fleet

San Antonio Community
Hospital
999 San Bernardino Rd.
Upland, CA 91786 (985-2811)
(10 West, exit at Euclid, go
North to Arrow Hwy., turn Rt go 8 blocks, Hospital on left)

Diana Karg
(nicorette gum)

4/24/91
Wednesday

J. McDonough

7:00 P.M.

4/16/91
Tuesday

(7/13)

4/8/92

4/5

10/30/91
S

Lorena Sing

7:00 P.M.
(2/3)

3/7

4/30/92

11/8/91
S
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(3/8)

5/8/92

Site

Location

Instructor

Begin Date
and Time

Research
Assistant

Research
Participants/
Total Group
(End Total)

06

07

08

09

10

San Bernardino Community
Hospital
1805 Medical Ctn. Dr.
San Bernardino, Ca
215 North to Baseline exit, West
to Medical Center Drive, North
to 17th st. East to last building
on left, in Fisher rm.)

Dr. Delong
(nicorette gum)

4/23/91
Tuesday

N. Sirichotirat

7:00 P.M.

Chief Auto Parts
1887 Business Center Dr.
San Bernardino, CA (Take
Waterman to Hospitality Lane,
West to "Black Angus
Restaurant, right on Business
Center Dr., first 2-story brown
Bldg, right side, 2nd floor, front
of bldg.)

Dee

St. Mary’s Hospital
18300 Highway 18, Apple valley
Victorville, CA
Rancho San Antonio Hospital
7777 Milliken Ave.
Rancho Cucamonga, CA 91730
(948-8000)
N.E. corner of Foothill and
Milliken, Park in 1st lot Urgent Care, Clinic held in
downstairs classroom
(basement) in main bldg.

5/6/91
Monday

1/5

Design:
Standard
or Experi
mental

11/7/91
E

(1/1)
at home

5/7/92

5/10

11/20/91
S

Lorena Sing

4 P.M.

Curtis Powell
J. McDonough
Dee
Shirlee Shirley

5/21/91
Tuesday
7 P.M.
July 15
Monday
7 P.M.

(2/8)

5/20/92

2/7

12/4/91

(2/3)

6/4/92

5/7

1/29/91

E

J. McDonough

E

(4/4)

St. Bernardines Hospital
Highland & Waterman
San Bernardino, CA

Diana
Budlinger

5/30/91
Tuesday
7 P.M.

0/3

Kaiser Permanente
Park Sierra Medical Offices
Conference 2A (2nd floor,
across from Lab)
10800 Magnolia Ave, Riverside,
CA

Shirlee Shirley

6/10/91
Monday

4/7

Jorma
Rasanen

YWCA
Redlands, CA

Penny Mitchell
Dee

7/29/92

12/24/91
S

6:30 P.M.

6/10/91
Monday

RCC/ Norco Campus
2001 2nd St.
Corona, CA 91760

6/25/91

San Gorgonia Hospital
Riverside County

7/15/91

Woodland Hills
Kaiser Permanente
Togona Canyon Rd.

Date for
6 & 12
Month
Follow
up (*)

(4/6)

canceled

canceled

Fern Car ness
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7/9/91
Tuesday
7:30 P.M.

canceled

canceled

6/24/92

Site

Location

Instructor

Begin Date
and Time

Research
Assistant

Research
Participants/
Total Group
(End Total)

11

Long Beach Community
Hospital

7/15/91

Chino Community Hospital
San Bernardino County

7/9/91

St. Bernardines Hospital
Highland & Waterman
San Bernardino, CA

Diana
Budlinger

7/30/91
Tuesday
7 P.M.

John Swanson

12

13

St. Mary’s Hospital
18300 Highway 18, Apple valley
Victorville, CA

8/13/91
Tuesday
7 P.M.

San Bernardino Community
Hospital
1805 Medical Ctn. Dr.
San Bernardino, Ca (215 N. to
Baseline exit, W. to Medical
Center Drive, N. to 17th st, E.
to last building on left, in
Fisher rm.)

8/13/91
Tuesday
7 P.M.

Ontario Parks & Recreation
San Bernardino County

8/13/91

Sylvia Dunn
529 Lee Ridge
Terrace,
Glendale,
91206 (818)
409-8218
246-9179 Hm
call after 6 PM

Saint Joseph’s Medical Center
Burbank, CA
(818) 843-5111 ext. 7470
Christy Kern

Pam Cannon
840-4456

Riverside Kaiser Permanente
Park Sierra Medical Offices
10800 Magnolia Ave, Riverside,
CA
(exit La Sierra Ave. N on
Magnolia)
Conference 2A (2nd floor,
across from Lab)

Design:
Standard
or Experi
mental

insufficient #

canceled

4/10

2/13/91

(2/2)

8/13/92

E

canceled

canceled

Glendale Adventist Medical
Center
Hwy 10 -> 210 -> 134, exit
Harvey Drive, Rt on Holley ->
L on Glen Oaks, L on Chevy
Chase (1 block on left corner of
Sinclair, (white bldg.), near
main entrance.
Mary Bergerson (818) 409-8020

Fontana Post Office
8282 Sierra Ave.
Fontana, CA 92335
1 block S of Foothill, 3-4 miles
N 10
Debbie Ortic - 822-8039

Date for
6 & 12
Month
Follow
up (*)

canceled

8/22/91
Thursday
7 P.M.
0/7

9/16/91
Monday
7 PM

9/18/91
Wed.
6 PM

canceled

3/23/92
8/14

John Swanson

Shirlee Shirley
Home phone #:
(818)851-5135
9/10/91

E
9/23/92

9/17/91
Tues.
6:30 PM

4/1/92
4/8

S

Lorena Sing
10/1/92
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Site

Location

Instructor

Begin Date
and Time

Research
Assistant

Research
Participants/
Total Group
(End Total)

14

15

16

St. Bernardines Hospital
Highland & Waterman
San Bernardino, CA

Jerry L. Pettis V.A. Hospital
Loma Linda, CA

Riverside Medical Clinic
6405 Day st.
Moreno Valley
91-60 E^ast, exit Day st., Rt 1-2
Blks,
Pink Bldg, Employee lounge

Corona Community Hosp.

18

19

Diana
Budlinger
(714) 883-8711
9/17/91
N. Sirichotirat

10/2/91
John Swanson
Hosea
Marquez
10/1,3,8,15,17
10/22,24,28

9/24/91
Tuesday
7 PM

Date for
6 & 12
Month
Follow
up (*)

Design:
Standard

or Experi
mental

4/8/92
6/8

S
10/8/92

10/2/91
Wed.
7:30 P.M.

3/5

4/6/92

3/3

10/6/92

S

10/8/91
Tuesday
7 PM

4/15/92
1/4

Jonna
Rasa nen

E
10/15/92

9/30/91

10/7/91
Monday
7 P.M.

West Covina Medical Clinic
1135 S. Sunset
West Covina, CA 91790
10 - exit & go L on West
Covina Parkway, Rt. on Sunset,
Clinic on 3rd level, Bldg, closes
at 9 PM
(past Queen of Valley Hospital,
next
Queen of Valley Medical Arts
Bldg.,
park in back)

Janie
Thompson
(818) 960-8614
ext. 204
10/1/91

10/8/91
Tuesday
7 P.M.

Mullikin Medical Centers
Pioneer Hospital
17806 S. Pioneer Blvd.
Artesia, CA 90701
(91 to Pioneer, go S. to 3rd
stop lite SE corner) (213) 8606611 ext. 4448

Gwy Salathe
10/8/91
T/Th clinic

10/8/91
Tuesday
5:30 7 P.M.

St. Mary’s Hospital
18300 Highway 18,
Apple valley, CA

10/1/91

Eisenhower Medical Center
39000 Bob Hope Dr.
Probst Bid., Diabetes Conf.
Center
10 • to Palm Springs, Bob Hope
Dr. exit, Rt., Bottom of hill, 1st
stop lite -Frank Sinatra
3 miles approx.

Virginia
Dreher

canceled

0/9
9 caff users
1 n/caff user

4/22/92
6/18

J. McDonough

10/22/92
10/8/91
Tuesday
7 PM

(619) 568-5805

S

canceled

10/8/91
Tuesday
1 PM

4/22/92

5/14

John Swanson

177

E

10/22/92

Site

Location

Instructor

Begin Date
and Time

Research
Assistant

Research
Participants/
Total Group
(End Total)

20

21

22

17

23

Eisenhower Medical Center
39000 Bob Hope Dr.
Probst Bid., Diabetes Conf.
Center
Conf. Rm
Eisenhower Medical Center
39000 Bob Hope Dr.
Probst Bid., Diabetes Conf.
Center
Conf. Rm

Virginia
Dreher
(619) 568-5805

10/8/91
Tuesday
3:15 PM

E
10/22/92

10/9/91
Wed.
1 PM

4/23/92
11/23

S
10/23/92

John Swanson

Inland Valley Medical Center
36485 Inland Valley Drive
Wildomar, CA

10/15/91

Hoag Hospital
301 Newport Blvd.
Newport Beach, CA
405 - Harbor (R) to beach or
toward Newport Blvd (Federon
on left). Make R 4-5 streets
before hospital (located on
bluff), If you
come to PCH Bid. you’ve gone
to far. On hospital rd., go past
parking structure, bear to R.

Donna Gordon
(714) 760-5519
(Mon-11/4/91)
11/4,7,11,140,
11/18,21,25,
12/2
(In Cancer
Cntr Bid, 1st
floor, Conf.
Rm. A)
Jonna
Rasanen

11/4/91
MonAThur
7-9 PM

Fullerton Internal Medical
Center
433 W. Bastanchury
Fullerton, CA 92635
91 W, exit Harbor/Fullerton
exit N Turn L at lite on
Bastanchury (Coco’s Rest, on
corner), go W past one lite,
Bldg is on Rt. side (Between
Harbor and Euclid) Room =
Main Lobby

Tim Watt
(714)738-8643
(714)774-3339

11/5/91
TuesAThur
6-8 PM

Riverside Kaiser Permanente
Park Sierra Medical Offices
Conference 2A (2nd floor)
10800 Magnolia Ave, Riverside,
CA

Shirlee Shirley
10/29/91

Glendale Adventist Medical
Center
Hwy 10 -> 210 •> 134, exit
Harvey Drive, Rt on Holley ->
L on Glen Oaks, L on Chevy
Chase (1 block on left corner of
Sinclair, (white bldg.), near
main entrance.
Mary Bergerson (818) 409-8020

Sylvia Dunn
529 Lee Ridge
Terrace,
Glendale,
91206 (818)
409-8218
246-9179 Hm
call after 6 PM
John Swanson

10/22/91
Tuesday
7 PM

canceled

5/14/92

S

3/11

11/14/92

11/5,7,120,14,
11/19,21,26

canceled

11/5/91
Tuesday
6:30 PM

5/20/92
7/12

N. Sirichotirat

178

Design:
Standard
or Experi
mental

4/22/92
3/7

John Swanson
Virginia
Dreher
(619) 568-5805

Date for
6 & 12
Month
Follow
up (*)

E
11/20/92

11/14/91
Thursday
7 P.M.

5/21/92

5/13

E

11/21/92

Site

Location

Instructor

Begin Date
and Time

Research
Assistant

Research
Participants/
Total Group
(End Total)

24

Glendale Adventist Medical
Center
Hwy 10 -> 210 -> 134, exit
Harvey Drive, Rt on Holley ->
L on Glen Oaks, L on Chevy
Chase (1 block on left corner of
Sinclair, (white bldg.), near
main entrance.
Mary Bergerson (818) 409-8020

Sylvia Dunn
529 Lee Ridge
Terrace,
Glendale,
91206 (818)
409-8218
246-9179 Hm
call after 6 PM
John Swanson

Hoag Hospital
301 Newport Blvd.
Newport Beach, CA
405 • Harbor (R) to beach or
toward Newport Blvd (Federon
on left), Make R 4-5 streets
before hospital (located on
bluff), If you
come to PCH Bid. you’ve gone
to far. On hospital rd., go past
parking structure, bear to R.

Donna Gordon
(714) 760-5519
(Mon-1/8/92)

30

28

Design:
Standard
or Experi
mental

7/13/92

1/8

S

1/13/93

0/7

4 to use
Clonadine
patch/one to
use nicorette
gum/ 2
would not
participate

Inland Valley Medical Center
36485 Inland Valley Drive
Wildomar, CA
25

1/6/92
Monday
7 P.M.

Date for
6 & 12
Month
Follow
up (*)

1/7/92
7 PM

Riverside Medical Clinic
6405 Day st.
Moreno Valley
91-60 East, exit Day st., Rt 1-2
Blks,
Pink Bldg, Employee lounge

Estelle
1/7/92

1/9/92
Tuesday
7 PM

West Covina Medical Clinic
1135 S. Sunset
West Covina, CA 91790
10 - exit & go L on West
Covina Parkway, Rt. on Sunset,
Clinic on 3rd level, Bldg, closes
at 9 PM
(past Queen of Valley Hospital,
next
Queen of Valley Medical Arts
Bldg,
park in back)

Janie
Thompson
(818) 960-8614
ext. 204
1/7/92

Eisenhower Medical Center
39000 Bob Hope Dr.
Rancho Mirage, CA
Rm 4E (fourth floor)
10 • to Palm Springs, Bob Hope
Dr. exit, Rt, Bottom of hill, 1st
stop lite -Frank Sinatra
3 miles approx.

Virginia
Dreher
(619) 568-5805
1/8/92

canceled

7/21/92
S

7/10
1/21/93

Mary Hawkins

1/14/92
T uesday
7 PM
7/28/92
S

3/5
1/28/93
Jorma
Rasanen

1/15/92
Wed.
5 PM

7/22/92
5/20

E
1/22/93

John Swanson

179

Site

Location

Begin Date
and Time

Instructor
Research
Assistant

Research
Participants/
Total Group
(End Total)

26

27

29

Riverside Kaiser Permanente
Park Sierra Medical Offices
Conference 2A (2nd floor)
10800 Magnolia Ave, Riverside,
CA

Shirlee Shirley
1/8/92

Chino Community Hospital
5451 Walnut
Chino, CA 91710
(215 - 60 (w), exit Central (S),
Walnut (Left) follow sign)
upstairs classroom

Janet Ferrin
1/6/92

Corona Community Hosp.
In another Bldg, not far from
the hospital
2600 South Main St.
Corona, CA

Terry Lynch
1/7/92

St. Bernardines Hospital
2101 N. Waterman Ave.
Highland & Waterman
San Bernardino, CA

Diana
Budlinger
(714) 883-8711
1/7/92

1/14/92
Tuesday
7 PM

Fullerton Internal Medical
Center
433 W. Bastanchury
Fullerton, CA 92635
91 W, exit Harbor/Fullerton
exit N Turn L at lite on
Bastanchury (Coco’s Rest, on
corner), go W past one lite.
Bldg is on Rt. side (Between
Harbor and Euclid) Room =
Main Lobby

Tim Watt
(714)738-8643
(714)774-3339
1/9/92
Tues/fhurs.

1/14/92
Tuesday
6 PM

Rancho San Antonio Hospital
7777 Milliken Ave.
Rancho Cucamonga, CA 91730
(948-8000)
N.E. corner of Foothill and
Milliken
Park in 1st lot • Urgent Care
Clinic held in downstairs
classroom (basement) in main
bldg.

Shirley Shirlee
1/13/92

St. Mary’s Desert Valley
Hospital
18300 Highway 18,
Apple valley, CA
Near Victorville

1/15/92
Wed.
6:30 PM

1/13/92
Monday
7 PM

Date for
6 & 12
Month
Follow
up (*)

Design:
Standard
or Experi
mental

canceled

7/27/92
4/4

E
1/27/93

Roger Grove
1/14/92
Tuesday
7 PM

canceled

canceled

7/21/92
5/13

Kalpna Shah

S
1/21/93

1/20/92
Monday
7 PM

8/3/92
1/4

J. McDonough

2/3/93

2/5/92
Wed.
7 PM

1/29/92

180

S

canceled

Site

Location

Instructor

Begin Date
and Time

Research
Assistant

Research
Participants/
Total Group
(End Total)

33

31

32

34

35

San Bernardino Community
Hospital
1805 Medical Ctn. Dr.
San Bernardino, Ca (215 N. to
Baseline exit, W. to Medical
Center Drive, N. to 17th st, E.
to last building on left, in
Fisher rm.)

Elois Diaz
2/4/92

Riverside Kaiser Permanente
Park Sierra Medical Offices
Conference 2A (2nd floor)
10800 Magnolia Ave, Riverside,
CA

Shirlee Shirley
2/4/92

Huntington Beach Health
Center
19582 Beach Blvd., Suite 100
Huntington Beach, CA 92648
Conference Center, 91 - 57 S,
Garden Grove W., exit Bend
blvd.

Faith Jansen
(714) 548-9917
2/3/92
Mon/Thurs.
Kalpna Shah

2/6/92
Thursday
6 PM

Hoag Hospital
301 Newport Blvd.
Newport Beach, CA
405 - Harbor (R) to beach or
toward Newport Blvd (Federon
on left), Make R 4-5 streets
before hospital (located on
bluff), If you
come to PCH Bid. you’ve gone
to far. On hospital rd., go past
parking structure, bear to R.

Donna Gordon
(714) 760-5519
2/3,6,10,13,20,
24,27, & 3/2
Mon7 Thurs.

2/6/92
Thursday
7 PM

Date for
6 & 12
Month
Follow
up (*)

Design:
Standard
or Experi
mental

2/11/92
Tuesday
7 PM
canceled

2/11/92
Tuesday
6:30 PM

8/25/92
5/11

Mary Hawkins

E
2/25/93

8/13/92
S

2/13
2/13/93

8/13/92
5/16

E
2/13/93

Jorma
Rasanen

Remax Building
Corner of Crown Valley and
Los Altos
Suite 150
Mission Viejo, CA

Jim Barnett
(714) 364-7772
2/20/92
Tues/Thurs

2/25/92
Tuesday
7 PM

Five-Star Club
Palm Desert, CA
Exit Monterey (E Bob Hope
Dr.), go S. past 2nd lite, turn
left, on Country Club rd., 2nd
lite turn rt on Cook St. (2
miles), 1st lite, 3/4 mile turn left
on Hovley. Business Park on
Beacon Hill (turn rt), at foot of
Beacon Hill,rt side, 2 white
bldg. -5 star club, enter at
corner

Virginia
Dreher
(619) 568-5805

3/3/92
Tuesday
5:30 P.M.

9/3/92
1/19

S
3/3/93

9/17/92

2/10

E

3/17/93
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Site

Location

Instructor

Begin Date
and Time

Research
Assistant

Research
Participants/
Total Group
(End Total)

36

38

37

39

Riverside Kaiser Permanente
Park Sierra Medical Offices
Conference 2A (2nd floor)
10800 Magnolia Ave, Riverside,
CA

Shirlee Shirley
2/24/92

Hoag Hospital
301 Newport Blvd.
Newport Beach, CA
405 - Harbor (R) to beach or
toward Newport Blvd (Federon
on left), Make R 4-5 streets
before hospital (located on
bluff), If you
come to PCH Bid. you’ve gone
to far. On hospital rd., go past
parking structure, bear to Rt.

Donna Gordon
(714) 760-5519
Tues/Thurs.
3/5/92

Mullikin Medical Centers
Pioneer Hospital - World Plaza
17806 S. Pioneer Blvd. (178th
st.)
Artesia, CA 90701 (Rm #104)
(91 to Pioneer, go S. to 3rd
stop lite SE corner) (213) 8606611 ext. 4448

Gwy Salathe
3/10/92

Hoag Hospital
301 Newport Blvd.
Newport Beach, CA
405 - Harbor (R) to beach or
toward Newport Blvd (Federon
on left). Make R 4-5 streets
before hospital (located on
bluff), If you
come to PCH Bid. you’ve gone
to far. On hospital rd., go past
parking structure, bear to Rt.

Donna Gordon
(714) 760-5519
Mon/Thurs.
3/5/92

St. Bernardines Hospital
2101 N. Waterman Ave.
Highland & Waterman
San Bernardino, CA

Janet Ferrin
Tues.
4/7/92

4/7/92
Tuesday
7 P.M.

Riverside Medical Clinic
6405 Day st.
Moreno Valley
91-60 East, exit Day st., Rt 1-2
Blks,
Pink Bldg, Employee lounge

Jerry Wazinski
Mon/Wed
4/6/92

4/8/92
Monday
7 P.M.

3/2/92
Monday
6:30 PM

Date for
6 & 12
Month
Follow
up (*)

Design:
Standard
or Experi
mental

9/16/92
1/3

E
3/16/93

3/10/92
Tuesday
7 PM
9/17/92
1/15

E
3/17/93

3/10/92
Tuesday
5:30 PM?

9/17/92
3/11

S
3/17/93

4/2/92
Thursday
7 P.M.

10/13/92
1/8

S
4/13/93

182

canceled

canceled

OTWERSrTY LIBRARY
LOMA LINDA. CALIFUhNIA

Site

Location

Instructor

Begin Date
and Time

Research
Assistant

Research
Participants/
Total Group
(End Total)

40

41

Chino Community Hospital
5451 Walnut
Chino, CA 91710
(215 - 60 (w), exit Central (S),
Walnut (Left) follow sign)
classroom on second floor

Janet Ferrin
Monday
4/13/92

Heart Institute
39-600 Bob Hope Dr.
Rancho Mirage, CA 92270

Virginia
Dreher
(619) 568-5805
4/16/92

4/16/92
Thursday
7 P.M.

Riverside Kaiser Permanente
Park Sierra Medical Offices
Conference 2A (2nd floor)
10800 Magnolia Ave
Riverside, CA

Shirlee Shirley
4/21/92

4/21/92
Tuesday
6:30 P.M.

4/13/92
Monday
7 P.M.

Date for
6 & 12
Month
Follow
up (*)

canceled

10/30/92
4/24

E
4/30/93

11/12/92
8/47

S
5/12/93

*Note: Six and twelve-month follow-up is from actual quit night, 3rd session

183

Design:
Standard
or Experi
mental

